1.0 Title Page

Clinical Study Protocol M15-925

A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

Incorporating Administrative Change 1 and Amendments 1, 2, 3 and 4

AbbVie Investigational Product: Upadacitinib

Date: 12 October 2017

Development Phase: 3

Study Design: A 24-week randomized, double-blind, parallel-group, active-controlled treatment period followed by an open label long-term extension period

EudraCT Number: 2016-000933-37

Investigators: Multicenter Trial (Investigator information is on file at AbbVie)

Sponsor: AbbVie*

*AbbVie* 1 North Waukegan Road
North Chicago, IL  60064
Sponsor/Emergency Contact:
AbbVie
1500 Seaport Blvd
Redwood City, CA 94063

Office: [Redacted]
Mobile: [Redacted]
Email: [Redacted]
Emergency 24 hour Number: [Redacted]

* The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country are provided within the clinical trial agreement with the Investigator/Institution and in the Clinical Trial Application with the Competent Authority.

This study will be conducted in compliance with the protocol, Good Clinical Practice and all other applicable regulatory requirements, including the archiving of essential documents.

Confidential Information
No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.
1.1 Protocol Amendment: Summary of Changes

Previous Protocol Versions

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>27 June 2016</td>
</tr>
<tr>
<td>Amendment 1</td>
<td>31 August 2016</td>
</tr>
<tr>
<td>Amendment 2</td>
<td>25 January 2017</td>
</tr>
<tr>
<td>Amendment 3</td>
<td>28 March 2017</td>
</tr>
<tr>
<td>Administrative Change 1</td>
<td>31 May 2017</td>
</tr>
</tbody>
</table>

The purpose of this amendment is to:

- Apply administrative changes throughout the protocol
  
  **Rationale:** Revised text to improve consistency and readability, and/or provide clarity

- Changed ABT-494 to upadacitinib throughout the protocol.
  
  **Rationale:** Revised to reflect the recently approved International Nonproprietary Name.

- Change the dose of upadacitinib from 30 mg QD to 15 mg QD throughout the study protocol.
  
  **Rationale:** Study M15-925 is being amended to replace the dose of upadacitinib that is being studied for the primary analysis. The current dose of upadacitinib 30 mg QD is being amended to 15 mg QD for patients not yet enrolled. This is based on data from the initial, placebo controlled periods of the Upadacitinib Phase 3 RA studies: Studies M13-549 (csDMARD-IR) and M13-542 (bDMARD-IR). The data from these studies showed that both the 15 and 30 mg QD doses achieved superior responses to placebo for all primary and ranked secondary endpoints at Week 12 with a profile consistent with the known profile from Phase 2 studies. No new safety signals were identified between doses. In these studies, the 15 mg QD dose provided response rates for efficacy endpoints that were at the top end of projections based on Phase 2 results, and the 30 mg dose provided little additional incremental benefit over the 15 mg dose, thus providing additional precision with which to estimate the
effect size that is anticipated in Study M15-925. This reassessment provides confidence that the 15 mg QD dose is positioned to support favorable comparisons with abatacept, and ultimately, regulatory submissions

- Update Section 1.2, Synopsis
  
  **Rationale:** Included Amendment 4 revisions and updates from Administrative Change 1

- Update Section 3.2, Benefits and Risks
  
  **Rationale:** Updated to include safety language for consistency in reporting and to provide updated dose selection information

- Update Section 5.1, Overall Study Design and Plan: Description
  
  **Rationale:** Clarified upadacitinib dose for Group 1 for subjects enrolled under Amendment 3 versus subjects enrolled under Amendment 4 or later.

- Update Section 5.2.2 Exclusion Criterion 19
  
  **Rationale:** Removed specific excipients to avoid confusion around food-product related sensitivities

- Update Section 5.2.3.1, Permitted Background RA Therapy
  
  **Rationale:** Revised to limit options for DMARD escalation to those currently recommended by ACR/EULAR guidelines

- Update Section 5.2.3.2, Prohibited Therapy: Table 1
  
  **Rationale:** Updated Table 1, Examples of Commonly Used Strong CYP3A Inhibitors and Inducers, to add Rifapentine

- Update Section 5.2.3.2, Prohibited Therapy
  
  **Rationale:** Revised to restrict oral use of traditional Chinese medications, some of which have the potential to interfere with upadacitinib metabolism

- Update Section 5.2.4, Contraception Recommendations
  
  **Rationale:** Updated female recommendation language to allow for use of injectable versions of combined hormonal contraceptives and for re-evaluation of fertility status (as may occur during long term extension period), to confirm that contraceptive measures are no longer required. Added male contraception language to clarify lack of effect of upadacitinib on male reproduction in preclinical models.
• Update Section 5.3.1.1, Study Procedures: TB Testing/TB Prophylaxis
  **Rationale:** Updated to clarify that history of positive Quantiferon and/or PPD test should be treated as a positive result at Screening. Updated to allow re-testing of Quantiferon through local lab for indeterminate results. Clarified duration of TB prophylaxis.

• Update Section 5.3.1.1, Study Procedures: Chest X-Ray
  **Rationale:** Included pulmonologist for assessment of CXRs

• Update Section 5.3.1.1, Study Procedures: Pregnancy Test
  **Rationale:** Updated for clarification on borderline serum pregnancy results

• Update Section 5.3.1.1, Study Procedures: Clinical Laboratory Tests
  **Rationale:** Updated for clarification on AE designation

• Update Section 5.3.1.1, Study Procedures: Clinical Laboratory Tests, Table 2
  **Rationale:** Added to inform that reliability of hsCRP/CRP for assessment of infection may be limited in the setting of JAK inhibition. Also advises that local testing of hsCRP/CRP should not be reported to the investigator as such blunting may result in unintentional bias.

• Update Section 5.3.1.1, Study Procedures: Hepatitis Screen
  **Rationale:** Updated for clarification.

• Update Section 5.3.3.1.3, Additional Variables
  **Rationale:** Included updates from Administrative Change 1

• Update Section 5.5.2, Identity of Investigational Product, Table 3
  **Rationale:** Updated for clarification on tablet description

• Update Section 5.5.5.1, Blinding of Investigational Product
  **Rationale:** Updated for clarification on blinded site personnel administering infusions

• Update Section 5.6.4, Selection of Doses in the Study
  **Rationale:** Updated to represent dose change based on new data from the Phase 3 RA program

• Update Section 6.1.1.3, Adverse Events of Special Interest
**Rationale:** Updated for clarification and consistency across upadacitinib programs and to represent AESIs based on upadacitinib and other JAK class studies

- Update Section 6.1.4, Adverse Event Collection Period
  **Rationale:** Updated for clarification
- Update Section 6.1.5, Adverse Event Reporting
  **Rationale:** Updated for clarification
- Update Section 6.1.6, Pregnancy
  **Rationale:** Updated for clarification
- Update Section 6.1.7, Toxicity Management
  **Rationale:** Included update from Administrative Change 1 and clarification on Hepatitis B reactivation, AE relationship with study drug and repeat laboratory testing. Updated to allow continued subject participation despite study drug interruption for serious infection per investigator discretion, if safe and has no impact on efficacy analysis. In Table 4, clarified hepatic-related toxicology management guideline and updated information on appropriate evaluation and/or management of potential Hepatitis B reactivation.

- Added Section 6.1.9, Cardiovascular Adjudication Committee
  **Rationale:** Study M15-925 will be added for review by the Cardiac Adjudication Committee for the upadacitinib program.
- Update Section 6.2.2, Reporting
  **Rationale:** Updated timeline for reporting Product Complaints to align with AbbVie SOP
- Update Section 8.1, Statistical and Analytical Plans
  **Rationale:** Clarified statistical analysis plan for subjects enrolled under Amendment 3 versus Amendment 4 or later
- Update Appendix C, Appendix D and Appendix F
  **Rationale:** Updated to be consistent with Amendment 4 revisions

An itemized list of all changes made to this protocol amendment can be found in Appendix S.
# 1.2 Synopsis

<table>
<thead>
<tr>
<th>AbbVie Inc.</th>
<th>Protocol Number: M15-925</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Study Drug: Upadacitinib</td>
<td>Phase of Development: 3</td>
</tr>
<tr>
<td>Name of Active Ingredient: Upadacitinib</td>
<td>Date of Protocol Synopsis: 12 October 2017</td>
</tr>
</tbody>
</table>

**Protocol Title:** A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

**Objectives:**

**Period 1**

To compare the safety and efficacy of upadacitinib 15 mg once daily (QD) versus abatacept intravenous (IV) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA.

**Period 2**

To evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.

**Investigators:** Multicenter

**Study Sites:** Approximately 200

**Study Population:**

Adult female and male subjects who are at least 18 years of age with a diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA. Subjects who have been treated ≥ 3 months prior to the screening visit with ≥ 1 bDMARD therapy and ≥ 3 months with csDMARDs and have never received abatacept, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration may be enrolled. Eligible study subjects must have ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits, and high-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L (central lab) at Screening. Subjects must have been on a stable dose of csDMARD therapy (restricted to methotrexate [MTX], chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for ≥ 4 weeks prior to the first dose of study drug.

**Number of Subjects to be Enrolled:** Approximately 550

**Methodology:**

This is a Phase 3, multicenter study that includes two periods. Period 1 is a 24-week randomized, double-blind, parallel-group, active-controlled treatment period designed to compare the safety and efficacy of upadacitinib 15 mg QD versus abatacept IV for the treatment of signs and symptoms of subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapies other than abatacept and are currently on a stable dose of csDMARDs. Period 2 is an open-label extension to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.
Methodology (Continued):
The study duration will include a 35-day maximum screening period; a 24-week randomized, double
blind, parallel-group, active controlled treatment period, with 30-day and 70-day follow-ups (Period 1);
an open-label long term extension period (up to 5 years) with a 30-day follow-up call or site visit
(Period 2);
Subjects who meet eligibility criteria will be randomized in a 1:1 ratio to one of two treatment groups:
- Group 1: upadacitinib 15 mg QD, N = 275 (Period 1)
- Group 2: Abatacept IV at Day 1, Weeks 2, 4, 8, 12, 16 and 20 (< 60 kg: 500 mg; 60 – 100 kg: 750 mg; > 100 kg: 1,000 mg, N = 275 (Period 1)
NOTE: In Period 1, subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose. This
study began enrolling under Amendment 3. Starting with Amendment 4, subjects randomized to Group 1
will receive 15 mg QD dose. In Period 2, subjects who enrolled under Amendment 3, including subjects
randomized to both Group 1 and Group 2, will continue to receive open-label upadacitinib 30 mg QD.
Subjects who enroll under Amendment 4 or later will receive open-label upadacitinib 15 mg QD.
Subjects enrolled under Amendment 3 will follow the requirements and study procedures specified in
Amendment 3.
Randomization will be stratified by number of prior bDMARD use (stratum 1: failed 1 or 2 biologics of
the same class; stratum 2: failed ≥ 3 biologics of the same class or failed biologics of multiple classes)
AND geographic region. Once 20% of total subjects have been randomized who have not completed
> 3 months of methotrexate, further screening of such methotrexate inexperienced subjects may be
suspended.
Subjects must have been on stable csDMARD(s) treatment for ≥ 4 weeks prior to the first dose of study
drug and must remain on a stable dose until Week 12; the csDMARD dose may be decreased only for
safety reasons. Starting at Week 12 (after Week 12 assessments have been performed), initiation of or
change in corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or
increasing doses for up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination
of MTX and leflunomide) is allowed as per local label.
Rescue therapy will be offered to subjects who meet the following criteria:
- Starting at Week 12, subjects who do not achieve ≥ 20% improvement in both TJC and SJC at
two consecutive visits will be rescued with optimizing (initiate or increase) background RA
medications: NSAIDs, corticosteroids, low-potency analgesics, acetaminophen or adding or
increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the
combination of MTX and leflunomide) and, if necessary, a burst of systemic corticosteroids
(prednisone equivalent ≤ 0.5 mg/kg/day for 3 consecutive days), intra-articular, intramuscular,
intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of
corticosteroids, dosage and frequency per standard of care, are allowed.
Subjects who complete the Week 24 visit (end of Period 1) will enter the open-label long term extension
portion of the study, Period 2 (up to 5 years). Subjects who are assigned to upadacitinib treatment group
in Period 1 will continue to receive upadacitinib 15 mg QD per original randomization assignment.
Subjects who are assigned to abatacept IV in Period 1 will be switched to receive upadacitinib 15 mg
QD.
An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24). Period 2
is open-label.
Diagnosis and Main Criteria for Inclusion/Exclusion:

Main Inclusion:
1. Adult male or female, at least 18 years old.
2. Diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/EULAR classification criteria for RA.
3. Subjects have been treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration AND have never received abatacept prior to first dose of study drug.
4. Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug:
   - The following csDMARDs are allowed (stable dose for ≥ 4 weeks prior to the first dose of study drug): oral or parenteral MTX (7.5 to 25 mg/week), sulfasalazine (≤ 3000 mg/day), hydroxychloroquine (≤ 400 mg/day), chloroquine (≤ 250 mg/day), and leflunomide (≤ 20 mg/day).
   - A combination of up to two background csDMARDs is allowed EXCEPT the combination of MTX and leflunomide.
5. Subject meets both of the following minimum disease activity criteria:
   a. ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits; and
   b. hsCRP ≥ 3 mg/L (central lab) at Screening Visit.

Main Exclusion:
1. Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib).
2. Prior exposure to abatacept.
3. History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms], or any arthritis with onset prior to age 17 years). Current diagnosis of secondary Sjogren's Syndrome is permitted.
4. Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase > 2 × upper limit of normal (ULN); serum alanine transaminase > 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula < 40 mL/min/1.73 m²; total white blood cell count < 2,500/μL; absolute neutrophil count < 1,500/μL; platelet count < 100,000/μL; absolute lymphocyte count < 800/μL; and hemoglobin < 10 g/dL.

Investigational Product: Upadacitinib
Dose: 15 mg QD
Mode of Administration: Oral
<table>
<thead>
<tr>
<th>Reference Therapy:</th>
<th>Period 1 only: Placebo for upadacitinib 15 mg QD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose:</td>
<td>N/A</td>
</tr>
<tr>
<td>Mode of Administration:</td>
<td>Oral</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference Therapy:</th>
<th>Period 1 only: abatacept</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose:</td>
<td>&lt; 60 kg: 500 mg; 60 – 100 kg: 750 mg; &gt; 100 kg: 1,000 mg</td>
</tr>
<tr>
<td>Mode of Administration:</td>
<td>IV: Day 1, Weeks 2, 4, 8, 12, 16, and 20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference Therapy:</th>
<th>Period 1 only: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose:</td>
<td>N/A</td>
</tr>
<tr>
<td>Mode of Administration:</td>
<td>IV: Day 1, Weeks 2, 4, 8, 12, 16, and 20</td>
</tr>
</tbody>
</table>

**Duration of Treatment:** Period 1: 24 weeks; Period 2: up to 5 years

**Criteria for Evaluation:**

**Efficacy:**

**Period 1:**
- The primary endpoint is the change from baseline in DAS28 (CRP) at Week 12 (non-inferiority).

Key secondary endpoints are:
- Change from baseline in DAS28 (CRP) at Week 12 (superiority)
- Proportion of subjects achieving Clinical Remission (CR) at Week 12 (superiority)
  - CR is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) < 2.6.

Additional endpoints are:
- Proportion of subjects achieving low disease activity (LDA) at Week 12 (non-inferiority).
  - LDA is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) ≤ 3.2.
- ACR20/50/70 response rates at all visits;
  - ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale [VAS]), Patient's Global Assessment of Disease Activity (VAS), Physician's Global Assessment of Disease Activity (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), or hsCRP.
- Change from baseline in individual components of ACR response at all visits;
- Change from baseline in DAS28(CRP) and DAS28 (erythrocyte sedimentation rate [ESR]) at all visits;
- Change from baseline in SF 36 at Weeks 4, 12 and 24;
- Change from baseline in morning stiffness at all visits;
- Proportion of subjects achieving LDA or CR based on DAS28 (CRP), DAS28 (ESR), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) criteria (see below) at all visits;
- Change from baseline in EQ-5D-5L at Weeks 4, 12 and 24;
Criteria for Evaluation (Continued):
Efficacy (Continued):
Period 1 (Continued):
- Change from baseline in Functional Assessment of Chronic Illness Therapy – fatigue (FACIT-F) at Weeks 4, 8, 12, 16 and 24;
- Change from baseline in Work Productivity and Activity Impairment (WPAI) at Weeks 4, 8, 12 and 24;
- Change from baseline in CDAI and SDAI at all visits;
- Proportion of subjects achieving MCID in change from baseline in HAQ-DI (defined as change from baseline in HAQ-DI ≤ –0.3) at all visits;
- ACR/EULAR Boolean remission at all visits.
- Systemic corticosteroid dose (including cumulative dose at serial time points in Period 1)

<table>
<thead>
<tr>
<th>DAS28 (CRP) and DAS28 (ESR)</th>
<th>SDAI</th>
<th>CDAI</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDA</td>
<td>≤ 3.2</td>
<td>≤ 11.0</td>
</tr>
<tr>
<td>CR</td>
<td>&lt; 2.6</td>
<td>≤ 3.3</td>
</tr>
</tbody>
</table>

Period 2:
Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Weeks 36, 48, and every 12 weeks thereafter until completion of the study:
- Change from baseline in DAS28 (CRP);
- Proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- Proportion of subjects achieving LDA based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- ACR20/50/70 response rates;
- Change from baseline in individual ACR components;
- Change from baseline in DAS28 (ESR);
- Change from baseline in HAQ-DI at all visits;
- Change from baseline in SF 36 at all visits;
- Change from baseline in morning stiffness;
- Concomitant corticosteroid use.
- ACR/EULAR Boolean remission

Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Week 48 only:
- Change from baseline in EQ-5D-5L;
- Change from baseline in FACIT-F;
- Change from baseline in WPAI RA.

Pharmacokinetic (Period 1 Only):
Blood samples for assay of upadacitinib and possibly other concomitant medications in plasma will be collected at Weeks 2, 4, 8, 12, 16, 20 and 24/Premature Discontinuation.
### Criteria for Evaluation (Continued):

#### Exploratory Research Variables and Validation Studies (Optional) (Period 1 Only):

Prognostic and predictive biomarker signatures may be evaluated. Samples for pharmacogenetic, epigenetic, transcriptomic, and proteomic and targeted protein investigations will be collected at various time points. Assessments will include but may not be limited to nucleic acids, proteins, metabolites, or lipids.

**Safety:**

Safety evaluations include adverse event (AE) monitoring, physical examinations, vital sign measurements, electrocardiogram (ECG), and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration.

### Statistical Methods:

#### Efficacy:

All efficacy analyses will be carried out using the Full Analysis Set population, which includes all randomized subjects who receive at least one dose of study drug.

**Period 1 Efficacy:**

#### Analysis of the Primary and Key Secondary Endpoints:

The primary efficacy endpoint will be assessed via non-inferiority comparison of upadacitinib to abatacept in change from baseline in DAS28 (CRP) at Week 12 using the 95% confidence interval (CI) of treatment difference against the pre-specified non-inferiority margin.

The two key secondary efficacy endpoints involve the superiority comparisons of upadacitinib to abatacept on change from baseline in DAS28 (CRP) at Week 12 as well as the proportion of subjects achieving CR based on DAS28 (CRP) at Week 12. The overall type I error rate of the primary and key secondary endpoints will be strongly controlled via sequential testing.

For the binary endpoint of CR, frequencies and percentages will be reported for each treatment group, and comparison of upadacitinib to abatacept will be conducted using the Cochran-Mantel-Haenszel test adjusting for main stratification factors. Non-responder imputation will serve as the primary analysis approach for missing data handling.

For the continuous endpoint of change from baseline in DAS28 (CRP), the mean, standard deviation, median, and range will be reported for each treatment group. Comparison between upadacitinib and abatacept will be carried out using the analysis of covariance model with treatment group as the fixed factor, and the corresponding baseline value and the main stratification factors as the covariates. Multiple imputations will serve as the primary analysis approach for missing data handling.

**Long-Term Efficacy for Period 1 and Period 2 Combined:**

Long-term efficacy by time point will be summarized using descriptive statistics.

#### Pharmacokinetic:

A non-linear mixed-effects modeling approach will be used to estimate the population central values and the empirical Bayesian estimates of the individual values of upadacitinib oral clearance (CL/F) and volume of distribution (V/F). Additional parameters may be estimated if useful in the interpretation of the data.
Statistical Methods (Continued):

Safety:
Safety analyses will be carried out using the Safety Analysis Set, which includes all subjects who receive at least one dose of study drug. Analyses will be conducted for Period 1 alone, as well as for Period 1 and Period 2 combined. Safety will be assessed by AEs, physical examination, laboratory assessments, ECG, and vital signs. Frequency tables and lists of subjects with treatment-emergent AEs by preferred term as in the Medical Dictionary for Regulatory Activities dictionary, by system organ class, by severity, and by relationship to the study drug as assessed by the Investigator will be provided. The changes from baseline in vital signs, physical examination results, and clinical laboratory values will be analyzed in a descriptive manner. Shift of laboratory values from baseline to defined time points will be tabulated.
1.3 List of Abbreviations and Definition of Terms

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR</td>
<td>American College of Rheumatology</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALC</td>
<td>absolute lymphocyte count</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine transaminase</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>analysis of covariance</td>
</tr>
<tr>
<td>anti-CCP</td>
<td>anti-cyclic citrullinated peptide</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate transaminase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
</tr>
<tr>
<td>BCG</td>
<td>Bacille Calmette-Guérin</td>
</tr>
<tr>
<td>bDMARD</td>
<td>biologic disease-modifying anti-rheumatic drug</td>
</tr>
<tr>
<td>bDMARD-IR</td>
<td>biologic disease-modifying anti-rheumatic drug-inadequate response</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily (Latin: bis in die)</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CDAI</td>
<td>clinical disease activity index</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CL/F</td>
<td>apparent clearance</td>
</tr>
<tr>
<td>CPK</td>
<td>creatine phosphokinase</td>
</tr>
<tr>
<td>CR</td>
<td>clinical remission</td>
</tr>
<tr>
<td>CRF</td>
<td>case report form</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>csDMARD</td>
<td>conventional synthetic disease-modifying anti-rheumatic drug</td>
</tr>
<tr>
<td>CSR</td>
<td>clinical study report</td>
</tr>
<tr>
<td>CXR</td>
<td>chest x-ray</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td>DAS</td>
<td>disease activity score</td>
</tr>
<tr>
<td>DMARD</td>
<td>disease-modifying anti-rheumatic drug</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>ePRO</td>
<td>electronic patient-reported outcome</td>
</tr>
<tr>
<td>EQ-5D-5L</td>
<td>EuroQoL-5D-5L</td>
</tr>
<tr>
<td>ESR</td>
<td>erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>EULAR</td>
<td>European League Against Rheumatism</td>
</tr>
<tr>
<td>FACIT-F</td>
<td>Functional Assessment of Chronic Illness Therapy – Fatigue</td>
</tr>
<tr>
<td>FAS</td>
<td>full analysis set</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle stimulating hormone</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GDH-PQQ</td>
<td>glucose dehydrogenase pyrroloquinolinequinone</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>Health Assessment Questionnaire – Disability Index</td>
</tr>
<tr>
<td>HBc Ab/anti-HBc</td>
<td>Hepatitis B core antibody</td>
</tr>
<tr>
<td>HBs Ab/anti-HBs</td>
<td>Hepatitis B surface antibody</td>
</tr>
<tr>
<td>HBs Ag</td>
<td>Hepatitis B surface antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>HCV Ab</td>
<td>Hepatitis C virus antibody</td>
</tr>
<tr>
<td>HDL-C</td>
<td>high-density lipoprotein cholesterol</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>hsCRP</td>
<td>high-sensitivity C-reactive protein</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference On Harmonization</td>
</tr>
<tr>
<td>IEC</td>
<td>independent ethics committee</td>
</tr>
<tr>
<td>IGRA</td>
<td>interferon-gamma release assay</td>
</tr>
<tr>
<td>IMP</td>
<td>investigational medicinal product</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>IR</td>
<td>inadequate response</td>
</tr>
<tr>
<td>IRB</td>
<td>institutional review board</td>
</tr>
<tr>
<td>IRT</td>
<td>interactive response technology</td>
</tr>
<tr>
<td>IUD</td>
<td>intrauterine device</td>
</tr>
<tr>
<td>IUS</td>
<td>intrauterine hormone-releasing system</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
</tbody>
</table>
JAK  Janus kinase
LDA  low disease activity
LDL-C  low-density lipoprotein cholesterol
MACE  major adverse cardiovascular event
MCID  Minimal clinically important difference
MDRD  modification of diet in renal disease
MedDRA  Medical Dictionary for Regulatory Activities
MI  multiple imputation
MTX  methotrexate
MTX-IR  methotrexate inadequate responder
NA  no assessment
NK  natural killer
NMSC  non-melanoma skin cancer
NRI  non-responder imputation
NRS  numerical rating scale
NSAID  non-steroidal anti-inflammatory drug
OC  observed cases
OLE  open-label extension
PCR  polymerase chain reaction
PD  premature discontinuation
PhGA  Physician's Global Assessment of Disease Activity
PK  pharmacokinetic
PPD  purified protein derivative
PRN  as needed (Latin: pro re nata)
PRO  patient-reported outcome
PT  preferred term
PtGA  Patient's Global Assessment of Disease Activity
QD  once daily (Latin: quaque die)
QTcF  QT interval corrected for heart rate using Fridericia's correction formula
RA  rheumatoid arthritis
RAVE®  EDC system from Medidata
RBC  red blood cell
RCT  randomized controlled trial
RNA  Ribonucleic acid
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>statistical analysis plan</td>
</tr>
<tr>
<td>SDAI</td>
<td>simplified disease activity index</td>
</tr>
<tr>
<td>SF-36</td>
<td>Short Form-36</td>
</tr>
<tr>
<td>SJC</td>
<td>swollen joint count</td>
</tr>
<tr>
<td>SOC</td>
<td>system organ class</td>
</tr>
<tr>
<td>SUSAR</td>
<td>suspected unexpected serious adverse reaction</td>
</tr>
<tr>
<td>T2T</td>
<td>treat-to-target</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TEAE</td>
<td>treatment-emergent adverse event</td>
</tr>
<tr>
<td>TJC</td>
<td>tender joint count</td>
</tr>
<tr>
<td>TNF</td>
<td>tumor necrosis factor</td>
</tr>
<tr>
<td>TNF-IR</td>
<td>anti-tumor necrosis factor inadequate responder</td>
</tr>
<tr>
<td>Tyk2</td>
<td>Tyrosine kinase 2</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>V/F</td>
<td>apparent volume of distribution</td>
</tr>
<tr>
<td>VAS</td>
<td>visual analog scale</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
</tbody>
</table>
2.0 Table of Contents

1.0 Title Page ................................................................................................. 1

1.1 Protocol Amendment: Summary of Changes ........................................... 3

1.2 Synopsis ..................................................................................................... 7

1.3 List of Abbreviations and Definition of Terms ......................................... 14

2.0 Table of Contents ...................................................................................... 18

3.0 Introduction ............................................................................................... 24

3.1 Differences Statement ............................................................................. 26

3.2 Benefits and Risks ................................................................................... 26

4.0 Study Objectives ...................................................................................... 30

5.0 Investigational Plan .................................................................................. 30

5.1 Overall Study Design and Plan: Description ........................................... 30

5.2 Selection of Study Population .................................................................. 38

5.2.1 Inclusion Criteria .................................................................................. 38

5.2.2 Exclusion Criteria ................................................................................ 40

5.2.3 Prior, Concomitant, and Prohibited Therapy ......................................... 44

5.2.3.1 Permitted Background RA Therapy .................................................. 44

5.2.3.2 Prohibited Therapy .......................................................................... 46

5.2.3.3 Rescue Therapy ................................................................................. 49

5.2.4 Contraception Recommendations ....................................................... 50

5.3 Efficacy, Pharmacokinetic, Exploratory Research and Validation
Studies, and Safety Assessments/Variables ................................................ 54

5.3.1 Efficacy and Safety Measurements Assessed and Flow Chart ............... 54

5.3.1.1 Study Procedures .............................................................................. 54

5.3.1.2 Collection and Handling of Optional Samples for Exploratory
Research and Validation Studies .............................................................. 71

5.3.1.2.1 Optional Samples for Exploratory Research and Validation
Studies ................................................................................................. 71

5.3.2 Drug Concentration Measurements .................................................... 73

5.3.2.1 Collection of Samples for Analysis .................................................. 73

5.3.2.2 Measurement Methods ................................................................. 73

5.3.3 Efficacy Variables ............................................................................... 74
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.3.3.1</td>
<td>Period 1 Variables ........................................................................</td>
<td>74</td>
</tr>
<tr>
<td>5.3.3.1.1</td>
<td>Primary Variable ...........................................................................</td>
<td>74</td>
</tr>
<tr>
<td>5.3.3.1.2</td>
<td>Key Secondary Variables ..................................................................</td>
<td>74</td>
</tr>
<tr>
<td>5.3.3.1.3</td>
<td>Additional Variables .......................................................................</td>
<td>74</td>
</tr>
<tr>
<td>5.3.3.2</td>
<td>Period 2 Variables ..........................................................................</td>
<td>76</td>
</tr>
<tr>
<td>5.3.4</td>
<td>Safety Variables ............................................................................</td>
<td>77</td>
</tr>
<tr>
<td>5.3.5</td>
<td>Pharmacokinetic Variables ................................................................</td>
<td>77</td>
</tr>
<tr>
<td>5.3.6</td>
<td>Exploratory Research Variables and Validation Studies .......................</td>
<td>77</td>
</tr>
<tr>
<td>5.3.6.1</td>
<td>Exploratory Research Variables and Validation Studies .......................</td>
<td>77</td>
</tr>
<tr>
<td>5.4</td>
<td>Removal of Subjects from Therapy or Assessment ..............................</td>
<td>78</td>
</tr>
<tr>
<td>5.4.1</td>
<td>Discontinuation of Individual Subjects ........................................</td>
<td>78</td>
</tr>
<tr>
<td>5.4.2</td>
<td>Discontinuation of Entire Study ..................................................</td>
<td>80</td>
</tr>
<tr>
<td>5.5</td>
<td>Treatments ....................................................................................</td>
<td>80</td>
</tr>
<tr>
<td>5.5.1</td>
<td>Treatments Administered ...................................................................</td>
<td>80</td>
</tr>
<tr>
<td>5.5.2</td>
<td>Identity of Investigational Product ............................................</td>
<td>82</td>
</tr>
<tr>
<td>5.5.2.1</td>
<td>Packaging and Labeling ...................................................................</td>
<td>83</td>
</tr>
<tr>
<td>5.5.2.2</td>
<td>Storage and Disposition of Study Drugs .........................................</td>
<td>83</td>
</tr>
<tr>
<td>5.5.3</td>
<td>Method of Assigning Subjects to Treatment Groups ............................</td>
<td>84</td>
</tr>
<tr>
<td>5.5.4</td>
<td>Selection and Timing of Dose for Each Subject ................................</td>
<td>85</td>
</tr>
<tr>
<td>5.5.5</td>
<td>Blinding .......................................................................................</td>
<td>86</td>
</tr>
<tr>
<td>5.5.5.1</td>
<td>Blinding of Investigational Product ...........................................</td>
<td>86</td>
</tr>
<tr>
<td>5.5.5.2</td>
<td>Blinding of Data for Independent Data Monitoring Committee (IDMC) ......</td>
<td>87</td>
</tr>
<tr>
<td>5.5.6</td>
<td>Treatment Compliance ....................................................................</td>
<td>87</td>
</tr>
<tr>
<td>5.5.7</td>
<td>Drug Accountability ........................................................................</td>
<td>88</td>
</tr>
<tr>
<td>5.6</td>
<td>Discussion and Justification of Study Design ...................................</td>
<td>89</td>
</tr>
<tr>
<td>5.6.1</td>
<td>Discussion of Study Design and Choice of Control Groups ....................</td>
<td>89</td>
</tr>
<tr>
<td>5.6.2</td>
<td>Appropriateness of Measurements ................................................</td>
<td>90</td>
</tr>
<tr>
<td>5.6.3</td>
<td>Suitability of Subject Population ................................................</td>
<td>90</td>
</tr>
<tr>
<td>5.6.4</td>
<td>Selection of Doses in the Study ....................................................</td>
<td>91</td>
</tr>
<tr>
<td><strong>6.0</strong></td>
<td><strong>Complaints</strong> ..............................................................................</td>
<td><strong>91</strong></td>
</tr>
<tr>
<td>6.1</td>
<td>Medical Complaints .........................................................................</td>
<td>92</td>
</tr>
<tr>
<td>6.1.1</td>
<td>Definitions ...................................................................................</td>
<td>92</td>
</tr>
</tbody>
</table>
### 6.1.1.1 Adverse Event ................................................................. 92
### 6.1.1.2 Serious Adverse Events .................................................. 93
### 6.1.1.3 Adverse Events of Special Interest ................................. 94
### 6.1.2 Adverse Event Severity .................................................... 95
### 6.1.3 Relationship to Study Drug ............................................... 95
### 6.1.4 Adverse Event Collection Period ....................................... 96
### 6.1.5 Adverse Event Reporting .................................................. 97
### 6.1.6 Pregnancy ......................................................................... 98
### 6.1.7 Toxicity Management ........................................................ 99
### 6.1.8 Data Monitoring Committee .............................................. 105
### 6.1.9 Cardiovascular Adjudication Committee .............................. 105
### 6.2 Product Complaint .............................................................. 105
### 6.2.1 Definition .......................................................................... 105
### 6.2.2 Reporting .......................................................................... 106

## 7.0 Protocol Deviations ............................................................... 106

### 8.0 Statistical Methods and Determination of Sample Size .......... 107

#### 8.1 Statistical and Analytical Plans ............................................ 107
#### 8.1.1 Analysis Populations ......................................................... 108
#### 8.1.1.1 Full Analysis Set ......................................................... 108
#### 8.1.1.2 Per Protocol Analysis Set ............................................. 108
#### 8.1.1.3 Safety Analysis Set ...................................................... 108
#### 8.1.2 Subject Accountability, Disposition and Study Drug Exposure ............................................. 109
#### 8.1.2.1 Subject Accountability ................................................ 109
#### 8.1.2.2 Subject Disposition ....................................................... 109
#### 8.1.2.3 Study Drug Exposure .................................................. 109
#### 8.1.3 Analysis of Demographic and Baseline Characteristics .......... 110
#### 8.1.4 Efficacy Analyses ............................................................. 110
#### 8.1.4.1 Efficacy Analysis for Period 1 ......................................... 110
#### 8.1.4.1.1 Primary Efficacy Variable ............................................ 110
#### 8.1.4.1.2 Key Secondary Efficacy Variables ............................... 111
#### 8.1.4.1.3 Other Efficacy Variables ............................................ 112
#### 8.1.4.1.4 Multiplicity Control for Primary and Key Secondary Endpoints ........ 112
8.1.4.1.5 Imputation Methods ............................................................................ 112
8.1.4.2 Long-Term Efficacy Analysis for Period 1 and Period 2
     Combined .................................................................................................... 113
8.1.5 Safety Analyses ..................................................................................... 113
8.1.5.1 General Considerations ........................................................................ 113
8.1.5.2 Analysis of Adverse Events .................................................................... 114
8.1.5.2.1 Treatment-Emergent Adverse Events (TEAE) .................................. 114
8.1.5.2.2 Serious Adverse Events and Death .................................................... 115
8.1.5.3 Analysis of Laboratory, Vital Sign, and ECG Data .............................. 115
8.1.6 Pharmacokinetic and Exposure-Response Analyses............................. 116
8.1.7 Statistical Analysis of Biomarker Data ................................................ 118
8.2 Determination of Sample Size .................................................................... 118
8.3 Randomization Methods ............................................................................ 119
9.0 Ethics ......................................................................................................... 119
9.1 Independent Ethics Committee (IEC) or Institutional Review
     Board (IRB) ............................................................................................... 119
9.2 Ethical Conduct of the Study ...................................................................... 120
9.3 Subject Information and Consent .............................................................. 120
10.0 Source Documents and Case Report Form Completion .................................. 121
10.1 Source Documents .................................................................................... 121
10.2 Case Report Forms ................................................................................ 122
11.0 Data Quality Assurance .......................................................................... 124
12.0 Use of Information .................................................................................. 125
13.0 Completion of the Study .......................................................................... 126
14.0 Investigator's Agreement .......................................................................... 127
15.0 Reference List .......................................................................................... 128

List of Tables

Table 1. Examples of Commonly Used Strong CYP3A Inhibitors and
         Inducers ................................................................................................... 47
Table 2. Clinical Laboratory Tests .................................................................. 67
Appendix Q. Work Productivity and Activity Impairment Questionnaire: Rheumatoid arthritis V2.0 (WPAI:RA) ................................................................. 169
Appendix R. Rheumatology Common Toxicity Criteria v.2.0 Example ..................... 172
Appendix S. Protocol Amendment: List of Changes .................................................... 184
3.0 Introduction

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown etiology. The hallmark feature of RA is an inflammatory process manifested by persistent symmetric polyarthritis of synovial joints which can ultimately lead to bone erosions, deformity, and disability. Left untreated, or inadequately treated, progressive functional impairment with increasing disability occurs leading to a reduction in quality of life. The prevalence of RA in the general population is approximately 1%, and increases with age in both genders, with women being more prone to developing RA than men. Early therapy with disease-modifying anti-rheumatic drugs (DMARDs) is the standard of care, including conventional synthetic DMARDs (csDMARDs) (e.g., methotrexate [MTX], sulfasalazine, hydroxychloroquine, and leflunomide), and biologic DMARDs (bDMARDs) (e.g., anti-tumor necrosis factor [TNF] and non-anti-TNF biologics).

The European League Against Rheumatism (EULAR) recommends a Treat-to-Target (T2T) approach to initiate therapy immediately after diagnosis of RA with a goal of achieving clinical remission (CR) or low disease activity (LDA), as these are associated with improved long-term outcomes.1-3 Also, in line with recent advances in early diagnosis, new classification criteria have been developed. The 2010 American College of Rheumatology (ACR)/EULAR classification criteria redefined the paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.4

JAK Inhibitor

Evidence suggests that inhibition of Janus kinase (JAK)-mediated pathways is a promising approach for the treatment of patients with this chronic disease.5 AbbVie is developing a small molecule inhibitor of JAK, upadacitinib, that may address the current needs.
The JAK family is composed of 4 family members: JAK1, 2, 3, and Tyrosine kinase 2 (Tyk2). These cytoplasmic tyrosine kinases are associated with membrane cytokine receptors such as common gamma-chain receptors and the glycoprotein 130 transmembrane proteins. Activation of JAK pathways initiates expression of survival factors, cytokines, chemokines, and other molecules that facilitate leukocyte cellular trafficking and cell proliferation which contribute to inflammatory and autoimmune disorders.

Hence, the JAK family has evoked considerable interest in the area of inflammatory diseases leading to the development of various JAK inhibitors with different selectivity profiles against JAK1, JAK2, JAK3, and Tyk2 which have demonstrated efficacy in individuals with RA. Tofacitinib, the first in this class, has been approved in the United States and in other countries for treating moderately to severely active RA patients. Although tofacitinib, a non-selective JAK inhibitor, improves the clinical signs and symptoms, and inhibits structural progression in RA patients, questions regarding the safety profile remain, including serious infections, herpes zoster reactivation, malignancies, and hematologic adverse events (AEs).

The second generation of JAK inhibitors, with different selectivity profiles against JAK1, JAK2, JAK3, and Tyk2, are in development. Upadacitinib is a novel selective JAK1 inhibitor being developed for the treatment of adult patients with moderately to severely active RA. In an in vitro setting, upadacitinib potently inhibits JAK1 activity, but to a lesser degree, inhibits the other isoforms, JAK2 and JAK3. The enhanced selectivity of upadacitinib against JAK1 may offer an improved benefit-risk profile in patients with RA. The clinical hypothesis is that upadacitinib should be effective in decreasing joint inflammation and damage associated with RA by interfering with JAK1-mediated signaling pathways (i.e., interleukin-6) without causing excessive anemia due to its reduced activity against JAK2 (IC_{50} 120 nM), which is essential for erythropoietin signaling. Upadacitinib is also less potent against JAK3 (IC_{50} 2.3 μM), an important component of lymphocyte activation and function. As such, treatment with upadacitinib, a selective JAK1 inhibitor with reduced JAK3 inhibition, could result in a decreased risk
for infection (including viral reactivation) and/or malignancy compared to a pan JAK
inhibitor or less selective JAK inhibitors.

In vitro studies suggest that upadacitinib is not an inhibitor of cytochrome P450 (CYP)
1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 at concentrations exceeding those relevant
clinically. Upadacitinib increased mRNA expression for CYP3A4 and CYP2B6 in vitro
in a concentration-dependent manner. However, physiologically-based pharmacokinetic
modeling suggests that upadacitinib does not affect plasma concentrations of concomitant
medications that are substrates for CYP3A or CYP2B6 at the relevant clinical doses.

Among subjects with laboratory evidence of systemic inflammation (as evidenced by
high-sensitivity C-reactive protein [hsCRP] > upper limit of normal [ULN]), treatment
with lower doses of upadacitinib (3 mg twice daily (BID) and 6 mg BID) was associated
with improvements in mean hemoglobin relative to placebo. At higher doses, there was a
reduction in mean hemoglobin; however, the mean hemoglobin levels remained within
normal range throughout the treatment period.

3.1 Differences Statement

Study M15-925 differs from other upadacitinib studies as it is the first study to evaluate
the safety and efficacy of upadacitinib vs. abatacept in subjects with inadequate response
to or intolerance to bDMARD treatment.

3.2 Benefits and Risks

Despite major progress in the treatment of RA, there still remains a large unmet medical
need, as only a small percentage of RA patients reach or maintain a status of LDA or CR
over time and some patients need to discontinue due to safety or tolerability issues.
Novel therapies are therefore needed to complement the available interventions to address
the unmet need.

The dose of upadacitinib selected for the Study M15-925 (once-daily formulation 15 mg
QD) was chosen based on an optimal benefit to risk profile from the first two Phase 3
studies from the RA program: Study M13-549 (csDMARD-IR) and Study M13-542 (bDMARD-IR). The data from these studies showed that both the 15 mg and 30 mg QD doses achieved superior responses to placebo for all primary and ranked secondary endpoints at Week 12 with a safety profile consistent with the known profile from Phase 2b studies (Studies M13-537 [MTX-IR: methotrexate inadequate responder] and M13-550 [TNF IR: anti-tumor necrosis factor inadequate responder].

Benefits

Efficacy Results from Phase 2 Studies with Upadacitinib

Data on the benefit of treatment with upadacitinib are available from Phase 2. The Phase 2 program for upadacitinib consisted of 2 randomized controlled trials (RCTs), both on stable background MTX therapy, in subjects with moderately to severely active RA and one open-label extension (OLE) study (Study M13-538; NCT02049138) for those subjects who had completed either one of the RCTs. Study M13-550 (NCT01960855) enrolled subjects who had an inadequate response to anti-TNF therapy and Study M13-537 (NCT02066389) enrolled subjects who had shown an inadequate response to MTX. A total of 4 twice daily (BID) and 1 once daily (QD) dose regimens of upadacitinib immediate release capsules (3 mg BID, 6 mg BID, 12 mg BID, 18 mg BID, and 24 mg QD) were evaluated.

In TNF-inadequate responder (TNF-IR) subjects, who represent the population with the greatest unmet need, the primary endpoint of ACR20 response rate at Week 12 was significantly greater at all doses of upadacitinib (up to 73%) compared with placebo (35%). In addition, numerically higher proportions of subjects achieved ACR50 and ACR70 responses and LDA (based on Disease Activity Score [DAS]28 C-Reactive Protein [CRP] and Clinical Disease Activity Index [CDAI]) in the upadacitinib dose groups versus placebo.

In MTX-inadequate responder (MTX-IR) subjects, the primary endpoint of ACR20 response rate at Week 12 was significantly greater (up to 82%) at all but the lowest dose
of upadacitinib compared with placebo (50%). At all doses of upadacitinib compared to placebo, significantly higher proportions of subjects achieved LDA and CR at Week 12.

**Risks**

The results of all genetic toxicology testing indicate that upadacitinib is not genotoxic.

Embryonic and Fetal Development studies were conducted to determine the developmental toxicity, including the teratogenic potential and toxicokinetics, of upadacitinib when administered to pregnant animals during the period of organogenesis. Results of these studies indicate that upadacitinib is teratogenic in both rats and rabbits. upadacitinib administration was associated with skeletal malformations in rats at all doses in the absence of maternal toxicity and cardiac malformations in rabbits concurrent with maternal toxicity (only at the high dose of 25 mg/kg/day). Based on these findings, all women of childbearing potential must agree to use protocol-specified pregnancy avoidance measures as outlined in the protocols.

Safety data from the two Phase 2 RCTs described above (N = 575) showed that the types and frequencies of AEs during upadacitinib treatment were consistent with subjects with moderately to severely active RA receiving immunomodulatory therapy. The incidences of AEs were numerically higher in the upadacitinib dose groups, with a trend toward higher rates with higher doses of upadacitinib. The most frequently reported AEs (≥ 5%) in the upadacitinib treated subjects were urinary tract infection, headache, upper respiratory tract infection, and nausea. There were 6 subjects (1.3% of total combined populations) with herpes zoster reactivation distributed across the upadacitinib dose groups, and 2 subjects (1.9%) in the placebo groups. In these two 12 week studies, a total of 2 subjects in the upadacitinib treatment groups reported malignancies. One subject reported non-melanoma skin cancers (NMSC) (basal cell and squamous cell carcinoma) and 1 subject was diagnosed with lung cancer 11 days after the final scheduled visit, and subsequently died 14 weeks after study completion. These events were reported by the Investigators as not possibly related to study drug. No events of gastrointestinal perforation were reported. Elevations of liver function tests were sporadic with no clear
dose response relationship observed. As observed with other JAK inhibitors, treatment with upadacitinib resulted in an increase in lipids (low-density lipoprotein cholesterol [LDL-C] and high density lipoprotein cholesterol [HDL-C]). There was a trend for lower red blood cell counts especially at the 2 highest doses (12 mg BID and 18 mg BID), lower white blood cell counts and reductions in Natural Killer (NK) cells.

The Phase 2 program with upadacitinib demonstrated efficacy for improvement in signs and symptoms of RA and the safety results were consistent with those known to be associated with JAK inhibition.\textsuperscript{13-21} Taken together, the safety and efficacy data from the Phase 2 program show a favorable benefit:risk profile for upadacitinib that supports further development of upadacitinib in Phase 3 in subjects with RA.

Many adverse events (AEs) (serious infections, herpes zoster reactivation, malignancies, and hematologic AEs) observed with pan-JAK inhibition are thought to be a consequence of lack of selectivity against the members of the JAK family of proteins. Upadacitinib is a novel selective JAK1 inhibitor with the ability to decrease inflammation mediated by JAK1 signaling while having less inhibitory effects on JAK2 and JAK3. This could potentially minimize some of the reported safety concerns with non-selective JAK inhibition which are thought to be mediated by inhibition of JAK2 and JAK3 signaling pathways.

The safety profile specific to upadacitinib is evolving with safety results to date consistent with those known to be associated with JAK inhibition. AEs in the categories of infection such as urinary tract infection, upper respiratory tract infection and herpes zoster reactivation have been reported as well as AEs in the categories of malignancies, and gastrointestinal disorders such as gastrointestinal perforation.

In addition, laboratory changes observed with upadacitinib include elevations of serum transaminases, lipids, creatinine and creatine phosphokinase; both increased and reduced hemoglobin, depending on baseline inflammatory burden; and reductions in white blood cell counts, including Natural Killer (NK) cells.
The results of all genetic toxicology testing indicate that upadacitinib is not genotoxic, however upadacitinib may be teratogenic, which necessitates avoidance of pregnancy in women of childbearing potential.

A detailed discussion of the pre-clinical and clinical toxicology, metabolism, pharmacology and safety experience with upadacitinib can be found in the current Investigator's Brochure.

Taken together, the safety and efficacy data from upadacitinib studies to date show a favorable benefit:risk profile for upadacitinib in the treatment of various autoimmune/inflammatory disorders and support the continued investigation of upadacitinib in patients with autoimmune/inflammatory conditions.

4.0 Study Objectives

Period 1

To compare the safety and efficacy of upadacitinib 15 mg QD versus abatacept on a background of csDMARD(s) for the treatment of signs and symptoms of RA in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA who have never received abatacept.

Period 2

To evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.

5.0 Investigational Plan

5.1 Overall Study Design and Plan: Description

This is a Phase 3, multicenter study that includes two periods. Period 1 is the 24-week randomized, double-blind, parallel-group, active-controlled treatment period designed to compare the safety and efficacy of upadacitinib 15 mg versus abatacept for the treatment
of signs and symptoms of subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapy and are currently on a stable dose of csDMARDs and have never received abatacept. Period 2 is an open-label long-term extension to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.

The study is designed to enroll approximately 550 subjects at approximately 200 study centers worldwide to meet scientific and regulatory objectives without enrolling an undue number of subjects in alignment with ethical considerations. Therefore, if the target number of subjects has been enrolled, there is a possibility that additional subjects in screening may not be enrolled.

The study duration will include a 35-day screening period; a 24-week randomized, double-blind, parallel-group, active controlled treatment period with 30 and 70 day follow-ups (Period 1); an open-label extension period of up to 5 years with a 30-day follow-up call or site visit (Period 2).

Subjects who meet eligibility criteria will be randomized in a 1:1 ratio to one of two treatment groups:

- **Group 1:** upadacitinib 15 mg QD, N = 275 (Period 1)
- **Group 2:** Abatacept IV at Day 1, Weeks 2, 4, 8, 12, 16 and 20 [< 60 kg: 500 mg; 60 – 100 kg: 750 mg; > 100 kg: 1,000 mg, N = 275 (Period 1)]

NOTE: In Period 1, subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose. This study began enrolling under Amendment 3. Starting with Amendment 4, subjects randomized to Group 1 will receive 15 mg QD dose. In Period 2, subjects who enrolled under Amendment 3, including subjects randomized to both Group 1 and Group 2, will continue to receive open-label upadacitinib 30 mg QD. Subjects who enroll under Amendment 4 or later will receive open-label upadacitinib 15 mg QD. Subjects enrolled under Amendment 3 will follow the requirements and study procedures specified in Amendment 3.
Subjects must have been on a stable dose of csDMARD(s) for ≥ 4 weeks prior to the first dose of study drug and must remain on a stable dose until Week 12; the csDMARD dose may be decreased only for safety reasons. Starting at Week 12, subjects who do not achieve ≥ 20% improvement in both TJC and SJC at two consecutive visits will be rescued with optimizing (initiate or increase) background RA medications: NSAIDs, corticosteroids, low-potency analgesics, acetaminophen, or adding or increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of MTX and leflunomide), and, if necessary, a burst of systemic corticosteroids (prednisone equivalent ≤ 0.5 mg/kg/day for 3 consecutive days), intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of corticosteroids, dosage and frequency per standard of care, are allowed as per local label.

Subjects who complete the Week 24 visit (end of Period 1) will enter the open-label long-term extension portion of the study, Period 2 (up to 5 years). Subjects who are assigned to upadacitinib in Period 1 will continue to receive upadacitinib 15 mg QD per original randomization assignment in an open-label manner. Subjects who are assigned to abatacept for 24 weeks of Period 1 will be switched to receive upadacitinib 15 mg QD in Period 2.

An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24) for the purpose of regulatory submission.

Study design schematics of Period 1 and Period 2 are shown in Figure 1 and Figure 2, respectively.
**Figure 1. Period 1 Study Design**

<table>
<thead>
<tr>
<th>Screening Period (Up to 35 days)</th>
<th>PERIOD 1: 24-Week, Randomized, Double-Blind, Treatment Period</th>
<th>Follow-Up Period (≠ 30 days and 70 days)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults with moderately to severely active RA who have had an inadequate response to biologic DMARD(s) AND have never received abatacept IV</td>
<td>All subjects on background csDMARD(s)</td>
<td></td>
</tr>
</tbody>
</table>
| Randomization 1:1 | Group 1: Upadacitinib 15 MG QD**  
*n=275* | Group 2: Abatacept IV  
*n=275* |
| W12 |  |  |
| Baseline |  |  |
| W24 |  |  |

csDMARD = conventional synthetic disease modifying anti-rheumatic drug; DMARD = disease modifying anti-rheumatic drug; n = number; QD = once daily; RA = rheumatoid arthritis; W = week

* The follow-up period is only for subjects who do not enter Period 2.

** Subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose. Starting with Amendment 4, subjects randomized to Group 1 will receive 15 mg QD dose.
Figure 2. Period 2 Study Design

<table>
<thead>
<tr>
<th>End of Period 1</th>
<th>PERIOD 2: Open-Label Extension Period (± 5 years)</th>
<th>Follow-Up Period (± 30 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Group 1: Upadacitinib 15 mg QD*  
Group 2: Abatacept IV  
Upadacitinib 15 mg QD*  
Upadacitinib 15 mg QD*  
W24  
W28  
W32  
W36  
(and every 12 weeks)

QD = once daily; W = week
* Subjects who enrolled under Amendment 3, including subjects on both upadacitinib and abatacept will continue to receive open-label upadacitinib 30 mg QD. Subjects who enroll under Amendment 4 or later will receive open-label upadacitinib 15 mg QD.

Screening Period

Within 35 days prior to the Baseline Visit, subjects will receive a full explanation of the study design and study procedures, provide a written informed consent, and undergo the screening procedures outlined in Appendix D. Lab values can be re-tested once during the screening period. If the re-tested lab value(s) remain(s) exclusionary, the subject will be considered a screen failure with no additional re-screening possible. Redrawing samples if previous samples were unable to be analyzed would not count as a retest since previous result was never obtained.

Subjects that initially screen fail for the study are permitted to re-screen once following re-consent. Lab values can be re-tested once during the rescreening period. For
additional re-screenings, AbbVie Therapeutic Area Medical Director approval is required. All screening procedures with the possible exceptions noted below will be repeated during re-screening. The subject must meet all the inclusion and none of the exclusion criteria at the time of re-screening in order to qualify for the study. There is no minimum period of time a subject must wait to re-screen for the study. If the subject had a complete initial screening evaluation including the assessment of an Interferon-Gamma Release Assay (IGRA; QuantiFERON Tuberculosis [TB] Gold In Tube test) and/or a purified protein derivative (PPD) test (or equivalent) (or both if required per local guidelines), or chest x-ray and electrocardiogram (ECG), these tests will not be required to be repeated for re-screening provided the conditions noted in Section 5.2 are met, there are no changes in the subject's medical history that would warrant re-testing, and no more than 90 days have passed.

**Period 1 (24-Week Randomized, Double-Blind Treatment Period)**

Period 1 will begin at the Baseline Visit (Day 1) and will end at the Week 24 Visit. At the Baseline Visit, subjects who meet all the inclusion criteria and none of the exclusion criteria described in Section 5.2.1 and Section 5.2.2 will be enrolled into the study and randomized to double-blind treatment. During this period of the study, subjects will visit the study site at Weeks 2, 4, 8, 12, 16, 20 and 24. A ± 3 day window is permitted around scheduled study visits. The last dose of oral study drug in Period 1 is taken the day prior to the Week 24 visit, and the last dose of intravenous study drug in Period 1 is infused at the Week 20 visit. Subjects who complete Period 1, but decide not to continue in Period 2 should complete the 30 and 70 day follow-up visits after the last dose of study drug.

- Starting at Week 12 subjects who do not achieve ≥ 20% improvement in both TJC and SJC at two consecutive visits should have background medication(s) adjusted or initiated (see below).
- Starting at Week 12, subjects who demonstrate worsening of joint count (SJC or TJC) from baseline at 2 consecutive visits should be discontinued from study drug and treated with standard of care at the discretion of the clinician.
Period 2 (Open Label Long-Term Extension Period [up to 5 Years])

- Period 2 will begin at the Week 24 Visit after all assessments have been completed. During Period 2, subjects will have a study visit at Weeks 28, 32, 36, 48, and every 12 weeks thereafter until completion of the study. A ± 7 day window is permitted around scheduled study visits.

- As was started at Week 12, subjects who demonstrate worsening of joint count (SJC or TJC) from baseline at 2 consecutive visits should be discontinued from study drug and treated according to standard of care and at the discretion of the clinician.

- Starting at Week 28 and thereafter, subjects who fail to achieve ≥ 20% improvement in both TJC and SJC from baseline at two consecutive visits, despite optimization of background RA therapies (see Section 5.2.3.1 for permitted background RA therapies) should be discontinued from study drug and treated according to standard of care and at the discretion of the clinician.

- Starting at Week 28 and thereafter, subjects who achieve ≥ 20% improvement in both TJC and SJC from baseline, but fail to achieve CDAI ≤ 10 at two consecutive visits, should be given the option (at the discretion of their physician) either to continue or discontinue study drug and be treated according to standard of care and at the discretion of the clinician.

Discontinuation of Study Drug and Continuation of Study Participation Period 1 and Period 2)

Subjects may discontinue study drug treatment but may choose to continue to participate in the study (refer to Section 5.4.1 for additional details). Subjects who prematurely discontinue study drug should complete a Premature Discontinuation (PD) visit as soon as possible, preferably within 2 weeks. Afterwards, subjects should follow the regular visit schedule as outlined in Appendix D and Appendix F, and adhere to all study procedures except for dispensing study drug and pharmacokinetic (PK) sample collection, and blood sample collection for optional exploratory research and validation studies. As the subject has discontinued study drug, all rescue- and efficacy-driven discontinuation criteria no longer apply. This includes the 20% TJC/SJC calculations at Week 12 and visits.
thereafter, as well as the CDAI calculation at Week 28, if applicable. If at any point a subject no longer wants to provide assessments (withdrawal of informed consent) following discontinuation of study drug, a second PD visit is not required.

**Premature Discontinuation of Study (Withdrawal of Informed Consent) (Period 1 and Period 2)**

Subjects may withdraw from the study completely (withdrawal of informed consent) for any reason at any time (refer to Section 5.4.1 for additional details). If a subject prematurely discontinues study drug treatment and study participation (withdrawal of informed consent), the procedures outlined for the Premature Discontinuation visit (PD visit) should be completed as soon as possible, preferably within 2 weeks of study drug discontinuation. In addition, if the subject is willing, a 30-day and a 70-day follow-up visit (or phone call if a visit is not possible) may occur in Period 1, and a 30-day follow-up visit (or phone call if a visit is not possible) may occur in Period 2, to determine the status of any ongoing adverse events/serious adverse events (AEs/SAEs) or the occurrence of any new AEs/SAEs.

**Follow-Up Visit**

Follow-Up Visits will occur approximately 30 days and 70 days after the last dose of study drug in Period 1 and will occur approximately 30 days after the last dose of study drug in Period 2, to obtain information on any new or ongoing AE/SAEs, and to collect vital signs and clinical laboratory tests.

Subjects will complete the Follow-Up Visit when they have either

- Completed the last visit of Period 1 (Week 24), but decided not to participate in the extension Period 2; OR
- Completed the last visit of Period 2; OR
- Prematurely discontinued study drug and study participation. This visit may be a telephone call if a site visit is not possible. Vital signs and laboratory test may not be required. The Follow-Up visit is not applicable for subjects who discontinued study drug and continued study participation and completed at
least one study visit at least approximately 70 days after the last dose of study drug in Period 1 and 30 days after the last dose of study drug in Period 2.

5.2 Selection of Study Population

It is anticipated that approximately 550 subjects with moderately to severely active RA will be randomized at approximately 200 study centers, globally.

A subject may be enrolled in this study provided that he/she has met all of the inclusion criteria specified in Section 5.2.1 and none of the exclusion criteria specified in Section 5.2.2 of this protocol.

5.2.1 Inclusion Criteria

1. Adult male or female, at least 18 years old.

2. Diagnosis of RA for $\geq 3$ months who also fulfill the 2010 ACR/EULAR classification criteria for RA.

3. Subjects have been treated for $\geq 3$ months prior to the screening visit with $\geq 1$ bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration AND have never received abatacept prior to first dose of study drug.

4. Subjects have been receiving csDMARD therapy $\geq 3$ months and on a stable dose for $\geq 4$ weeks prior to the first dose of study drug.
   - The following csDMARDs are allowed (stable dose for $\geq 4$ weeks prior to the first dose of study drug): oral or parenteral MTX (7.5 to 25 mg/week), sulfasalazine (≤ 3000 mg/day), hydroxychloroquine (≤ 400 mg/day), chloroquine (≤ 250 mg/day), and leflunomide (≤ 20 mg/day).
   - A combination of up to two background csDMARDs is allowed EXCEPT the combination of MTX and leflunomide.

5. Subject meets both of the following disease activity criteria:
a. ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits; and
b. hsCRP ≥ 3 mg/L (central lab) at Screening Visit.

6. Stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen/paracetamol must have been at a stable dose ≥ 1 week prior to the first dose of study drug; oral corticosteroids (equivalent to prednisone ≤ 10 mg/day) or inhaled corticosteroids for stable medical conditions are allowed but must have been at a stable dose ≥ 4 weeks prior to the first dose of study drug.

7. Subjects must have discontinued all bDMARDs prior to the first dose of study drug. The washout period for bDMARDs prior to the first dose of study drug is specified below or should be at least five times the mean terminal elimination half-life of a drug:
   - ≥ 4 weeks for etanercept;
   - ≥ 8 weeks for adalimumab, infliximab, certolizumab, golimumab, and tocilizumab;
   - ≥ 1 year for rituximab OR ≥ 6 months if B cells have returned to pretreatment level or normal reference range (central lab) if pretreatment levels are not available.

8. Subjects must have discontinued all high-potency opiates at least 1 week and oral traditional Chinese medicine for at least 4 weeks prior to the first dose of study drug (refer to Section 5.2.3.2 for prohibited medications).

9. Women of childbearing potential (refer to Section 5.2.4), must not have a positive serum pregnancy test at the Screening Visit and must have a negative urine pregnancy test at the Baseline Visit prior to study drug dosing.

   Note: Subjects with borderline serum pregnancy tests at Screening must have a serum pregnancy test ≥ 3 days later to document continued lack of a positive result.

10. If female, subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential practicing at least one protocol
specified method of birth control (refer to Section 5.2.4), that is effective from Study Day 1 through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

- Additional local requirements may apply. Refer to Appendix C for local requirements

11. If male, and subject is sexually active with female partner(s) of childbearing potential, he must agree, from Study Day 1 through 30 days after the last dose of study drug, to practice the protocol-specified contraception (refer to Section 5.2.4)

- Additional local requirements may apply. Refer to Appendix C for local requirements.

12. Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Rationale for Inclusion Criteria

1 – 8 To select the appropriate subject population

9 – 11 Upadacitinib is teratogenic in both rats and rabbits. The effect of upadacitinib on human pregnancy and reproduction is unknown

12 In accordance with harmonized Good Clinical Practice (GCP)

5.2.2 Exclusion Criteria

1. Prior exposure to any JAK inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib).

2. Prior exposure to abatacept.

3. History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive
arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms], or any arthritis with onset prior to age 17 years). Current diagnosis of secondary Sjogren's Syndrome is permitted.

4. Has been treated with intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, or intra-tendon sheath corticosteroids in the preceding 8 weeks prior to the first dose of study drug.

5. Has been treated with any investigational drug within 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.

6. Female who is pregnant, breastfeeding, or is considering becoming pregnant during the study or for approximately 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

7. Male who is considering fathering a child or donating sperm during the study or for approximately 30 days after the last dose of study drug.

8. Any active, chronic or recurrent viral infection that, based on the Investigator's clinical assessment, makes the subject an unsuitable candidate for the study, including hepatitis B virus (HBV) or hepatitis C virus (HCV), recurrent or disseminated (even a single episode) herpes zoster, disseminated (even a single episode) herpes simplex, or human immunodeficiency virus (HIV). Active HBV, HCV and HIV are defined as:
   - HBV: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for Hepatitis B core antibody (HBc Ab) positive (+) subjects;
   - HCV: HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody (HCV Ab).
   - HIV: confirmed positive anti-HIV antibody (HIV Ab) test.

9. Subject has active TB or meets TB exclusionary parameters (refer to Section 5.3.1.1 for specific requirements for TB testing).
10. Systemic use of known strong cytochrome P450 (CYP)3A inhibitors or strong CYP3A inducers from Screening through the end of the study (refer to Table 1 for examples of commonly used strong CYP3A inhibitors and inducers).

11. Receipt of any live vaccine within 4 weeks prior to the first dose of study drug, or expected need of live vaccination during study participation including at least 12 weeks after the last dose of IV study drug and 4 weeks after the last dose of oral study drug.

12. History of any malignancy except for successfully treated NMSC or localized carcinoma in situ of the cervix.

13. History of clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months.

14. History of gastrointestinal perforation (other than appendicitis or penetrating injury), diverticulitis or significantly increased risk for GI perforation per investigator judgement.

15. Conditions that could interfere with drug absorption including but not limited to short bowel syndrome.

16. Subject has been a previous recipient of an organ transplant.

17. History of clinically significant medical conditions or any other reason that in the opinion of the Investigator would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug.

18. Active infection(s) requiring treatment with parenteral anti-infectives within 30 days, or oral anti-infectives within 14 days prior to the first dose of study drug.

19. History of an allergic reaction or significant sensitivity to constituents of the study drugs (and its excipients) and/or other products in the same class.

20. Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug:
   - Serum aspartate transaminase (AST) $> 2 \times$ ULN;
• Serum alanine transaminase (ALT) > 2 × ULN;
• Estimated glomerular filtration rate (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula < 40 mL/min/1.73 m²;
• Total white blood cell (WBC) count < 2,500/μL;
• Absolute neutrophil count (ANC) < 1,500/μL;
• Platelet count < 100,000/μL;
• Absolute lymphocyte count < 800/μL;
• Hemoglobin < 10 g/dL.

21. History of any of the following cardiovascular conditions:
• Moderate to severe congestive heart failure (New York Heart Association class III or IV)
• Recent history (within past 6 months) cerebrovascular accident (CVA), myocardial infarction, coronary stenting
• Uncontrolled hypertension as defined by a persistent systolic blood pressure (BP) > 160 mmHg or diastolic BP > 100 mmHg. For subjects with known hypertension, the subject's BP must be stable for at least 4 weeks on current, stable anti-hypertensive medications
• Any other condition which, in the opinion of the Investigator, would put the subject at risk by participating in the protocol.

22. Clinically relevant or significant ECG abnormalities, including ECG with QT interval corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) > 500 msec. The QTcF criterion does not apply in patients with a pacemaker or any conduction abnormality such as bundle branch block.

**Rationale for Exclusion Criteria**

1 – 4 To select the appropriate subject population
6, 7 Upadacitinib is teratogenic in both rats and rabbits. The impact of upadacitinib on human pregnancies is unknown
5, 8 – 22 To ensure safety of the subjects throughout the study
5.2.3 **Prior, Concomitant, and Prohibited Therapy**

Any medication or vaccine (including over-the-counter or prescription medicines, vitamins and/or herbal supplements including folic acid) that the subject is receiving within 28 days prior to Screening, or receives during the study, must be recorded along with the reason for use, date(s) of administration including start and end dates, and dosage information including dose, route, and frequency on the appropriate electronic case report form (eCRF). Also, medications including but not limited to DMARDs taken for RA since date of RA diagnosis (based on subject recollection and available medical records) should be entered into the appropriate eCRF.

The AbbVie Therapeutic Area Medical Director should be contacted if there are any questions regarding concomitant or prior therapies.

5.2.3.1 **Permitted Background RA Therapy**

Subjects should continue on their stable (≥ 4 weeks prior to the first dose of study drug) background csDMARD therapy (restricted to oral or parenteral MTX, [7.5 to 25 mg/week;], sulfasalazine [≤ 3000 mg/day], hydroxychloroquine, [≤ 400 mg/day], chloroquine [≤ 250 mg/day], and leflunomide [≤ 20 mg/day]) up to Week 32. At any time, the csDMARD dose may be decreased only for safety reasons. Subjects taking MTX should take a dietary supplement of oral folic acid (or equivalent, such as folinic acid) throughout study participation. Folic acid dosing and timing of regimen should be followed according to Investigator's instructions. AbbVie will not provide the csDMARDs (or folic acid, if taking MTX).

Subjects should continue on their stable doses of NSAIDs, acetaminophen/paracetamol, oral corticosteroids (equivalent to prednisone ≤ 10 mg/day), or inhaled corticosteroids.

- If taking any of the above on a scheduled basis, they should continue to take them as they did at study entry with no change in dose or frequency, including on study visit days.
● If not taking any of the above at baseline, these must not be initiated except where permitted by protocol (specific time period or protocol-defined rescue)

● If taking any of the above, including low potency analgesics, i.e., tramadol, codeine, hydrocodone, or propoxyphene at baseline on an as-needed basis (PRN), they should continue to use them for the same reason and same dose each time but they should not be taken within the 24 hours prior to any study visit to avoid bias in outcome measurements.

In the event of tolerability (or other safety) issues, the doses of these medications may be decreased or discontinued with substitution of another permitted medication from that class (see Section 5.2.3.2 for prohibited therapies).

PRN use of inhaled corticosteroids is permitted at any time.

Starting at Week 12 subjects who do not achieve ≥ 20% improvement in both TJC and SJC compared to baseline at two consecutive visits should have background medication(s) adjusted or initiated (see below).

● Initiation of or change in corticosteroids, NSAIDs, acetaminophen or adding or increasing doses in csDMARDs (restricted to oral or parenteral MTX, sulfasalazine, hydroxychloroquine, chloroquine and leflunomide except the combination of MTX and leflunomide; see Inclusion Criterion 4) is allowed as per local label. For RA flare treatment, no more than 3 consecutive days of systemic corticosteroids (maximum dose of 0.5 mg/kg of prednisone or its equivalent) is allowed, after which subject should resume their usual daily oral corticosteroid dose.

● Starting at Week 12 (after Week 12 assessments have been performed) and thereafter, intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of corticosteroids, dosage and frequency per standard of care, are allowed. To avoid confounding effects of systemic absorption of intra-articular corticosteroids, joint injections should be avoided, if possible, within 21 days prior to the next scheduled study visit. For the analysis of the TJC and SJC, injected joints will be considered "not assessable" for 3 months from the time of the intra-articular injection.
5.2.3.2 Prohibited Therapy

**JAK Inhibitor**

Prior exposure to JAK inhibitors (including but not limited to tofacitinib [Xeljanz®], baricitinib, and filgotinib) is not allowed.

**Corticosteroids**

Oral corticosteroids > 10 mg prednisone/day or equivalent and intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath corticosteroids are NOT allowed in Period 1 except as described in Section 5.2.3.1 for treatment of an RA flare.

**Any csDMARD/Immunosuppressive Not Listed in Section 5.2.3.1**

**Biologic Therapies**

All biologic therapies with the exception of blinded abatacept are prohibited during the study (i.e., Periods 1 and 2).

Subjects must have discontinued the bDMARD prior to the first dose of study drug as specified in the washout procedures (Inclusion Criterion 7, Section 5.2.1). For all other bDMARDs, contact the Therapeutic Area Medical Director for the washout period required prior to the first dose of study drug.

Examples of biologic therapies include but are not limited to the following:

- Humira® (adalimumab)
- Enbrel® (etanercept)
- Remicade® (infliximab)
- Kineret® (anakinra)
- Rituxan® (rituximab)
- Cimzia® (certolizumab pegol)
- Simponi® (golimumab)
● Actemra® (tocilizumab)
● Raptiva® (efalizumab)
● Tysabri® (natalizumab)
● Stelara® (ustekinumab)
● Benlysta® (belimumab)

**Strong CYP3A Inhibitors or Inducers**

Systemic use of known strong CYP3A inhibitors or strong CYP3A inducers is excluded from the Screening Visit through the end of the study (i.e., end of Period 2). The most common strong CYP3A inhibitors and inducers are listed in Table 1.

**Table 1. Examples of Commonly Used Strong CYP3A Inhibitors and Inducers**

<table>
<thead>
<tr>
<th>Strong CYP3A Inhibitors</th>
<th>Strong CYP3A Inducers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boceprevir</td>
<td>Carbamazepine</td>
</tr>
<tr>
<td>Cobicistat</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>Rifampin</td>
</tr>
<tr>
<td>Conivaptan</td>
<td>Rifapentine</td>
</tr>
<tr>
<td>Grapefruit (fruit or juice)</td>
<td>St. John's Wort</td>
</tr>
<tr>
<td>Indinavir</td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td></td>
</tr>
<tr>
<td>Lopinavir/Ritonavir</td>
<td></td>
</tr>
<tr>
<td>Mibefradil</td>
<td></td>
</tr>
<tr>
<td>Nefazodone</td>
<td></td>
</tr>
<tr>
<td>Nelfinavir</td>
<td></td>
</tr>
<tr>
<td>Posaconazole</td>
<td></td>
</tr>
<tr>
<td>Ritonavir</td>
<td></td>
</tr>
<tr>
<td>Saquinavir</td>
<td></td>
</tr>
<tr>
<td>Telaprevir</td>
<td></td>
</tr>
<tr>
<td>Telithromycin</td>
<td></td>
</tr>
<tr>
<td>Troleandomycin</td>
<td></td>
</tr>
<tr>
<td>Voriconazole</td>
<td></td>
</tr>
</tbody>
</table>
**Opiates**

High potency opiates are not permitted during the study (i.e., Periods 1 and 2), and subjects must have discontinued high potency opiates at least 1 week prior to the first dose of study drug, including (but not limited to):

- oxycodone
- oxymorphone
- fentanyl
- levorphanol
- buprenorphine
- methadone
- hydromorphone
- morphine
- meperidine

**Investigational Drugs**

Subjects who have been treated with any investigational drug within 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug are excluded from participation in this study. Investigational drugs are also prohibited during the study.

**Vaccines**

Although not mandated by the protocol, vaccines recommended by local guidelines should be considered. If the subject and investigator choose to administer live vaccines, these vaccines must be completed (per local label) 4 weeks before the first dose of study drug with appropriate precautions and is not allowed during study participation including at least 12 weeks after the last dose of IV study drug and at least 4 weeks after last dose of oral study drug.

Examples of live vaccines include, but are not limited to, the following:
● Monovalent live influenza A (H1N1) (intranasal);
● Seasonal trivalent live influenza (intranasal);
● Herpes zoster;
● Rotavirus;
● Varicella (chicken pox);
● Measles-mumps-rubella or measles mumps rubella varicella;
● Oral polio vaccine;
● Smallpox;
● Yellow fever;
● Bacille Calmette-Guérin (BCG);
● Typhoid.

Examples of common vaccines that are inactivated, toxoid or biosynthetic, include but are not limited to: injectable influenza vaccine, pneumococcal and, pertussis (Tdap) vaccines).

**Traditional Chinese Medicine**

Traditional oral Chinese medicine is not permitted during the study as these may interfere with upadacitinib metabolism and exposure and may impact efficacy and safety of upadacitinib treatment. Subjects must have discontinued traditional Chinese medicine at least 4 weeks prior to the first dose of study drug.

**5.2.3.3 Rescue Therapy**

Rescue therapy will be offered to subjects who meet the following criteria from Week 12 to Week 24:

Starting at Week 12 and thereafter, subjects who do not achieve ≥ 20% improvement in both TJC and SJC as compared to baseline at two consecutive visits will be rescued by optimizing (initiate or increase) background RA medications.
• Initiation of or change in csDMARDs (concomitant use of up to 2 csDMARDs except the combination of MTX and leflunomide; see Inclusion Criterion 4) is allowed as per local label.

• Initiation or change in NSAIDs, acetaminophen, corticosteroids, low-potency analgesics, and, if necessary, a burst of systemic corticosteroids (prednisone equivalent \( \leq 0.5 \) mg/kg/day for 3 consecutive days) intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of corticosteroids, dosage and frequency per standard of care, are allowed as per local label.

Starting at Week 12 and thereafter, subjects who demonstrate worsening of joint count (SJC or TJC) from baseline at 2 consecutive visits should be discontinued from study drug and treated according to standard of care and at the discretion of the clinician.

5.2.4 Contraception Recommendations

Contraception Recommendation for Females

A woman who is postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) is not considered to be a woman of childbearing potential and is not required to follow contraception recommendations. Postmenopausal is defined as:

• Age \( \geq 55 \) years with no menses for 12 or more months without an alternative medical cause; or

• Age < 55 years with no menses for 12 or more months without an alternative medical cause AND a follicle stimulating hormone (FSH) level > 40 mIU/mL.

If the female subject is < 55 years of age:

AND has had no menses for \( \geq 12 \) months AND has no history of permanent surgical sterilization (defined above), FSH should be tested at Screening.
If FSH is not tested, it is assumed that the subject is of childbearing potential and protocol-specified contraception is required.

If the FSH is tested and the result is consistent with post-menopausal status, contraception is not required.

If the FSH is tested and the result is consistent with pre-menopausal status, contraception is required, and a serum pregnancy test must be performed (see Section 5.3.1.1, pregnancy test).

For a female subject at any age:

- Female subjects with menses within the past 12 months are of childbearing potential and FSH is therefore not required but contraception is required.
- Female subjects who are surgically sterile (defined above) are not of childbearing potential and therefore no FSH testing or contraception is required.

A woman who does not meet the definition of postmenopausal or permanently surgically sterile is considered of childbearing potential and is required to practice at least one of the following highly effective methods of birth control that is effective from Study Day 1 (or earlier) through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

- Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal, injectable) associated with the inhibition of ovulation, initiated at least 30 days prior to Study Day 1.
- Progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, initiated at least 1 month prior to Study Day 1.
- Bilateral tubal occlusion/ligation.
- Vasectomized partner(s), provided the vasectomized partner verbally confirms receipt of medical assessment of the surgical success, and is the sole sexual partner of the WOCBP trial participant.
- Intrauterine device (IUD).
- Intrauterine hormone-releasing system (IUS).
- True abstinence (if acceptable per local requirements): Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable].

If required per local practices, male or female condom with or without spermicide OR cap, diaphragm or sponge with spermicide should be used in addition to one of the highly effective birth control methods listed above (excluding true abstinence).

If during the course of the study a woman becomes surgically sterile or post-menopausal (defined above) and complete documentation is available, contraceptive measures as defined above are no longer required.

It is important to note that contraception requirements described above are specifically intended to prevent pregnancy during exposure to the investigational therapy upadacitinib. The concomitant csDMARDs (i.e., methotrexate, sulfasalazine, etc.) have been prescribed per standard of care prior to study entry and are allowed to be continued during the study. Contraception should continue while the subject is on the concomitant csDMARD(s) and that duration of contraception after discontinuation of the csDMARD(s) should be based on the local label.

Additional local requirements may apply. Refer to Appendix C for additional local requirements.

**Contraception Recommendation for Males**

Based on data from animal studies (including a fertility study) there is no effect of upadacitinib on male reproduction. The effects of upadacitinib on human male reproduction have not been determined.
For a male subject who is surgically sterile (vasectomy with medical assessment confirming surgical success) OR has a female partner who is postmenopausal or permanently sterile, no contraception is required.

A male subject who is sexually active with female partner(s) of childbearing potential must agree from Study Day 1 through 30 days after the last dose of study drug to practice contraception with:

- Condom use and female partner(s) using at least one of the contraceptive measures as defined in the protocol for female study subjects of childbearing potential. OR
- True abstinence: Refraining from heterosexual intercourse-when this is in line with the preferred and usual lifestyle of the subject. (Note: Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable).

Additionally, male subject agrees not to donate sperm from Study Day 1 through at least 30 days after the last dose of study drug.

Male subjects are responsible for informing his partner(s) of the risk of becoming pregnant and for reporting any pregnancy to the study doctor. If a pregnancy occurs, a partner authorization form requesting pregnancy outcome information will be requested from the pregnant partner.

It is important to note that contraception and sperm donation recommendations described above are specifically intended to prevent pregnancy during and after exposure to the investigational therapy upadacitinib. The concomitant csDMARDs (i.e., methotrexate, sulfasalazine, etc.) have been prescribed per standard of care prior to study entry and are allowed to be continued during the study. Contraception should continue while the subject is on the concomitant csDMARD(s) and that duration of contraception and the requirement not to donate sperm after discontinuation of the csDMARD(s) should be based on the local label.
Additional local requirements may apply. Refer to Appendix C for local requirements.

5.3 Efficacy, Pharmacokinetic, Exploratory Research and Validation Studies, and Safety Assessments/Variables

5.3.1 Efficacy and Safety Measurements Assessed and Flow Chart

Study procedures described are listed in the following section of this protocol and are summarized in tabular format in Appendix D, Appendix E, and Appendix F.

5.3.1.1 Study Procedures

The study procedures outlined in Appendix D and Appendix F are discussed in detail in this section, with the exception of exploratory research and validation studies (discussed in Section 5.3.1.2.1), drug concentration measurements (discussed in Section 5.3.2), the collection of prior and concomitant medication information (discussed in Section 5.2.3), and the collection of AE information (discussed in Section 6.0). All study data will be recorded in source documents and on the appropriate eCRFs.

Informed Consent

At the Screening visit, the subject will sign and date a study specific, IEC/IRB approved, informed consent form for the study (i.e., includes both Periods 1 and 2) before any study procedures are performed or any medications are withheld from the subject in order to participate in this study. Separate written consent will be required for each subject in order to participate in the optional exploratory research and validation studies. The separate written consent may be part of the main consent form. Subjects can withdraw informed consent at any time.

Details regarding how informed consent will be obtained and documented are provided in Section 9.3.
Inclusion/Exclusion Criteria

Subjects will be evaluated to ensure they meet all inclusion criteria and have none of the exclusion criteria at both Screening and Baseline Visits.

Medical and Surgical History

A complete non-RA-related medical and surgical history, including history of alcohol and nicotine use, will be taken from each subject during the Screening Visit. Additionally, a list of each subject's specific RA-related medical and surgical history will be recorded at Screening. History of herpes zoster, herpes zoster vaccination, and hepatitis B vaccination status will be recorded as part of the medical history. An updated medical history will be obtained prior to study drug administration at Baseline, to ensure the subject is still eligible for enrollment.

A detailed medical history with respect to TB risk factors will be documented in the study source documentation. This information will include BCG vaccination, cohabitation with individuals who have had TB, and travel to, residence in, or work in TB endemic locations.

Patient Questionnaires

Subjects will complete the following questionnaires as specified in Appendix D and Appendix F; a validated translation will be provided in their local language, as applicable:

Period 1

- Patient's Global Assessment of Disease Activity Visual Analog Scale (VAS) (Appendix J)
- Patient's Assessment of Pain VAS (Appendix K)
- Health Assessment Questionnaire – Disability Index (HAQ-DI) to assess the physical function and health-related quality of life of each subject (Appendix L)
● Patient's Assessment of Severity and Duration of Morning Stiffness NRS (Appendix M)
● EuroQoL-5D-5L (EQ-5D-5L) (Appendix N)
● Short Form-36 (SF-36) (Appendix O)
● FACIT-F (Appendix P)
● WPAI RA (Appendix Q)

**Period 2**

● Patient's Global Assessment of Disease Activity VAS (Appendix J)
● Patient's Assessment of Pain VAS (Appendix K)
● HAQ-DI to assess the physical function and health-related quality of life of each subject (Appendix L)
● Morning Stiffness Rating Scale (NRS) (Appendix M)
● EQ-5D-5L (Appendix N)
● SF-36 (Appendix O)
● FACIT-F (Appendix P)
● WPAI RA (Appendix Q)

All patient-reported outcomes (PROs) collected electronically.

The subject should complete the questionnaires before site personnel perform any clinical assessments and before any interaction with site personnel has occurred to avoid biasing the subject's response.

**TB Testing/TB Prophylaxis**

The TB screening tests are diagnostic test results to be interpreted in the context of the subject's epidemiology, history, exam findings, etc., and it is the responsibility of the Investigator to determine if a subject has previous, active, or latent TB. Expert consultation for the evaluation and/or management of TB may be considered per Investigator discretion.
At screening, all subjects will be assessed for evidence of increased risk for TB by a risk assessment form (Appendix I) and tested for TB infection by QuantiFERON-TB Gold test. The PPD Skin Test should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless both tests are required per local guidelines). The site staff will complete the TB risk assessment form and enter the data into an appropriate eCRF. TB risk assessment form will be completed annually for all subjects, regardless of TB test results.

If a subject had a negative QuantiFERON-TB Gold (and/or PPD) test (or IGRA equivalent such as T-SPOT TB test) within 90 days prior to Screening and source documentation is available, the test does not need to be repeated, provided nothing has changed in the subject's medical history to warrant a repeat test. These cases may be discussed with the AbbVie Therapeutic Area Medical Director. The results of the TB test(s) will be retained at the site as the original source documentation.

Subjects with a negative TB test and chest x-ray (CXR) not suggestive of active TB or prior TB exposure may be enrolled.

Subjects with a positive TB test must be assessed for evidence of active TB versus latent TB, including signs and symptoms and CXR. Subjects with no signs or symptoms and a CXR not suggestive of active TB may be enrolled after initiation of TB prophylaxis (see below).

Subjects with evidence of active TB must not be enrolled.

For subjects with a negative TB test result at Screening or most recent evaluation, an annual TB follow-up test will be performed. If an annual TB test is newly positive (seroconversion), a chest x-ray (CXR) needs to be performed as soon as possible to aid in distinguishing active versus latent TB. Any positive TB screen after the patient has started the study, should be reported as an adverse event of latent TB or active TB (as applicable).
If the subject is experiencing signs or symptoms suspicious for TB or something has changed in the subject's medical history to warrant a repeat test before the next scheduled annual TB re-test, the case (including the TB test results) must be discussed with the AbbVie TA MD.

TB test:

- Subjects with documentation of prior positive result of QuantiFERON-TB Gold Test (or equivalent) and/or PPD are not required to repeat either test at Screening or during the study and should be considered positive.
- For regions that require both PPD and QuantiFERON-TB Gold testing, both will be performed. If either PPD or QuantiFERON-TB Gold is positive, the TB test is considered positive.
- The PPD Skin Test (also known as a TB Skin Test or Mantoux Test) should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless both tests are required per local guidelines).
- If only a PPD is placed at screening, then the TB test to be used for the remainder of the study for that subject is the PPD. Similarly, if a subject enters the study with a QuantiFERON-TB Gold test (or equivalent) alone, then the subject should have their annual TB test performed with a QuantiFERON-TB Gold test.
- If the QuantiFERON-TB Gold Test is NOT possible (or if both the QuantiFERON-TB Gold Test and the PPD Skin Test are required per local guidelines): the PPD Skin Test (also known as a TB Skin Test) will be performed. The TB Skin Test should be read by a licensed healthcare professional between 48 and 72 hours after administration. A subject who does not return within 72 hours will need to be rescheduled for another skin test. The reaction will be measured in millimeters (mm) of induration and induration ≥ 5 mm for RA subjects is considered a positive reaction. The absence of induration will be recorded as "0 mm" not "negative." Subjects who have had an ulcerating reaction to the TB Skin Test in the past should not be re-exposed and the TB Skin Test should be considered positive.
● If the QuantiFERON-TB Gold test is indeterminate, then the investigator should perform a local QuantiFERON-TB Gold test (or through the central laboratory if not locally available) to rule out a positive test result. If testing remains indeterminate or is positive, then the subject is considered to be positive for the purpose of this study. If the testing result is negative, then the patient is considered to be negative.

TB prophylaxis:

At screening, if the subject has evidence of latent TB, prophylactic treatment must be initiated at least 2 weeks prior to administration of study drug (or per local guidelines, whichever is longer); At least 6 months of prophylaxis needs to be completed to remain in the study.

Of note: Rifampicin or Rifapentine is not allowed for TB prophylaxis.

Subjects with a prior history of latent TB that have documented completion of a full course of anti-TB therapy will be allowed to enter the study provided nothing has changed in the subject's medical history to warrant repeat treatment. For subjects with completion of a full course of anti-TB therapy, but insufficient documentation, the investigator should consult with the AbbVie TA MD.

Newly initiated prophylactic treatment should be captured in the eCRF and in the source documents. Prior therapy should be captured in the eCRF.

During the study, subjects with new evidence of latent TB should initiate prophylactic treatment immediately per local guidelines and complete at least 6 months of prophylaxis. TB prophylaxis should be initiated and study drug(s) should not be withheld. 2 to 4 weeks later, the subject should be re-evaluated (unscheduled visit) for signs and symptoms as well as laboratory assessment of toxicity to TB prophylaxis.

Chest X-Ray (CXR)

A CXR (posterior-anterior and lateral views) is required:
For all subjects at Screening to rule out the presence of TB or other clinically relevant findings. The CXR will not be required if the subject had a previous normal CXR (posterior-anterior and lateral views) within 90 days of Screening, provided all source documentation is available at the site, as outlined below and provided nothing has changed in the subject's medical history to warrant a repeat test.

Every 48 weeks for subjects with TB risk factors as identified by the TB risk assessment form (Appendix I), or for subjects living in areas endemic for TB or for subjects with newly positive PPD and/or QuantiFERON-TB Gold test.

Subjects can have a repeat CXR at any time during the study as warranted, based on the opinion of the Investigator.

A radiologist or pulmonologist must perform an assessment of the CXR. The Principal Investigator will indicate the clinical significance of any findings and will sign and date the report. In the assessment of the CXR, the Principal Investigator or their delegate must indicate the presence or absence of (1) calcified granulomas, (2) pleural scarring/thickening, and (3) signs of active TB. If the CXR demonstrates changes suggestive of previous TB (e.g., calcified nodule, fibrotic scar, apical or basilar pleural thickening) or other findings that are clinically significant, the Principal Investigator should contact the AbbVie Medical Monitor before enrolling the subject.

**12-Lead ECG**

For all subjects, a resting 12-lead ECG will be performed at screening, Week 48 and every 48 weeks thereafter, as specified in Appendix D and Appendix F. For subjects who do not enter Period 2 or prematurely discontinue from study, an ECG will be performed at their final visit as indicated in Appendix D and Appendix F. A qualified physician will interpret the clinical significance of any abnormal finding, sign, and date each ECG. ECG with QT interval corrected for heart rate using Fridericia's correction formula (QTcF) should be reported (or calculated) and documented in the source documents and later transcribed on to the appropriate eCRF if QTcF prolongation is observed. A valid QTcF cannot be calculated in subjects who have a pacemaker or supraventricular or ventricular
conduction abnormalities. In cases of QTcF prolongation, the baseline QTcF will need to be entered into the appropriate eCRF for comparison as well. In addition, any clinically significant findings will be documented in the source documents and later transcribed onto the appropriate eCRF. Each signed original ECG will be monitored by the responsible site monitor and kept with subject's source documents onsite.

For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at Screening will not be required, provided source documentation is available and provided nothing has changed in the subject's medical history to warrant a repeat test. If there are other findings that are clinically significant, the Investigator must contact the AbbVie Therapeutic Area Medical Director before enrolling the subject.

Subjects can have a repeat ECG at any time during the study as warranted, based on the opinion of the Investigator.

**Height and Weight**

Height will be measured at the Screening Visit only (with shoes off). Body weight will be measured at all scheduled visits, as specified in Appendix D and Appendix F. All measurements will be recorded in metric units where applicable.

**Vital Signs**

Vital sign determinations of systolic and diastolic blood pressure in sitting position, pulse rate, respiratory rate, and body temperature will be obtained at visits specified in Appendix D and Appendix F. Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blood draws are performed.

**Physical Examination**

A complete physical examination will be performed at the designated study visits as specified in Appendix D and Appendix F. The physical examination at the Baseline Visit will serve as the baseline physical examination for the entire study. Physical examination abnormalities noted by the Investigator at Baseline prior to the first dose of study drug
will be recorded in the subject's medical history; abnormalities noted after the first dose of study drug will be evaluated and documented by the Investigator as to whether or not the abnormality is an AE (see Section 6.1.1.1 for AE definition). All findings, whether related to an AE or part of each subject's medical history, will be captured on the appropriate eCRF page.

At any time, a symptom-directed physical examination can be performed as deemed necessary by the Investigator.

**Physician Global Assessment of Disease Activity VAS**

At visits specified in Appendix D and Appendix F, the Physician will rate global assessment of subject's current disease activity ranging from 0 to 100 independent of the subject's self-assessment using the VAS, which consists of a horizontal 100 mm line anchored at either end by opposite adjectives reflecting the spectrum/severity of the parameters assessed (Appendix G).

**TJC and SJC Assessment**

**TJC Assessment**

An assessment of 68 joints (Appendix H) will be done for tenderness by pressure manipulation on physical examination at visits specified in Appendix D and Appendix F. Joint pain/tenderness will be classified as: present ("1"), absent ("0"), replaced ("9") or no assessment ("NA").

**SJC Assessment**

An assessment of 66 joints (Appendix H) will be done by directed physical examination at visits specified in Appendix D and Appendix F. The joints to be examined for swelling are the same as those examined for tenderness, except the hip joints are excluded. Joint swelling will be classified as present ("1"), absent ("0"), replaced ("9") or no assessment ("NA").
Any injected joints will be considered as "not assessed" ("NA") for 3 months from the time of the intra-articular injection.

If possible, the TJC and SJC should be performed by an independent and blinded joint assessor who should not perform any other study related procedures.

In order to minimize variability, the same independent joint assessor should evaluate the subject at each visit for the duration of the trial as much as possible. A back-up independent joint assessor should be identified. The independent joint assessors should be a qualified medical professional (e.g., nurse, physician's assistant, physician). Any other joint assessor must be trained and competent in performing such assessments. It is the responsibility of the Investigator to ensure that all assessors are qualified and trained to perform joint assessments. If the independent assessor is not available, the pre-identified back-up assessor should perform such assessments.

**CDAI**

The CDAI calculation is required to determine if a subject fails to achieve low disease activity and will be performed at the Week 28 visit. An Interactive Response Technology (IRT) will calculate CDAI with input from site personnel on joint counts and the subject's and physician's Global Assessment PtGA and phGA) of RA Disease Activity score.

The calculation used to determine CDAI score at Week 28 is as follows:

\[ \text{CDAI} = \text{TJC}28 + \text{SJC}28 + \text{PtGA} \text{ (cm)} + \text{PhGA} \text{ (cm)} \]

NOTE: Investigator should optimize background RA therapies (as rescue) in subjects who failed to achieve a 20% reduction in both tender and swollen joint count.

**Pregnancy Test**

A serum pregnancy test will be performed for all women of childbearing potential at the Screening Visit. The serum pregnancy test will be sent to and performed by the central laboratory. If the serum pregnancy test is positive the subject is considered a screen
failure. If the serum pregnancy test is borderline, it should be repeated ≥ 3 days later to determine eligibility. If the repeat serum pregnancy test is:

- Positive, the subject is considered a screen failure;
- Negative, the subject can be enrolled into the trial;
- Still borderline ≥ 3 days later, this will be considered documentation of continued lack of a positive result and the subject can be enrolled into the trial in the absence of clinical suspicion of pregnancy and other pathological causes of borderline results.

In Period 1, a urine pregnancy test will be performed for all women of childbearing potential at the Baseline Visit prior to the first dose of study drug and at all subsequent visits. More frequent pregnancy tests will be performed throughout the study if required per local/country requirements.

- If the baseline urine pregnancy test performed at the site is negative, then dosing with study drug may begin. If the baseline urine pregnancy test performed at the site is positive, dosing with study drug must be withheld and a serum pregnancy test is required. The serum pregnancy test will be sent to and performed by the central laboratory. If the serum pregnancy test is negative, study drug may be started. If the serum pregnancy test is positive, study drug must be permanently discontinued. In the event a serum pregnancy test comes back borderline, a repeat test is required (≥ 3 days later) to document continued lack of a positive result.
- If a urine pregnancy test at post-baseline is positive, study drug needs to be temporarily discontinued and a serum pregnancy test is required. The serum pregnancy test will be sent to and performed by the central laboratory. If the serum pregnancy test is negative, study drug may be restarted. If the serum pregnancy test is positive, study drug must be permanently discontinued. In the event a serum pregnancy test comes back borderline, a repeat test is required (≥ 3 days later) to document continued lack of a positive result.
In Period 2, for women of childbearing potential, a urine pregnancy test will be performed at all visits and monthly at home between scheduled study visits. The results of the monthly at home tests will be communicated to the site. If a urine pregnancy test is positive, the subject must stop dosing, return to the study site and have blood drawn for a serum pregnancy test that will be analyzed at the central laboratory.

At each visit, the study staff should review the pregnancy avoidance recommendations with each woman of childbearing potential and male subjects with a partner of childbearing potential, and document this discussion in the subject's source records.

If during the course of the study a woman becomes surgically sterile or post-menopausal and complete documentation as described in Section 5.2.4 is available, pregnancy testing is no longer required.

A pregnant or breastfeeding female will not be eligible for participation in this study or continuation on study drug.

**Clinical Laboratory Tests**

Samples will be obtained for the clinical laboratory tests listed in Table 2. Unscheduled clinical labs may be obtained at any time during the study if deemed appropriate per Investigator's discretion. A certified central laboratory will be utilized to process and provide results for the clinical laboratory tests. All abnormal laboratory tests that are considered clinically significant by the Investigator will be followed to a satisfactory resolution.

The central laboratory chosen for this study will provide instructions regarding the collection, processing, and shipping of these samples.

Blood samples will be obtained for the laboratory tests at visits specified in Appendix D and Appendix F. Blood draws should be performed only after all questionnaires (HAQ DI, Patient's Assessment of Pain, etc.), clinical assessments, and vital sign determinations are obtained.
For clinic visits where samples for serum chemistry tests are collected, subjects should be fasting (a minimum 8-hour fast) whenever possible. If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study source documentation.

Urine samples will be obtained for urinalysis testing at visits specified in Appendix D and Appendix F. The central laboratory will be responsible for performing a macroscopic urinalysis (urine dipstick) on the collected urine specimens. Specified abnormal macroscopic urinalyses defined as leukocytes, nitrite, protein, ketones, or blood greater than negative, or glucose greater than normal will be followed up with a microscopic analysis at the central laboratory.

For any laboratory test value outside the reference range that the Investigator considers to be clinically significant, the Investigator should apply the standard of care for medical evaluation and treatment per local guidelines:

- The Investigator will repeat the test to verify the out-of-range value.
- The Investigator will follow the out-of-range value to a satisfactory clinical resolution.

A laboratory test value that requires a subject to be discontinued from study drug or requires a subject to receive treatment will be recorded as an AE. Other laboratory abnormalities, including those which meet the toxicity management criteria outlined in Section 6.1.7 (Toxicity Management), may be recorded as AEs at the discretion of the investigator.
### Table 2. Clinical Laboratory Tests

<table>
<thead>
<tr>
<th>Hematology (Central Lab)</th>
<th>Clinical Chemistry(^a) (Central Lab)</th>
<th>Urinalysis(^b) (Central Lab)</th>
<th>Other Laboratory Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematocrit</td>
<td>BUN</td>
<td>Specific gravity</td>
<td>Central Lab Tests:</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>Creatinine</td>
<td>Ketones</td>
<td>Serum pregnancy</td>
</tr>
<tr>
<td>RBC count</td>
<td>Total bilirubin</td>
<td>pH</td>
<td>(bHCG) test(^d)</td>
</tr>
<tr>
<td>WBC count</td>
<td>INR (reflex only)(^e)</td>
<td>Protein</td>
<td>HBs Ag(^f)</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>ALT</td>
<td>Blood</td>
<td>HBs Ab(^g)</td>
</tr>
<tr>
<td>Bands Lymphocytes</td>
<td>AST</td>
<td>Glucose</td>
<td>HBc Ab(^h)</td>
</tr>
<tr>
<td>Monocytes</td>
<td>Alkaline phosphatase</td>
<td>Urobilinogen</td>
<td>HBV DNA PCR (reflex only)(^i)</td>
</tr>
<tr>
<td>Basophils</td>
<td>CPK</td>
<td>Bilirubin</td>
<td>HCV Ab (\text{HCV RNA}) (reflex only)(^j)</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>Sodium Potassium</td>
<td>Leukocytes</td>
<td>HIV Ab (^k)</td>
</tr>
<tr>
<td>Platelet count</td>
<td>Chloride</td>
<td>Nitrates</td>
<td>QuantiFERON-TB Gold(^l)</td>
</tr>
<tr>
<td></td>
<td>Calcium</td>
<td>Microscopic examination,</td>
<td>Rheumatoid Factor(^m)</td>
</tr>
<tr>
<td></td>
<td>Inorganic phosphate</td>
<td>if needed</td>
<td>Anti-CCP autoantibodies(^n)</td>
</tr>
<tr>
<td></td>
<td>Uric acid Cholesterol</td>
<td></td>
<td>hs-CRP(^o)</td>
</tr>
<tr>
<td></td>
<td>LDL-C</td>
<td></td>
<td>FSH(^p)</td>
</tr>
<tr>
<td></td>
<td>HDL-C</td>
<td></td>
<td>MRB Panel(^k)</td>
</tr>
<tr>
<td></td>
<td>Total protein</td>
<td></td>
<td>Local Lab Tests:</td>
</tr>
<tr>
<td></td>
<td>Glucose</td>
<td></td>
<td>Urine pregnancy test(^q)</td>
</tr>
<tr>
<td></td>
<td>Triglycerides</td>
<td></td>
<td>ESR</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ALT = alanine aminotransferase; AST = aspartate aminotransferase; bHCG = beta human chorionic gonadotropin; BUN = blood urea nitrogen; CCP = cyclic citrullinated peptide; CK-MB = creatine kinase-MB isozymes; CPK = creatine phosphokinase; DNA = deoxyribonucleic acid; ESR = erythrocyte sedimentation rate; FSH = follicle stimulating hormone; HBc Ab = hepatitis B core antibody; HBs Ab = hepatitis B surface antibody; HBs Ag = hepatitis B surface antigen; HBV = hepatitis B virus; HCV Ab = hepatitis C virus antibody; HDL-C = high-density lipoprotein cholesterol; HIV = human immunodeficiency virus; hsCRP = high-sensitivity C-reactive protein; INR = international normalized ratio; LDL-C = low-density lipoprotein cholesterol; PCR = polymerase chain reaction; RBC = red blood cell; RNA = ribonucleic acid; TB = tuberculosis; WBC = white blood cell

a. Minimum 8-hour fast. If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study source documentation.

b. A urine dipstick macroscopic urinalysis will be completed by the central laboratory at all required visits. A microscopic analysis will be performed in the event the dipstick results show leukocytes, nitrite, protein, ketones, or blood greater than negative or glucose greater than normal.

c. INR will only be measured if ALT and/or AST > 3 × ULN.

d. A serum pregnancy test will be performed for all women of childbearing potential at the Screening Visit and if postbaseline urine pregnancy test turns positive.
Table 2. Clinical Laboratory Tests (Continued)

e. At Screening only.
f. If PPD not performed.
g. In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject. Results of hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event management. Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib. In Period 2, the central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.
h. At screening for female subjects < 55 years old AND has had no menses for \( \geq 12 \) months AND has no history of permanent surgical sterilization (defined in Section 5.2.4) an FSH should be tested.
i. An urine pregnancy test will be performed for all female subjects of childbearing potential at the Baseline Visit prior to the first dose of study drug and all subsequent visits. If the baseline urine pregnancy test performed at the site is negative, then dosing with study drug may begin. If the baseline urine pregnancy test performed at the site is positive, dosing with study drug must be withheld and a serum pregnancy test is required. The serum pregnancy test will be sent to and performed by the central laboratory. If the serum pregnancy test is positive, study drug must be permanently discontinued. In the event a pregnancy test comes back borderline, a repeat test is required. If a urine pregnancy test postbaseline is positive, study drug needs to be temporarily discontinued and a serum pregnancy test is required. If the serum pregnancy test is negative, study drug may be restarted. If the serum pregnancy test is positive, study drug must be permanently discontinued.
j. Anti-HIV Ab will be performed at Screening, unless prohibited by local regulations. The Investigator must discuss any local reporting requirements to local health agencies with the subject. The site will report confirmed positive results to their health agency per local regulations, if necessary. If a subject has a confirmed positive result, the Investigator must discuss with the subject the potential implications to the subject's health and subject should receive or be referred for clinical care promptly. A subject will not be eligible for study participation if test results indicate a positive HIV infection. AbbVie will not receive results from the testing and will not be made aware of any positive result.
k. If needed to assess B cell counts in subjects who have discontinued rituximab, see Inclusion Criterion 7.

Hepatitis Screen

All subjects will be tested for the presence of HBV and HCV at Screening.

Hepatitis B Virus (HBV):

Subjects will be tested for the presence of HBV at screening using the following tests:

- HBs Ag (Hepatitis B surface antigen)
- HBc Ab/anti-HBc (Hepatitis B core antibody)
- HBs Ab/anti-HBs (Hepatitis B surface antibody)
A positive result for HBs Ag will be exclusionary.

A negative result for HBs Ag will be tested (automatic reflex testing) for core antibodies (HBc Ab) and surface antibodies (HBs Ab).

- A negative test result for HBc Ab does not require HBV DNA PCR qualitative testing and the subject may be enrolled ([Figure 3, Scenarios A and B](#)). For a subject who has had a HBV vaccination (should document in the medical history), a positive test result for HBs Ab is expected and the subject may be enrolled ([Figure 3, Scenario B](#)).*
- A positive test result for HBc Ab requires HBV DNA PCR testing (automatic reflex testing) ([Figure 3, Scenarios C and D](#)).
  - A positive result for HBV DNA or a result that exceeds detection sensitivity will be exclusionary.
  - A subject with a negative result for HBV DNA may be enrolled.

*For subjects who have had a HBV vaccination (should document in the medical history), a positive test result for HBs Ab is expected and these subjects may be enrolled.
Hepatitis C Virus (HCV):

Blood samples for Hepatitis C serology will be obtained at the Screening Visit. A positive HCV Ab will trigger an HCV RNA test. A subject will not be eligible for study participation if test results indicate active Hepatitis C (HCV RNA detectable in any subject with anti HCV Ab).

HIV

Subjects with HIV infection are excluded from study participation. HIV testing will be performed at Screening, unless prohibited by local regulations. The Investigator must discuss any local reporting requirements to local health agencies with the subject. The site will report confirmed positive results to their health agency per local regulations, if necessary. If a subject has a confirmed positive result, the Investigator must discuss with the subject the potential implications to the subject's health and subject should receive or be referred for clinical care promptly. A subject will not be eligible for study participation if test results indicate a positive HIV infection. AbbVie will not receive results from the testing and will not be made aware of any positive result.

Randomization/Drug Assignment

All Screening laboratory results must be reviewed, signed, and dated by the Principal Investigator or Sub-investigator prior to the Baseline Visit. Subjects will not be enrolled into the study if laboratory or other Screening result abnormalities are deemed clinically significant by the Principal Investigator or Sub-investigator.

Subjects will be eligible for randomization if they continue to meet all of the selection criteria (Section 5.2) at Baseline and are willing to continue in the study.

Subjects will be randomized in a 1:1 ratio using interactive response technology (IRT) to receive double-blind study drug in one of the following treatment groups:

- Group 1: upadacitinib 15 mg QD, N = 275 (Period 1)
- Group 2: Abatacept, N = 275 (Period 1)
Randomization will be stratified by number of prior bDMARD use (stratum 1: failed 1 or 2 biologics of the same class; stratum 2: failed multiple classes of biologics or \( \geq 3 \) biologics of the same class) and geographic region. Once 35% of the total subjects have been randomized in stratum 2, further screening of subjects who meet stratum 2 criteria may be suspended. Once 20% of total subjects have been randomized who have not completed > 3 months of methotrexate, further screening of such methotrexate inexperienced subjects may be suspended.

See Section 5.5.3 for details.

**Study Drug Dispensing, Dosing, and Compliance**

Study drug will be dispensed to subjects beginning at Baseline (Day 1) and as specified in Appendix D and Appendix F. The first dose of study drug will be administered after all other Baseline (Day 1) procedures are completed. Subjects will maintain a dosing diary for all study drug administered outside of the study visit (i.e., at home) to capture dosing dates and times. At visits specified in Appendix D and Appendix F, the site personnel will review and retain a copy of the dosing diary, returned study drug kits, and empty study drug packaging to verify compliance.

All relevant dosing information will be entered into the eCRF at each visit. (Refer to Section 5.5 for additional information).

### 5.3.1.2 Collection and Handling of Optional Samples for Exploratory Research and Validation Studies

#### 5.3.1.2.1 Optional Samples for Exploratory Research and Validation Studies

In Period 1, subjects will have the option to provide samples for exploratory research and validation studies. Subjects may still participate in the study even if they decide not to participate in this optional exploratory research/validation study. The procedures for obtaining and documenting informed consent are discussed in Section 9.3.
Exploratory research can help to improve our understanding of how individuals respond to drugs and our ability to predict which subjects would benefit from receiving specific therapies. In addition, exploratory research may help to improve our understanding of how to diagnose and assess/monitor RA by assessing associations between disease characteristics, outcomes data, and biomarkers of interest.

Validation studies, including those related to the development of potential in vitro diagnostic tests, may be carried out retrospectively in order to assess associations between events of interest (i.e., efficacy and/or safety events) and candidate biomarkers.

AbbVie (or people or companies working with AbbVie) will store the exploratory research/validation studies samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on upadacitinib (or drugs of this class) or RA and related conditions continues, but for no longer than 20 years after the completion of the study.

All subjects are preferred to have been fasting for a minimum of 8 hours prior to sample collection. If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study documentation. The following samples will be collected according to Appendix E from each subject who consents to provide samples for exploratory research/validation studies:

- DNA samples for pharmacogenetic or epigenetic analyses
- RNA samples for transcriptomic and/or epigenetic analyses
- Serum and plasma samples for systemic analyses including, but not limited to, proteomics and metabolomics

Samples will be shipped to AbbVie or a designated laboratory for DNA/RNA extraction, if applicable, and/or analyses or long-term storage. Instructions for the preparation and shipment of the samples will be provided in the laboratory manual.
5.3.2 Drug Concentration Measurements

5.3.2.1 Collection of Samples for Analysis

Blood samples for assay of upadacitinib will be collected as follows:

- Week 2 prior to dosing;
- Weeks 4, 8, 12, 16, 20 and 24/PD at any time during the visit.

On the Week 2 visit day, if possible, subjects should take the study drug dose at the clinic after collecting the PK blood sample, except if the subjects regularly take the study drug dose at night. Those subjects who regularly take the study drug dose at night should continue to take study drug according to their normal schedule. For all other visits, subjects can take the study drug dose on visit days at their regular schedule and not necessarily at the clinic.

The date and accurate time of the PK sample collection will be recorded on the lab requisition form. The date and accurate time of the last two study drug doses will be recorded on the eCRF to the nearest minute.

Refer to the study specific laboratory manual for detailed instructions on sample collection, processing, and shipment.

5.3.2.2 Measurement Methods

Plasma concentrations of upadacitinib will be determined by the Drug Analysis Department at AbbVie using a validated liquid chromatography/mass spectrometry method.
5.3.3  Efficacy Variables

5.3.3.1  Period 1 Variables

5.3.3.1.1  Primary Variable

The primary endpoint is the change from baseline in DAS28 (CRP) at Week 12 (non-inferiority).

DAS28 (CRP) score will be determined based on a continuous scale of combined measures of TJC, SJC, Patient's Global Assessment of Disease Activity (PtGA) (in mm), and hsCRP (in mg/L) at Week 12.

\[
\text{DAS28 (CRP)} = 0.56 \times \sqrt{\text{TJC28}} + 0.28 \times \sqrt{\text{SJC28}} + 0.36 \times \ln(hsCRP + 1) + 0.014 \times \text{PtGA} + 0.96
\]

* TJC28 refers to the Subject's total Tender Joint Count out of the provided 28 evaluated joints.
** SJC28 refers to the Subject's total Swollen Joint Count out of the provided 28 evaluated joints.
& hsCRP refers to the high-sensitivity c-reactive protein lab value. hsCRP unit in the DAS28 (CRP) equation is expressed as mg/L.
» PtGA refers to the Patient's Global Assessment of Disease Activity. Where $\sqrt{}$ is square root and ln is natural log.

5.3.3.1.2  Key Secondary Variables

Key secondary endpoints in Period 1 are:

1. Change from baseline in DAS28 (CRP) at Week 12 (superiority);
2. Proportion of subjects achieving Clinical Remission (CR) at Week 12 (superiority);
   CR is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) < 2.6 (superiority).

5.3.3.1.3  Additional Variables

Additional endpoints are:
- Proportion of subjects achieving low disease activity (LDA) at Week 12 (non-inferiority). LDA is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) ≤ 3.2.

- ACR20/50/70 response rates at all visits (non-inferiority); ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale [VAS]), Patient's Global Assessment of Disease Activity (VAS), Physician's Global Assessment of Disease Activity (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), or hsCRP;

- Change from baseline in individual components of ACR response at all visits;

- Change from baseline in DAS28 (CRP) and DAS28 (erythrocyte sedimentation rate [ESR]) at all visits;

- Change from baseline in morning stiffness at all visits;

- Proportion of subjects achieving LDA or CR based on DAS28 (CRP), DAS28 (ESR), Simplified Disease Activity Index (SDAI), and CDAI criteria (see below) at all visits;

- Change from baseline in CDAI and SDAI at all visits;

- Proportion of subjects achieving MCID in change from baseline in HAQ-DI (defined as change from baseline in HAQ-DI ≤ –0.3 ) at all visits;

- ACR/EULAR Boolean remission at all visits.

- Systemic corticosteroid dose (including cumulative dose at serial time points in Period 1)

<table>
<thead>
<tr>
<th>DAS28 (CRP) and DAS28 (ESR)</th>
<th>SDAI</th>
<th>CDAI</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDA</td>
<td>≤ 3.2</td>
<td>≤ 11.0</td>
</tr>
<tr>
<td>CR</td>
<td>&lt; 2.6</td>
<td>≤ 3.3</td>
</tr>
</tbody>
</table>

ACR20/50/70 response rates will be determined based on 20%/50%/70% or greater improvement in TJC and SJC and ≥ 3 of the 5 measures of Patient's Assessment of Pain (VAS), Patient's Global Assessment of Disease Activity (VAS), Physician's Global Assessment of Disease Activity (VAS), HAQ-DI, or hsCRP.
Additional endpoints are:

- Change from baseline in SF-36 (at Weeks 4, 12 and 24);
- Change from baseline in EQ-5D-5L (at Weeks 4, 12 and 24);
- Change from baseline in FACIT-F (at Weeks 4, 8, 12, 16 and 24);
- Change from baseline in WPAI RA (at Weeks 4, 8, 12 and 24).

5.3.3.2 Period 2 Variables

Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Weeks 36, 48, and every 12 weeks thereafter until completion of the study:

- Change from baseline in DAS28 (CRP);
- Proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- Proportion of subjects achieving LDA based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- ACR20/50/70 response rates;
- Change from baseline in individual ACR components;
- Change from baseline in DAS28 (ESR);
- Change from baseline in SF-36 at all visits;
- Change from baseline in morning stiffness;
- Concomitant corticosteroid use;
- ACR/EULAR Boolean remission.

Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Week 48 only:

- Change from baseline in EQ-5D-5L;
- Change from baseline FACIT-F;
- Change from baseline WPAI RA.
5.3.4 Safety Variables

Safety evaluations include adverse event monitoring, physical examinations, vital sign measurements, ECG, and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration.

5.3.5 Pharmacokinetic Variables

Plasma upadacitinib concentrations will be obtained at the times indicated in Appendix D. A non-linear mixed-effects modeling approach will be used to estimate the population central values and the empirical Bayesian estimates of the individual values of upadacitinib oral clearance (CL/F) and volume of distribution (V/F). Additional parameters may be estimated if useful in the interpretation of the data.

5.3.6 Exploratory Research Variables and Validation Studies

5.3.6.1 Exploratory Research Variables and Validation Studies

Optional samples may be collected to conduct exploratory investigations into known and novel biomarkers. The types of biomarkers to be analyzed may include, but are not limited to nucleic acids, proteins, lipids, or metabolites.

Biomarker assessments may be used to assess and generate prognostic, predictive, or surrogate biomarker signatures. These assessments may be explored in the context of RA or related conditions and/or upadacitinib or drugs of similar classes. The results from these analyses are exploratory in nature and may not be included with the clinical study report.

The samples may also be used to develop new therapies, research methods or technologies. In addition, samples from this study may be banked for future use. Samples may then be used to validate putative biomarker signatures obtained from a prospective study, leading to the development of diagnostic tests.
5.4 Removal of Subjects from Therapy or Assessment

5.4.1 Discontinuation of Individual Subjects

Subjects can request to be discontinued from participating in the study at any time for any reason including but not limited to disease progression or lack of response to treatment. The Investigator may discontinue any subject's participation for any reason, including an AE, safety concerns, lack of efficacy, or failure to comply with the protocol. See Section 6.1.7 for toxicity management criteria.

Subjects will have study drug discontinued immediately if any of the following occur:

- Clinically significant abnormal laboratory results or AEs, which rule out continuation of the study drug, as determined by the Investigator or the AbbVie Therapeutic Area Medical Director.
- Serious infections (e.g., sepsis) which cannot be adequately controlled within 2 weeks by anti-infective treatment or would put the subject at risk for continued participation in the trial as determined by the Investigator.
- The Investigator believes it is in the best interest of the subject.
- The subject requests withdrawal from the study.
- Inclusion or exclusion criteria violation was noted after the subject started study drug, when continuation of the study drug would place the subject at risk as determined by the AbbVie Therapeutic Area Medical Director.
- Introduction of prohibited medications or dosages when continuation of the study drug would place the subject at risk, as determined by the AbbVie Therapeutic Area Medical Director.
- Subject is non-compliant with TB prophylaxis (if applicable) or develops active TB at any time during the study.
- The subject becomes pregnant while on study drug.
- Malignancy, except for localized NMSC or carcinoma in-situ of the cervix.
- Subject is significantly non-compliant with study procedures which would put the subject at risk for continued participation in the trial as determined by the Investigator or the AbbVie Therapeutic Area Medical Director.
• Subject develops a gastrointestinal perforation.
• Beginning at Week 12, subject has a TJC or SJC worse than baseline at two consecutive visits (scheduled or unscheduled).
• Starting at Week 28 and thereafter, subject fails to show at least 20% improvement in TJC and SJC compared to baseline at 2 consecutive visits, despite optimization of background RA therapies.
• Starting at 28 weeks and thereafter, subjects who achieve ≥ 20% improvement in both TJC and SJC from baseline but fail to achieve CDAI ≤ 10 at two consecutive visits will be given the option, at the discretion of the investigator, either to continue or discontinue study drug and be treated according to standard of care and at the discretion of the investigator.

In order to minimize missing data for efficacy and safety assessments, subjects who prematurely discontinue study drug treatment should continue to be followed for all regularly scheduled visits, unless they have decided to discontinue the study participation entirely (withdrawal informed consent). Subjects should be advised on the continued scientific importance of their data even if they discontinue treatment with study drug early.

If a subject is discontinued from study drug, the procedures outlined for the Premature Discontinuation visit (PD visit) should be completed as soon as possible, preferably within 2 weeks of study drug discontinuation. In addition, if subject is willing, a 30-day (and 70-day if within Period 1) follow-up phone call (or visit) after the last dose of study drug may be completed to ensure all treatment emergent AEs/SAEs have been resolved. Subjects who discontinue the study prematurely after randomization will not be replaced.

All attempts must be made to determine the date of the last study drug dose and the primary reason for discontinuation of study drug or study participation. The information will be recorded on the appropriate eCRF page. However, these procedures should not interfere with the initiation of any new treatments or therapeutic modalities that the Investigator feels are necessary to treat the subject's condition. Following discontinuation
of study drug, the subject will be treated in accordance with the Investigator's best clinical judgment irrespective of whether the subject decides to continue participation in the study.

Lost to Follow-Up

For subjects to be considered lost to follow-up, reasonable attempts must be made to obtain information on the final status of the subject. At a minimum, two phone calls must be made and one certified letter must be sent and documented in the subject's source documentation.

5.4.2 Discontinuation of Entire Study

AbbVie may terminate this study prematurely, either in its entirety or at any study site, for reasonable cause provided that written notice is submitted in advance of the intended termination. The Investigator may also terminate the study at his/her site for reasonable cause, after providing written notice to AbbVie in advance of the intended termination. Advance notice is not required by either party if the study is stopped due to safety concerns. If AbbVie terminates the study for safety reasons, AbbVie will immediately notify the Investigator by telephone and subsequently provide written instructions for study termination.

5.5 Treatments

5.5.1 Treatments Administered

There are two active study drugs in Period 1. The first is daily upadacitinib and the second is abatacept IV.

Upadacitinib, or matching placebo, will be taken orally once daily (QD), beginning on Day 1 (Baseline), and should be taken at approximately the same time each day. Abatacept or placebo (0.9% Sodium Chloride Injection, or Solution for Infusion 100 mL) will be administered by intravenous infusion. The study drug can be taken with or without food. Subjects will continue their weekly stable background therapy of
csDMARD(s). AbbVie will not supply csDMARD(s) (nor folic acid or equivalent, such as folinic acid, for subjects who are on MTX).

Abatacept, or placebo (0.9% Sodium Chloride Injection, or Solution for Infusion 100 mL), will be given intravenously (IV) on Day 1, Week 2, Week 4, then every 4 weeks (q4) thereafter, with the last dose at Week 20. Dosing for abatacept is as follows: < 60 kg: 500 mg; 60 – 100 kg: 750 mg; >100 kg: 1,000 mg. The entire, fully diluted abatacept solution should be administered over a period of 30 minutes and must be administered with an infusion set and a sterile, non-pyrogenic, low-protein-binding filter (pore size of 0.2 to 1.2 μm). Abatacept requires reconstitution with sterile water as well as dilution prior to infusion with 0.9% Sodium Chloride Injection or Solution for Infusion 100 mL. Sites are to follow the commercially available preparation instructions for reconstitution and dilution of abatacept and only use silicone-free syringes. AbbVie will supply abatacept and the silicone-free syringes. Other preparation materials will be provided by the sites.

The maltose that is contained in the abatacept formulation can interfere with the readings of blood glucose monitors that use test strips with glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ). The GDH-PQQ based glucose monitoring systems may react with the maltose present in abatacept, resulting in falsely elevated blood glucose readings on the day of infusion. On study visit days where blinded abatacept is infused, patients that require blood glucose monitoring should be advised to consider methods that do not react with maltose, such as those based on glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, or glucose hexokinase test methods.

Subjects will be dispensed with oral study drug QD (either upadacitinib 15 mg or matching placebo) and receive IV study drug infusions on Day 1, Week 2, Week 4, then q4 thereafter (either abatacept or matching placebo).
Starting at Week 24 (after all assessments have been completed), subjects will be dispensed study drug (upadacitinib 15 mg QD) in an open-label fashion until the completion of Period 2.

5.5.2 Identity of Investigational Product

The individual study drug information is presented in Table 3.

Table 3. Identity of Investigational Product

<table>
<thead>
<tr>
<th>Investigational Product</th>
<th>Mode of Administration</th>
<th>Formulation</th>
<th>Strength</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upadacitinib (ABT-494)</td>
<td>Oral</td>
<td>Film-coated Tablet</td>
<td>15 mg</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Upadacitinib (ABT-494)</td>
<td>Oral</td>
<td>Film-coated Tablet</td>
<td>30 mg</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Placebo for upadacitinib (ABT-494)</td>
<td>Oral</td>
<td>Film-coated Tablet</td>
<td>NA</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Infusion</td>
<td>Powder</td>
<td>250 mg</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Placebo for abatacept</td>
<td>Infusion</td>
<td>0.9 Sodium Chloride Injection or Solution for Infusion 100 mL</td>
<td>NA</td>
<td>Various**</td>
</tr>
</tbody>
</table>

** Can be sourced from approved marketed products from various commercial manufacturers depending on availability.

0.9% Sodium Chloride (saline) Injection or Solution for Infusion 100 mL will be supplied with commercially available and locally sourced material. Sites are responsible for obtaining 0.9% Sodium Chloride Injection or Solution for Infusion 100 mL intravenous infusion bags/bottles to be used as diluent and as a vehicle of administration for abatacept from a licensed pharmacy or wholesaler. 0.9% Sodium Chloride Injection or Solution for Infusion will be administered to those subjects not receiving active abatacept as well as those subjects receiving active abatacept. AbbVie may provide 0.9% Sodium Chloride Injection or Solution for Infusion 100 mL if necessary based on local requirements.

Each site will be responsible for maintaining drug accountability records including product description, manufacturer, and/or lot numbers for 0.9% Sodium Chloride Injection or Solution for Infusion 100 mL.
5.5.2.1 Packaging and Labeling

Upadacitinib and matching placebo will be packaged in bottles with quantities sufficient to accommodate study design. Each kit label will contain a unique kit number. This kit number is assigned to a subject via IRT and encodes the appropriate study drug to be dispensed at the subject's corresponding study visit. Each kit will be labeled as required per country requirements. Labels must remain affixed to the kits. All blank spaces on the label will be completed by the site staff prior to dispensing to the subjects.

Abatacept will be packaged 1 vial per kit. Silicone-free syringes will also be provided. Only silicone-free syringes should be used when preparing doses of abatacept. Each kit label will contain a unique kit number. This kit number is assigned to a subject via IRT and encodes the appropriate study drug to be dispensed at the subject's corresponding study visit. Each kit will be labeled as required per country requirements. Labels must remain affixed to the kits. All blank spaces on the label will be completed by the site staff prior to dispensing to the subjects.

The commercially sourced 0.9% Sodium Chloride Injection or Solution for Infusion (100 mL) will not be labeled as an Investigational Medicinal Product (IMP) prior to the handling by the unblinded pharmacist or qualified designee. 0.9% Sodium Chloride Injection or Solution for Infusion (100 mL) will instead be labeled with a blinded dispensing label by the unblinded pharmacist or qualified designee as required. Dispensing labels must remain affixed to the material. If an IMP label on the 0.9% Sodium Chloride Injection or Solution for Infusion is mandated by local agencies, labels may be applied on the overwrap and will be removed by the unblinded pharmacist or qualified designee prior to administration.

5.5.2.2 Storage and Disposition of Study Drugs

Upadacitinib, or placebo, must be stored at controlled room temperature (15° to 25°C/59° to 77°F). Abatacept must be stored at refrigerated temperature (2° to 8°C/36° to 46°F) and protected from light. 0.9% Sodium Chloride Injection or Solution for Infusion should be stored per the locally approved commercial label, SmPC or packaging insert. Study
drug must not be frozen at any time. The investigational products are for investigational use only and are to be used only within the context of this study. The study drug supplied for this study must be maintained under adequate security and stored under the conditions specified on the label until dispensed for subject use or destroyed as appropriate.

5.5.3 Method of Assigning Subjects to Treatment Groups

All subjects will be randomized using IRT. Before the study is initiated, IRT directions will be provided to each site.

All subjects will be assigned a unique identification number by the IRT at the Screening Visit. For subjects that re-screen, the Screening number assigned by the IRT at the initial Screening visit should be used; a new Screening number should not be requested.

Subjects will be eligible for randomization if they continue to meet all of the selection criteria (Section 5.2) at Baseline and are willing to continue in the study.

Subjects will be randomized in a 1:1 ratio using interactive response technology (IRT) to receive double-blind study drug in one of the following treatment groups:

- Group 1: Upadacitinib 15 mg QD, N = 275 (Period 1)
- Group 2: Abatacept approximately 10 mg/kg IV, N = 275 (Period 1)

Randomization will be stratified by number of prior bDMARD use (stratum 1: failed 1 or 2 biologics of the same class; stratum 2: failed ≥ 3 biologics of the same class or failed biologics of multiple classes), and geographic region. Once 35% of the total subjects have been randomized in stratum 2, further screening of subjects who meet stratum 2 criteria may be suspended. Once 20% of total subjects have been randomized who have not completed > 3 months of methotrexate, further screening of such methotrexate inexperienced subjects may be suspended.
The IRT will assign a randomization number that will encode the subject's treatment group assignment according to the randomization schedule generated by the Statistics Department at AbbVie.

IRT will provide the appropriate study drug kit number(s) to dispense to each subject. Study drug will be administered at the study visits as summarized in Section 5.3.1.1. Returned study drug should not be re-dispensed to any subject.

5.5.4 Selection and Timing of Dose for Each Subject

Subjects should take study drug as outlined in Section 5.5.1.

On dosing days that occur on study visit days, subjects should follow the regular dosing schedule (refer to Section 5.3.2.1 regarding Week 2 visit).

Each subject's dosing schedule should be closely monitored by the site at each study visit by careful review of the subject's dosing diary. This will ensure that all subjects enrolled into the study maintain their original dosing schedule beginning with the first dose of study drug (Baseline/Day 1).

If a subject should forget to take their upadacitinib (or matching placebo) dose at their regularly scheduled dosing time, they should take the forgotten dose as soon as they remember the dose was missed as long as it is at least 10 hours before their next scheduled dose. If a subject only remembers the missed dose within 10 hours before next scheduled dose, the subject should skip the missed dose and take the next dose at the scheduled time.

If the subject experiences a study drug interruption for > 7 consecutive days during Weeks 1 through 24 (Period 1) or > 30 consecutive days after Week 24 (Period 2), they should notify the Investigator, and study drug should be discontinued.

In Period 1, the last dose of oral study drug should be taken the day before the Week 24 visit, and the last dose of intravenous study drug will be dispensed at the Week 20 visit.

In Period 1, the last dose of oral study drug should be taken the day before the Week 24 visit, and the last dose of intravenous study drug will be dispensed at the Week 20 visit.
5.5.5 Blinding

5.5.5.1 Blinding of Investigational Product

All AbbVie personnel with direct oversight of the conduct and management of the trial (with the exception of AbbVie Drug Supply Management Team and unblinded monitors conducting study drug accountability), the Investigator, study site personnel, and the subject will remain blinded to each subject's treatment throughout the study. An unblinded pharmacist (or designated unblinded personnel) will be used for the receiving and preparation of the blinded doses across the treatment groups. Upadacitinib tablets (active and placebo) will be identical in appearance. Upadacitinib study drug will be delivered to the study drug preparation designee or pharmacist in a blinded label format.

Abatacept and 0.9% Sodium Chloride Injection or Solution for Infusion (if applicable) will be delivered to the unblinded study drug preparation designee or unblinded pharmacist (or designated unblinded personnel) in an open-label format. The unblinded pharmacist (or designated unblinded personnel) will prepare the dosing of abatacept, or placebo, (in a blinded manner) following the commercially available preparation instructions as appropriate based on the subject's assigned treatment group and then provide to blinded site personnel. The blinded site personnel will administer infusions to subjects.

The IRT will provide access to unblinded subject treatment information in the case of medical emergency.

In the event of a medical situation that requires unblinding of the study drug assignment, the Investigator is requested to contact the AbbVie Therapeutic Area Medical Director prior to breaking the blind. However, if an urgent therapeutic intervention is necessary which warrants breaking the blind prior to contacting the AbbVie Therapeutic Area Medical Director, the Investigator can directly access the IRT system to break the blind without AbbVie notification or agreement. Unblinding is available in the IRT system via the Unblind Subject transaction, which is available only to the Investigator. If the IRT system is unavailable, unblinding may occur by contacting EndPoint technical support via
either phone (preferred) or email [REDACTED]. For country-specific phone numbers, please see the following website: http://www.endpointclinical.com/help-desk/. In the event that the blind is broken before notification to the AbbVie Therapeutic Area Medical Director, we request that the AbbVie Therapeutic Area Medical Director be notified within 24 hours of the blind being broken. The date and reason that the blind was broken must be conveyed to AbbVie and recorded on the appropriate eCRF.

An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24). Study sites and subjects will remain blinded for the duration of Period 1.

5.5.5.2 Blinding of Data for Independent Data Monitoring Committee (IDMC)

An external Data Monitoring Committee (DMC) comprised of persons independent of AbbVie and with relevant expertise in their field will review unblinded safety data from the ongoing study. The primary responsibility of the DMC will be to protect the safety of the subjects participating in this study.

A separate DMC charter will be prepared outside of the protocol and will describe the roles and responsibilities of the DMC members, frequency of data reviews, and relevant safety data to be assessed.

Communications from the DMC to the Study Teams will not contain information that could potentially unblind the team to subject treatment assignments.

5.5.6 Treatment Compliance

The Investigator or his/her designated and qualified representatives will administer/dispense study drug only to subjects enrolled in the study in accordance with the protocol. The study drug must not be used for reasons other than that described in the protocol.
Subject dosing will be recorded on a subject dosing diary. Subjects will be instructed to return all drug containers (even if empty) to the study site personnel at each clinic visit. The study site personnel will document compliance in the study source documents.

### 5.5.7 Drug Accountability

The Investigator or his/her representative will verify that study drug supplies are received intact and in the correct amounts. This will be documented by signing and dating the Proof of Receipt or similar document and by registering the arrival of drug through the IRT. The original Proof of Receipt Note and the IRT confirmation sheet will be kept in the site files as a record of what was received.

In addition, an IRT will be used to document investigational product accountability including but not limited to date received, the lot number, kit number(s), date dispensed, subject number, and the identification of the person dispensing the drug.

All empty/used study drug packaging will be inventoried by the site and verified by a designated unblinded drug accountability monitor. Empty/used study drug packaging should be returned by the subject at each visit for accountability and compliance purposes and new packaging issued as necessary. Empty/used packaging will be retained (unless prohibited by local law) until the site monitor is on site to confirm the returned study drug. Unblinded site monitor(s) and site staff will complete study drug accountability via IRT, source documents, subject dosing diaries, and by visually inspecting the packaging whenever possible. After drug accountability has been completed, used packaging and unused study drug will be destroyed on site according to local procedures or regulations or returned to the destruction depot by the site monitor (for those sites that do not meet AbbVie's documentation requirements for on-site destruction). The use of a third party vendor for drug destruction must be pre-approved by AbbVie. For sites performing on-site drug destruction or using a third party vendor for drug destruction, a copy of the destruction methodology and date of destruction should be maintained at the site's facility.
5.6 Discussion and Justification of Study Design

5.6.1 Discussion of Study Design and Choice of Control Groups

This study includes two periods:

Period 1 is a 24-week, randomized, double-blind, active-treatment period to compare safety and efficacy of upadacitinib versus abatacept in subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapy (EXCEPT abatacept) and who are on a stable dose of csDMARDs. Period 1 is designed to test non-inferiority of upadacitinib versus abatacept for achieving the primary endpoint change from baseline in DAS28(CRP) at Week 12, and other secondary efficacy parameters. Although primary outcome will be assessed at Week 12, the blinded comparator study will continue until Week 24.

All subjects initially assigned to abatacept will have the option to enter Period 2 and to receive upadacitinib from Week 24 onwards. Previous studies with both upadacitinib and abatacept have demonstrated robust and statistically significant improvement in disease activity at 12 week compared to placebo with moderate additional improvement observed with abatacept at 24 compared to 12 weeks. In a clinical trial with Abatacept in a TNF inadequate responder population, near-maximal improvements were noted at Week 12 (abatacept SmPC), and thus comparison of upadacitinib to Abatacept at Week 12 should be a valid reflection of relative efficacy of upadacitinib vs. Abatacept. Durability of the comparison will be performed at 24 weeks as a secondary outcome.

Starting at Week 12 (after the 12 Week assessment), if subjects do not show a 20% improvement in tender and swollen joint count two consecutive visits, then they will be rescued per Section 5.2.3.3.

Subjects not responding to therapy can discontinue study drug (or withdraw from study) at any time for any reason during the study in order to receive standard of care. For subjects who demonstrate no response to therapy beginning at Week 12 through the period prior to Week 24, discontinuation of study drug is advised for subjects who
demonstrate worsening of TJC or SJC from baseline on 2 consecutive visits. If at 28 weeks, subjects fail to achieve ≥ 20% improvement from baseline in both TJC and SJC at two consecutive visits, study drug should be discontinued. Beginning at 28 weeks, subjects who achieve ≥ 20% improvement in both TJC and SJC but who fail to achieve a CDAI ≤ 10 at two consecutive visits, the option will be given, at the discretion of the investigator, either to continue study drug or discontinue study drug and initiate standard of care as determined by the investigator.

The purpose of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1. Subjects will continue to receive upadacitinib 15 mg QD in an open-label manner.

5.6.2 Appropriateness of Measurements

Standard statistical, clinical, and laboratory procedures will be utilized in this study. All efficacy measurements in this study are standard for assessing disease activity in subjects with RA. All clinical and laboratory procedures in this study are standard and generally accepted.

5.6.3 Suitability of Subject Population

The intended study population is moderately to severely active RA patients who have had an inadequate response to or intolerance to prior bDMARD treatment. Key entry criteria are to enroll adult female and male subjects who are at least 18 years of age with a diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/EULAR classification criteria for RA. Eligible study subjects must have ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits, and hsCRP level ≥ 3 mg/L (above ULN, central lab) at Screening. Subjects who have been treated ≥ 3 months prior to the screening visit with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration AND have never received abatacept may be enrolled. Subjects must have been on a stable background of csDMARD therapy (restricted to
MTX, chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for \( \geq 4 \) weeks prior to the first dose of study drug.

### 5.6.4 Selection of Doses in the Study

One dose of the once-daily formulation of upadacitinib will be evaluated: upadacitinib 15 mg QD. The dose selection in this study is based on analyses of data from two Phase 2 studies in RA subjects (Studies M13-537 and M13-550) as well as results from the first two Phase 3 studies in the RA program: Study M13-549 (csDMARD-IR) and Study M13-542 (bDMARD-IR). The dose selected for Study M15-925, upadacitinib 15 mg QD, dosed for up to 5 years, is expected to be efficacious with an acceptable safety profile.

Results from Studies M13-549 (csDMARD-IR) and M13-542 (bDMARD-IR) showed that both the 15 and 30 mg QD doses of upadacitinib achieved superior responses to placebo for all primary and ranked secondary endpoints at Week 12 and demonstrated a safety profile consistent with the known profile of upadacitinib from Phase 2 studies. Therefore, upadacitinib 15 mg was selected for comparison to abatacept in this Phase 3 trial in RA patients who are intolerant or inadequate responders to prior biologic DMARDs.

### 6.0 Complaints

A Complaint is any written, electronic, or oral communication that alleges deficiencies related to the physical characteristics, identity, quality, purity, potency, durability, reliability, safety, effectiveness, or performance of a product/device after it is released for distribution.

Complaints associated with any component of this investigational product must be reported to the Sponsor (Section 6.2.2). For AEs, please refer to Section 6.1. For product complaints, please refer to Section 6.2.
6.1 Medical Complaints

The Investigator will monitor each subject for clinical and laboratory evidence of AEs on a routine basis throughout the study. The Investigator will assess and record any AE in detail including the date of onset, event diagnosis (if known) or sign/symptom, severity, time course (end date, ongoing, intermittent), relationship of the AE to study drug, and any action(s) taken. For SAEs considered as having "no reasonable possibility" of being associated with study drug, the Investigator will provide other cause(s) of the event. For AEs to be considered intermittent, the events must be of similar nature and severity. AEs, whether in response to a query, observed by site personnel, or reported spontaneously by the subject will be recorded.

All AEs will be followed to a satisfactory conclusion.

6.1.1 Definitions

6.1.1.1 Adverse Event

An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

Such an event can result from use of the drug as stipulated in the protocol or labeling, as well as from accidental or intentional overdose, drug abuse, or drug withdrawal. Any worsening of a pre-existing condition or illness is considered an AE. Worsening in severity of a reported AE should be reported as a new AE. Laboratory abnormalities and changes in vital signs are considered to be AEs only if they result in discontinuation from the study drug, necessitate therapeutic medical intervention, and/or if the investigator considers them to be AEs.
An elective surgery/procedure scheduled to occur during the study will not be considered an AE if the surgery/procedure is being performed for a pre-existing condition and the surgery/procedure has been pre-planned prior to study entry. However, if the pre-existing condition deteriorates unexpectedly during the study (e.g., surgery performed earlier than planned), then the deterioration of the condition for which the elective surgery/procedure is being done will be considered an AE.

6.1.1.2 Serious Adverse Events

If an AE meets any of the following criteria, it is to be reported to AbbVie as an SAE within 24 hours of the site being made aware of the SAE.

- **Death of Subject**: An event that results in the death of a subject.

- **Life-Threatening**: An event that, in the opinion of the investigator, would have resulted in immediate fatality if medical intervention had not been taken. This does not include an event that would have been fatal if it had occurred in a more severe form.

- **Hospitalization or Prolongation of Hospitalization**: An event that results in an admission to the hospital for any length of time or prolongs the subject's hospital stay. This does not include an emergency room visit or admission to an outpatient facility.

- **Congenital Anomaly**: An anomaly detected at or after birth, or any anomaly that results in fetal loss.

- **Persistent or Significant Disability/Incapacity**: An event that results in a condition that substantially interferes with the activities of daily living of a study subject. Disability is not intended to include experiences of relatively minor medical significance such as headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle).
Important Medical Event Requiring Medical or Surgical Intervention to Prevent Serious Outcome

An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above (i.e., death of subject, life-threatening, hospitalization, prolongation of hospitalization, congenital anomaly, or persistent or significant disability/incapacity). Additionally, any elective or spontaneous abortion or stillbirth is considered an important medical event. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

For serious adverse events with the outcome of death, the date and cause of death will be recorded on the appropriate case report form.

6.1.1.3 Adverse Events of Special Interest

The following AEs of special interest will be monitored during the study (see detailed toxicity management in Section 6.1.7):

- Serious infections
- Opportunistic infections
- Herpes Zoster
- Tuberculosis
- Malignancy
- Non-Melanoma Skin Cancer (NMSC)
- Malignancy excluding NMSC
- Lymphoma
- Gastrointestinal Perforations
- Adjudicated cardiovascular events (e.g., major adverse cardiovascular event [MACE])
6.1.2 Adverse Event Severity

The Investigator will classify adverse events according to the Rheumatology Common Toxicity Criteria v.2.0.22

6.1.3 Relationship to Study Drug

The investigator will use the following definitions to assess the relationship of the adverse event to the use of study drug:

**Reasonable Possibility**

After consideration of factors including timing of the event, biologic plausibility, clinical judgment, and potential alternative causes, there is sufficient evidence (information) to suggest a causal relationship.

**No Reasonable Possibility**

After consideration of factors including timing of the event, biologic plausibility, clinical judgment, and potential alternative causes, there is insufficient evidence (information) to suggest a causal relationship.

For relationship assessments, events assessed as having a reasonable possibility of being related to the study drug will be considered "associated." Events assessed as having no reasonable possibility of being related to study drug will be considered "not associated."

In addition, when the investigator has not reported a relationship or deemed it not assessable, AbbVie will consider the event associated.
If an Investigator's opinion of no reasonable possibility of being related to study drug is given, an Other cause of event must be provided by the investigator for the serious adverse event.

6.1.4 Adverse Event Collection Period

All AEs reported from the time of study drug administration until up to 70 days following discontinuation of study drug administration (depending on if discontinuation occurs in Period 1 or Period 2) have elapsed will be collected, whether solicited or spontaneously reported by the subject. Subjects who discontinue study drug treatment but continue to participate in the study will have SAEs and nonserious AEs collected for the remainder of study participation. In addition, SAEs and protocol-related nonserious AEs will be collected from the time the subject signed the study-specific informed consent.

Adverse event information will be collected as shown in Figure 4.

Figure 4. Adverse Event Collection

Additionally, in order to assist the adjudication process, additional information on any potential cardiovascular events will be collected, if applicable.

In the case of any of the following reported events, the supplemental cardiovascular events eCRF should be completed:
• Cardiac events;
• Myocardial infarction or unstable angina;
• Heart failure;
• Cerebral vascular accident and transient ischemic attack;

In the case of a reported AE of herpes zoster infection, a Supplemental AE eCRF should be completed.

6.1.5 Adverse Event Reporting

In the event of an SAE, whether associated with study drug or not, the Investigator will notify Clinical Pharmacovigilance within 24 hours of the site being made aware of the SAE by entering the SAE data into the electronic data capture (EDC) system (RAVE®). SAEs that occur prior to the site having access to the RAVE system, or if RAVE is not operable, should be documented on the SAE Non-CRF forms and emailed (preferred route) or faxed to Clinical Pharmacovigilance within 24 hours of the site being made aware of the SAE.

Email: [Redacted]
FAX to: [Redacted]

For safety concerns, contact the Immunology Safety Team at:

Immunology Safety Team
[Redacted]
1 North Waukegan Road
North Chicago, IL 60064

Office: [Redacted]
Email: [Redacted]
For any subject safety concerns, please contact the physician listed below:

Primary Therapeutic Area Medical Director:

AbbVie Inc.
1500 Seaport Blvd.
Redwood City, CA 94063

Contact Information:
Office:
Mobile:
Email:

In emergency situations involving study subjects when the primary Therapeutic Area Medical Director is not available by phone, please contact the 24-hour AbbVie Medical Escalation Hotline where your call will be re-directed to a designated backup AbbVie Therapeutic Area Medical Director:

Phone: [Redacted]

The sponsor will be responsible for Suspected Unexpected Serious Adverse Reactions (SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with Global and Local Regulations. The reference document used for SUSAR reporting in the European Union countries will be the most current version of the Investigator's Brochure.

6.1.6 Pregnancy

Pregnancy in a study subject must be reported to AbbVie within 1 working day of the site becoming aware of the pregnancy. Subjects who become pregnant during the study must have study drug discontinued (Section 5.4.1).

Information regarding a pregnancy occurrence in a study subject or the partner of an enrolled subject and the outcome of the pregnancy will be collected. Pregnancies in study
subjects and their partners will be identified from the date of the first dose through 98 days (Period 1)/30 days (Period 2) following the last dose of study drug and the pregnancy will be followed to outcome.

Pregnancy in a study subject is not considered an AE. The medical outcome for either mother or infant, meeting any serious criteria including an elective or spontaneous abortion, is considered an SAE and must be reported to AbbVie within 24 hours of the site becoming aware of the event.

Subjects and their partners should avoid pregnancy throughout the course of the study, starting with the Screening Visit through 98 days (Period 1)/30 days (Period 2) after the last study drug administration for female subjects and through 30 days after the last study drug administration for male subjects. Male subjects should refrain from donating sperm for up to 30 days post last dose of study drug. Results of a positive pregnancy test or confirmation of a pregnancy will be assessed starting with the Screening Visit through the final study visit. In the event of pregnancy occurring in the partner of an enrolled subject, written informed consent for release of medical information from the partner must be obtained prior to the collection of any pregnancy-specific information and the pregnancy will be followed to outcome.

6.1.7 Toxicity Management

The toxicity management of the AEs including AEs of special interest consists of safety monitoring (review of AEs on an ongoing basis, and periodical/ad hoc review of safety issues by a safety data monitoring committee), interruption of study drug dosing with appropriate clinical management if applicable, and discontinuation of the subjects from study drug. The management of specific AEs and laboratory parameters is described below.

For subjects who discontinued study drug but continued study participation and are on standard of care therapies, these toxicity management requirements do not apply
(including alerts from the central lab) and any intolerability to standard of care therapies should be managed by the prescribing physician.

**Infusion Reactions (according to package insert for Abatacept):** Acute infusion-related events (adverse reactions occurring within 1 hour of the start of the infusion) were more common in the abatacept-treated patients than placebo-treated patients (9.4% for abatacept, 7.2% for placebo). The most frequently reported events with abatacept (1 – 2%) were dizziness, headache, and hypertension. Acute infusion-related events that were reported in > 0.1% and ≤ 1% of patients treated with abatacept included cardiopulmonary symptoms such as hypotension, increased blood pressure, decreased blood pressure, and dyspnea; other symptoms included nausea, flushing, urticaria, cough, hypersensitivity, pruritus, rash, and wheezing. Most of these reactions were mild to moderate. The occurrence of anaphylaxis remained rare between the double blind and long-term open-label experience. Hypersensitivity was reported uncommonly. Other reactions potentially associated with hypersensitivity to the medicinal product, such as hypotension, urticaria, and dyspnea, that occurred within 24 hours of abatacept infusion, were uncommon. If any serious allergic or anaphylactic reaction occurs, intravenous abatacept therapy should be discontinued immediately and appropriate therapy initiated, and the use of abatacept should be permanently discontinued.

**Serious Infections:** Subjects should be closely monitored for the development of signs and symptoms of infection during and after treatment with study drug. Study drug should be interrupted if a subject develops a serious infection or an opportunistic infection. A subject who develops a new infection during treatment with study drug should undergo prompt diagnostic testing appropriate for an immunocompromised subject. As appropriate, antimicrobial therapy should be initiated, and the subject should be closely monitored. Study drug may be restarted once the infection has been successfully treated. Subjects who develop active TB or experience Hepatitis B reactivation must be discontinued from study drug.

**Serious Gastrointestinal Events:** Subjects presenting with the onset of signs or symptoms of a serious gastrointestinal event should be evaluated promptly for early
identification of gastrointestinal perforation. If the diagnosis of gastrointestinal perforation is confirmed, the subject must be discontinued from study drug.

**Cardiovascular Events (MACE):** Subjects presenting with potential cardiovascular events should be carefully monitored. These events will be reviewed and adjudicated by an independent Cardiovascular Adjudication Committee in a blinded manner.

**Malignancy:** Subjects who develop malignancy other than NMSC or carcinoma in situ of the cervix must be discontinued from study drug. Information including histopathological results should be queried for the confirmation of the diagnosis.

**ECG Abnormality:** Subjects must be discontinued from study drug for an ECG change considered clinically significant and with reasonable possibility of relationship to study drug OR a confirmed absolute QTcF value > 500 msec.

**Management of Select Laboratory Abnormalities:** For any given laboratory abnormality, the Investigator should assess the subject, apply the standard of care for medical evaluation and treatment following any local guidelines. Specific toxicity management guidelines for abnormal laboratory values are described in Table 4 and may require an appropriate supplemental eCRF be completed. All abnormal laboratory tests that are considered clinically significant by the Investigator will be followed to a satisfactory resolution. If a repeat test is required per Table 4, the repeat testing must occur as soon as possible.
<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Toxicity Management Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>• If hemoglobin &lt; 8 g/dL interrupt study drug dosing and confirm by repeat testing with a new sample.</td>
</tr>
<tr>
<td></td>
<td>• If hemoglobin decreases ≥ 3.0 g/dL from baseline without an alternative etiology, interrupt study drug dosing and confirm by repeat testing with new sample.</td>
</tr>
<tr>
<td></td>
<td>• If hemoglobin decreases ≥ 3.0 g/dL from baseline and an alternative etiology is known, the subject may remain on study drug at the investigator's discretion.</td>
</tr>
<tr>
<td></td>
<td>• If confirmed, continue to withhold study drug until hemoglobin value returns to normal reference range or its baseline value.</td>
</tr>
<tr>
<td>Absolute neutrophil count (ANC)</td>
<td>• If confirmed &lt; 1000 cells/μL by repeat testing with new sample, interrupt study drug dosing until ANC value returns to normal reference range or its baseline value.</td>
</tr>
<tr>
<td></td>
<td>• Discontinue study drug if confirmed &lt; 500 cells/μL by repeat testing with new sample.</td>
</tr>
<tr>
<td>Absolute lymphocyte counts (ALC)</td>
<td>• If confirmed &lt; 500 cells/μL by repeat testing with new sample, interrupt study drug dosing until ALC returns to normal reference range or its baseline value.</td>
</tr>
<tr>
<td>Total white blood cell count</td>
<td>• If confirmed &lt; 2000 cells/μL by repeat testing with new sample, interrupt study drug dosing until white blood cell count returns to normal reference range or its baseline value.</td>
</tr>
<tr>
<td>Platelet count</td>
<td>• If confirmed &lt; 50,000 cells/μL by repeat testing with new sample, interrupt study drug dosing until platelet count returns to normal reference range or its baseline value.</td>
</tr>
</tbody>
</table>
**Table 4. Specific Toxicity Management Guidelines for Abnormal Laboratory Values (Continued)**

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Toxicity Management Guideline</th>
</tr>
</thead>
</table>
| AST or ALT           | • Interrupt study drug immediately if confirmed ALT or AST > 3 × ULN by repeat testing with new sample and either a total bilirubin > 2 × ULN or an international normalized ratio > 1.5.  
  o INR will only need to be measured in subjects with ALT or AST > 3 × ULN by the central lab. A repeat test of INR is not needed for determination if above toxicity management criteria are met.  
• Interrupt study drug immediately if confirmed ALT or AST > 3 × ULN by repeat testing with new sample along with appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).  
• Interrupt study drug immediately if confirmed ALT or AST > 5 × ULN by repeat testing with new sample for more than 2 weeks.  
• Interrupt study drug immediately if confirmed ALT or AST > 8 × ULN by repeat testing with new sample.  
Subjects who meet any of the above criteria should be evaluated for an alternative etiology of the ALT or AST elevation and managed as medically appropriate. The investigator should contact the AbbVie TA MD to discuss the management of a subject when an alternative etiology has been determined. The alternative etiology should be documented appropriately in the eCRF; study drug should be discontinued if no alternative etiology can be found.  
For any confirmed ALT or AST elevations > 3 ULN, complete supplemental hepatic eCRF.  
• Subjects with HBe Ab+ (irrespective of HBs Ab status) and negative HBV DNA at screening who develop the following should have HBV DNA by PCR testing performed within one week:  
  o ALT > 5 × ULN OR  
  o ALT or AST > 3 × ULN and either a total bilirubin > 2 × ULN or INR > 1.5 OR  
  o ALT or AST > 3 × ULN along with clinical signs of possible hepatitis  
• A positive result for HBV DNA PCR testing in these subjects will require immediate interruption of study drug and a hepatologist consultation should occur within one week for recommendation regarding subsequent treatment. |
Table 4. Specific Toxicity Management Guidelines for Abnormal Laboratory Values (Continued)

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Toxicity Management Guideline</th>
</tr>
</thead>
</table>
| Serum Creatinine     | • If serum creatinine is $> 1.5 \times$ the baseline value and $> ULN$, repeat the test for serum creatinine (with subject in an euvolemic state) to confirm the results. If the results of the repeat testing still meet this criterion then interrupt study drug and re-start study drug once serum creatinine returns to $\leq 1.5 \times$ baseline value and $\leq ULN$.  
• If confirmed serum creatinine $\geq 2$ mg/dL interrupt study drug, and re-start study drug once serum creatinine returns to normal reference range or its baseline value. 
For the above serum creatinine elevation scenarios, complete supplemental renal eCRF. |
| Creatine Phosphokinase | • If confirmed CPK value $\geq 4 \times ULN$ (if symptomatic or asymptomatic), complete supplemental CPK eCRF.  
• If confirmed CPK $\geq 4 \times ULN$ accompanied by symptoms suggestive of myositis or rhabdomyolysis, interrupt study drug, complete supplemental CPK eCRF, and contact AbbVie Therapeutic Area Medical Director. |

For allowed study drug interruption, the following rules apply:

**Period 1**

- Allow study drug interruption up to 7 consecutive days for AEs and emergency surgery. Elective surgery will not be allowed during this 24-week period.
- If the subject must undergo emergency surgery, the study drug should be interrupted at the time of the surgery. After emergency surgery, allow reintroduction of study drug once the physician has examined the surgical site and determined that it has healed and there is no sign of infection.

**Period 2**

- Allow study drug interruption up to 30 consecutive days.
- If the subject undergoes elective surgery, the study drug should be interrupted 2 weeks prior to the planned surgery. Allow reintroduction of study drug once
the physician has examined the surgical site and determined that it has healed and there is no sign of infection.

- If the subject must undergo emergency surgery, the study drug should be interrupted at the time of surgery. Allow reintroduction of study drug once the physician has examined the surgical site and determined that it has healed and there is no sign of infection.

6.1.8 Data Monitoring Committee

An external DMC will review unblinded safety data. See Section 5.5.5.2 for details.

6.1.9 Cardiovascular Adjudication Committee

An independent committee of physician experts in cardiovascular adjudication will be utilized to assess potential cardiovascular AEs in a blinded manner as defined by the Cardiovascular Adjudication Committee charter.

6.2 Product Complaint

6.2.1 Definition

A Product Complaint is any Complaint (see Section 6.0 for the definition) related to the biologic or drug component of the product.

For a product this may include, but is not limited to, damaged/broken product or packaging, product appearance whose color/markings do not match the labeling, labeling discrepancies/inadequacies in the labeling/instructions (example: printing illegible), missing components/product, or packaging issues.

Any information available to help in the determination of causality to the events outlined directly above should be captured.
6.2.2 Reporting

Product Complaints concerning the investigational product must be reported to the Sponsor within 1 business day of the study site's knowledge of the event via the Product Complaint form. Product Complaints occurring during the study will be followed-up to a satisfactory conclusion. All follow-up information is to be reported to the Sponsor (or an authorized representative) and documented in source as required by the Sponsor. Product Complaints associated with adverse events will be reported in the study summary. All other complaints will be monitored on an ongoing basis.

Product Complaints may require return of the product with the alleged complaint condition. In instances where a return is requested, every effort should be made by the Investigator to return the product within 30 days. If returns cannot be accommodated within 30 days, the site will need to provide justification and an estimated date of return.

The description of the complaint is important for AbbVie in order to enable AbbVie to investigate and determine if any corrective actions are required.

7.0 Protocol Deviations

AbbVie does not allow intentional/prospective deviations from the protocol unless when necessary to eliminate an immediate hazard to study subjects. The Principal Investigator is responsible for complying with all protocol requirements, and applicable global and local laws regarding protocol deviations. If a protocol deviation occurs (or is identified) after a subject has been enrolled, the Principal Investigator is responsible for notifying IEC/IRB regulatory authorities (as applicable), and the following AbbVie Clinical Contacts:
Such contact must be made as soon as possible to permit a review by AbbVie to determine the impact of the deviation on the subject and/or the study.

Examples of protocol deviations include the following:

- Subject entered into the study even though she/he did not satisfy entry criteria;
- Subject who developed withdrawal criteria during the study and was not withdrawn;
- Subject who received wrong treatment or incorrect dose;
- Subject who received excluded or prohibited concomitant treatment.

### 8.0 Statistical Methods and Determination of Sample Size

#### 8.1 Statistical and Analytical Plans

Unless otherwise specified, statistical tests will be at two-sided significance level of 0.05 for efficacy analyses and all other analyses. Specifically, 95% confidence interval will be used for non-inferiority evaluation, and a superiority test will be deemed significant if the P value is less than or equal to 0.05.

An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24).
The statistical analysis described in this section applies to subjects who are enrolled under Amendment 4 or later. For the subjects enrolled under Amendment 3, no formal statistical analysis is intended.

Completed and specific details of the statistical analysis will be described and fully documented in the Statistical Analysis Plan (SAP). The SAP will be finalized prior to the Week 24 analysis database lock. The statistical analyses will be performed using SAS (SAS Institute Inc., Cary, NC, USA).

8.1.1 Analysis Populations

8.1.1.1 Full Analysis Set

The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug. The FAS will be used for all efficacy and baseline analyses.

8.1.1.2 Per Protocol Analysis Set

The Per Protocol Analysis Set represents a subset of the FAS and consists of all FAS subjects who did not meet any major protocol violations during the study. Definitions of major protocol violations will be detailed in the SAP. Additional analysis may be conducted on the Per Protocol analysis set, in order to evaluate the impact of major protocol violations.

8.1.1.3 Safety Analysis Set

The Safety Analysis Set consists of all subjects who received at least one dose of study drug. For the Safety Analysis Set, subjects are assigned to a treatment group based on the treatment actually received, regardless of the treatment randomized.
8.1.2 **Subject Accountability, Disposition and Study Drug Exposure**

8.1.2.1 **Subject Accountability**

The following will be summarized by site and by treatment group as well as overall, separately for Period 1 and Period 2: number of subjects randomized, the number of subjects who received at least one dose of study drug, the number of subjects who completed, the number of subjects who prematurely discontinued study drug, and the number of subjects who prematurely discontinued study participation.

8.1.2.2 **Subject Disposition**

Separately for Period 1 and Period 2, the number and percentage of subjects who are randomized, received at least one dose of study drug, prematurely discontinued study drug, prematurely discontinued study participation, and completed will be summarized by treatment group and overall. Reasons for premature discontinuation of study drug and study participation will be summarized separately for all randomized subjects by treatment group and overall, with frequencies and percentages by reason for discontinuation.

8.1.2.3 **Study Drug Exposure**

Exposure to study drug will be summarized for the Safety Analysis Set for Period 1 alone as well as for Period 1 and Period 2 combined. The exposure to study drug (days) will be summarized with the mean, standard deviation, median, and range for each treatment group.

Study drug compliance will be summarized for each treatment group for Period 1. The compliance is defined as the number of tablets taken (i.e., the difference between the number of tablets dispensed and the number of tablets returned) during the subject's participation in Period 1 divided by the number of tablets a subject is supposed to take each day times the length of time that the subject was in the Treatment Phase of Period 1.
8.1.3 Analysis of Demographic and Baseline Characteristics

Demographic and baseline characteristics will be summarized by treatment group and overall for the FAS. For the purpose of this analysis, baseline data for each subject will be the data collected immediately prior to the first dose of study drug in Period 1.

Summary statistics for continuous variables will include the number of observations, mean, standard deviation, median, and range. For discrete variables, frequencies and percentages for each category will be summarized.

Medical history will be presented by counts and percentages of subjects, broken down by Body System and Diagnosis.

Prior therapy and medication will be summarized by treatment group. Prior therapy and medication will include all therapies and medications with a start date prior to the date of first dose of study drug.

Concomitant medications will also be summarized with frequencies and percentages for each treatment group. All medications administered during study drug exposure will be included.

8.1.4 Efficacy Analyses

All efficacy analyses will be carried out using the FAS population, which includes all randomized subjects who receive at least one dose of study drug.

8.1.4.1 Efficacy Analysis for Period 1

8.1.4.1.1 Primary Efficacy Variable

The primary endpoint is the non-inferiority comparison of upadacitinib to abatacept on change from baseline in DAS28 (CRP) at Week 12.
Analysis of the primary endpoint will be conducted on the FAS based on treatment as randomized. The mean, standard deviation, median, and range will be reported for each treatment group.

Between-group comparison of upadacitinib and abatacept will be performed using the analysis of covariance (ANCOVA) model with treatment as the fixed factor, and the corresponding baseline value and the main stratification factors as the covariates. The non-inferiority of upadacitinib to abatacept on change from baseline in DAS28(CRP) at Week 12 will be evaluated against a non-inferiority margin of 0.6 using the 95% confidence interval (CI) of treatment difference from the ANCOVA model. The margin of 0.6 was derived considering both the meta-analysis of placebo-subtracted effect of biologics in DAS28 on biologic-inadequate responder populations as well as the EULAR response criteria of "no response" for no clinically meaningful change.

For the primary analysis, multiple imputation will be used. The analysis will be repeated using Observed Cases (OC). Supportive analysis will also be conducted on the Per Protocol Analysis Set.

Treatment difference together with its 95% CI on the primary endpoint will be summarized in demographic subgroups including age, gender, weight, body mass index, race, and geographical region to assess the consistency of the treatment effect. Additional subgroup summaries based on baseline disease characteristics and stratification factors will also be conducted. However, no formal non-inferiority comparison will be performed at subgroup level.

**8.1.4.1.2 Key Secondary Efficacy Variables**

Key secondary endpoints are listed in Section 5.3.3.1.2.

For the binary endpoint proportion of subjects achieving Clinical Remission (CR), frequencies and percentages will be reported for each treatment group. Comparison of upadacitinib to abatacept will be conducted using the Cochran-Mantel-Haenszel test adjusting for main stratification factors.
For the continuous endpoint change from baseline in DAS28(CRP), the mean, standard deviation, median, and range will be reported for each treatment group. Superiority of upadacitinib to abatacept on change from baseline in DAS28(CRP) at Week 12 will also be evaluated based on the same ANCOVA model as in the non-inferiority comparison.

See Section 8.1.4.1.5 for imputation methods.

8.1.4.1.3 Other Efficacy Variables

Additional efficacy variables are listed in Section 5.3.3.1.3 and will be summarized for all visits, including visits beyond Week 24. For binary endpoints, frequencies and percentages will be reported for each treatment group. For continuous endpoints, the change from baseline mean, standard deviation, median, and range will be reported for each treatment group.

8.1.4.1.4 Multiplicity Control for Primary and Key Secondary Endpoints

In order to preserve Type I error, a step-down approach will be used to test the primary and key secondary endpoints where statistical significance can be claimed for a lower ranked endpoint only if the previous endpoint in the sequence meets the requirements of significance.

8.1.4.1.5 Imputation Methods

The following methods will be used for missing data imputation:

**Observed Cases (OC):** The OC analysis will not impute values for missing evaluations, and thus a subject who does not have an evaluation on a scheduled visit will be excluded from the OC analysis for that visit.

**Multiple Imputation (MI):** The MI analysis imputes missing data multiple times under appropriate random variation and thus generates multiple imputed "pseudo-complete"
datasets. Results will be aggregated across the multiple imputed datasets, overcoming drawbacks of the single imputation methods.

**Non-Responder Imputation (NRI):** NRI applies to binary endpoints only. In NRI analysis, subjects who prematurely discontinue study drug will be considered non-responders after discontinuation.

The NRI approach will serve as the primary analysis approach for key binary endpoints. The MI approach will serve as the primary analysis approach for key continuous endpoints. Sensitivity analyses based on OC will also be conducted for key endpoints.

8.1.4.2 Long-Term Efficacy Analysis for Period 1 and Period 2 Combined

The efficacy endpoints of long-term efficacy analysis are listed in Section 5.3.3.2 and will be summarized for all visits.

Long-term efficacy by time point will be summarized using descriptive statistics. For binary endpoints, frequencies and percentages will be summarized. For continuous endpoints, the mean and standard deviation will be reported.

8.1.5 Safety Analyses

8.1.5.1 General Considerations

Safety analyses will be carried out using the Safety Analysis Set. Analyses will be conducted for Period 1 alone, as well as for Period 1 and Period 2 combined.

Safety analyses are based on treatments actually received. Safety will be assessed by AEs, physical examination, laboratory assessments, ECG, and vital signs. Frequency tables and lists of subjects with treatment-emergent AEs by preferred term as in the Medical Dictionary for Regulatory Activities (MedDRA) dictionary, by system organ class, by severity, and by relationship to the study drug as assessed by the Investigator will be provided. The changes from baseline in vital signs, physical examination results,
and clinical laboratory values will be analyzed in a descriptive manner. Shift of laboratory values from baseline to defined time points will be tabulated.

Missing safety data will not be imputed.

**8.1.5.2 Analysis of Adverse Events**

Unless otherwise specified, the following conventions apply for both the Period 1 safety analysis and the combined safety analysis of Period 1 and Period 2.

**8.1.5.2.1 Treatment-Emergent Adverse Events (TEAE)**

AEs will be coded using MedDRA. A TEAE is defined as AE that began or worsened in severity after initiation of study drug.

AEs starting more than 70 days following the last dose of study drug for subjects on abatacept and AEs starting more than 30 days following the last dose of study drug for subjects on upadacitinib will not be included in summaries of TEAEs. For subjects who continued into Period 2, AEs that are reported in Period 2 will be captured in the combined safety analysis of Period 1 and Period 2.

As a general safety summary, the number and percentage of subjects experiencing TEAEs will be summarized for each treatment group for the following AE categories:

- All AEs;
- All severe AEs;
- All reasonably possibly related AEs;
- All SAEs;
- Frequent AEs (reported in 5% of subjects or more in any treatment group);
- Frequent reasonably possibly related AEs (reported in 5% of subjects or more in any treatment group);
- Discontinuations due to AEs;
- Death.
Additional AEs may be considered for tabulation/summary based on recommendations from Clinical and Safety as deemed appropriate.

TEAEs will be summarized and presented by system organ classes (SOCs) and preferred terms (PTs) using MedDRA. The SOCs will be presented in alphabetical order, and the PTs will be presented in alphabetical order within each SOC.

TEAE will also be summarized by maximum severity and by maximum relationship.

The AEs of special interest (including but not limited to serious infection, opportunistic infection, herpes zoster, TB, gastrointestinal perforations, malignancies, MACE, renal dysfunction, anemia, increased CPK, and drug-related hepatic disorders) will be summarized. Event rate (per 100 patient years) for AEs of special interest will also be summarized for the combined safety analysis of Period 1 and Period 2.

All AEs leading to discontinuation of study drug will be presented in listing format. A listing by treatment group of TEAEs grouped by SOC and MedDRA preferred term with subject identification numbers will be generated.

8.1.5.2.2 Serious Adverse Events and Death

All treatment-emergent SAEs and AEs leading to death will also be presented in listing format. In addition, SAEs will be summarized by SOC and MedDRA PT.

8.1.5.3 Analysis of Laboratory, Vital Sign, and ECG Data

Changes from baseline by visit, and changes from baseline to minimum value, maximum value, and final values in continuous laboratory data, and vital signs will be summarized by treatment group.

Baseline values are defined as the last non-missing measurements recorded on or before the date of the first dose of study drug in Period 1.
The laboratory data will be categorized as Grade 1, Grade 2, Grade 3, and Grade 4 according to OMERACT criteria (Rheumatology Common Toxicity Criteria v.2.0). For creatinine phosphokinase, serum creatinine, and parameters that are not covered in the OMERACT criteria, NCI CTC criteria will be used. The shift tables will tabulate the number and percentage of subjects with baseline and post-baseline values by grade levels.

Listings will be provided for potentially clinically significant laboratory values and vital signs.

8.1.6 Pharmacokinetic and Exposure-Response Analyses

Individual upadacitinib plasma concentrations at each study visit will be tabulated and summarized with appropriate statistical methods.

Data from this study may be combined with data from other studies for the population PK and exposure-response analyses. Population PK and exposure-response analyses of only data from this study may not be conducted. The following general methodology will be used for the population PK and exposure-response analyses.

Population PK analyses will be performed using the actual sampling time relative to dosing. PK models will be built using a non-linear mixed-effects modeling approach with non-linear mixed-effects modeling (NONMEM) software (Version 7, or a higher version). The structure of the starting PK model will be based on the PK analysis of data from previous studies. The CL/F and V/F of upadacitinib will be the PK parameters of major interest in the analyses. If necessary, other parameters, including the parameters describing absorption characteristics, may be fixed if useful in the analysis.

The evaluation criteria described below will be used to examine the performance of different models.

1. The objective function of the best model is significantly smaller than the alternative model(s).
2. The observed and predicted concentrations from the preferred model are more randomly distributed across the line of unity (a straight line with zero intercept and a slope of one) than the alternative model(s).

3. Visual inspection of model fits, standard errors of model parameters and change in inter-subject and intra-subject error.

Once an appropriate base PK model (including inter- and intra-subject error structure) is developed, empirical Bayesian estimates of individual model parameters will be calculated by the posterior conditional estimation technique using non-linear mixed-effects modeling. The relationship between these conditional estimates CL/F and V/F values with only potentially physiologically relevant or clinically meaningful covariates (such as subject age, sex, body weight, concomitant medications, laboratory markers of hepatic or renal function, etc.) will be explored using stepwise forward selection method, or another suitable regression/smoothing method at a significance level of 0.05. After identification of all relevant covariates, a stepwise backward elimination of covariates from the full model will be employed to evaluate the significance (at $P < 0.005$, corresponding to a decrease in objective function $> 7.88$ for one degree of freedom) of each covariate in the full model.

Linear or non-linear relationships of primary PK parameters with various covariates will be explored.

Relationships between upadacitinib exposure and clinical observations (primary efficacy variable) will be explored. Exposure-response relationships for secondary efficacy variables and/or some safety measures of interest may also be explored. The relationship between exposure (e.g., population PK model predicted average concentrations, area under the curve, trough concentrations, the individual model-predicted PK profiles, or some other appropriate measure of exposure) and drug effect will be explored. Several classes of models (e.g., linear, log-linear, exponential, $E_{\text{max}}$, sigmoid $E_{\text{max}}$, etc.) will be evaluated to characterize the exposure-response relationship based on observed data.
Results of the PK and exposure-response analyses may be summarized in a separate report prior to regulatory filing of upadacitinib for the treatment of RA, rather than in the CSR.

Additional analyses will be performed if useful and appropriate.

8.1.7 Statistical Analysis of Biomarker Data

If the optional exploratory research variables including an additional panel of prognostic, and predictive biomarkers are evaluated, then those data may be analyzed as follows. The association of biomarkers to the efficacy and safety endpoints may be explored for each biomarker one at a time, and also for combinations of biomarkers via some multivariate predictive modeling algorithms. Optimal multivariate combinations of biomarkers that associate with efficacy endpoints, subject response/non-response (with respect to appropriate clinical endpoints), and also with safety endpoints may be explored via a variety of statistical predictive modeling algorithms. Also cut-points for individual biomarkers and optimal combinations of biomarkers that differentiate the subject response with respect to efficacy/safety endpoints may be explored. The significance of these multivariate combinations of biomarkers may be assessed via at least 20 iterations of 5-fold cross-validation.

8.2 Determination of Sample Size

The planned total sample size of 550 (N = 275 per arm) can provide more than 90% power for the non-inferiority assessment on the primary endpoint using a non-inferiority margin of 0.6 at two-sided significance level of 0.05, assuming true difference between upadacitinib and abatacept in change from baseline in DAS28 (CRP) is 0.5 with an assumed standard deviation of 2.0 and accounting for a 10% drop rate. Under the planned sample size, superiority comparison of upadacitinib to abatacept in change from baseline in DAS28 (CRP) is powered at approximately 80%. The planned sample size can also provide approximately 80% power for superiority comparison of upadacitinib to abatacept in DAS CR at two-sided significance level of 0.05 and accounting for a 10% dropout rate, where the assumed DAS CR response rate is 31% for upadacitinib and 20% abatacept.
8.3 Randomization Methods

Subjects will be randomly assigned in a 1:1 ratio to one of the two treatment groups:

- Group 1: Upadacitinib 15 mg QD, N = 275 (Period 1)
- Group 2: Abatacept, N = 275 (Period 1)

Randomization will be stratified by number of prior bDMARD use (stratum 1: failed 1 or 2 biologics of the same class; stratum 2: failed ≥ 3 biologics of the same class or failed biologics of multiple classes) and geographic region. Once 35% of the total subjects have been randomized in stratum 2, further screening of subjects who meet stratum 2 criteria may be suspended. Once 20% of total subjects have been randomized who have not completed > 3 months of methotrexate, further screening of such methotrexate inexperienced subjects may be suspended.

See Section 5.5.3 for details.

9.0 Ethics

9.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)

Good Clinical Practice requires that the clinical protocol, any protocol amendments, the Investigator's Brochure, the informed consent, and all other forms of subject information related to the study (e.g., advertisements used to recruit subjects) and any other necessary documents be reviewed by an IEC/IRB. The IEC/IRB will review the ethical, scientific and medical appropriateness of the study before it is conducted. IEC/IRB approval of the protocol, informed consent, and subject information and/or advertising, as relevant, will be obtained prior to the authorization of drug shipment to a study site.

Any amendments to the protocol will require IEC/IRB approval and approval by Regulatory Authority(ies), if required by local law regulations, prior to implementation of any changes made to the study design. The investigator will be required to submit,
maintain and archive study essential documents according to International Conference on Harmonization (ICH) GCP and all other applicable regulatory requirements.

Any SAEs that meet the reporting criteria, as dictated by local regulations, will be reported to both responsible Ethics Committees and Regulatory Agencies, as required by local regulations. During the conduct of the study, the Investigator should promptly provide written reports (e.g., ICH Expedited Reports, and any additional reports required by local regulations) to the IEC/IRB of any changes that affect the conduct of the study and/or increase the risk to subjects. Written documentation of the submission to the IEC/IRB should also be provided to AbbVie.

9.2 Ethical Conduct of the Study

The study will be conducted in accordance with the protocol, ICH guidelines, applicable regulations and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. Responsibilities of the clinical investigator are specified in Appendix A.

9.3 Subject Information and Consent

The Investigator or his/her representative will explain the nature of the study to the subject, and answer all questions regarding this study. Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject, the person who administered the informed consent, and any other signatories according to local requirements. A copy of the informed consent will be given to the subject and the original will be placed in the subject's medical record. An entry must also be made in the subject's dated source documents to confirm that informed consent was obtained prior to any study-related procedures and that the subject received a signed copy.

Information regarding incentives for subjects and information regarding provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the study can be found in the informed consent.
Samples for exploratory research/validation studies will only be collected if the subject has voluntarily signed and dated the separate written consent for exploratory research/validation studies, approved by an IRB/IEC, after the nature of the testing has been explained and the subject has had an opportunity to ask questions. The separate written consent must be signed before the exploratory research/validation studies samples are collected and testing is performed. If the subject does not consent to the exploratory research/validation studies, it will not impact the subject's participation in the study.

In the event a subject withdraws from the main study, optional exploratory research/validation samples will continue to be stored and analyzed unless the subject specifically withdraws consent for the optional samples. If consent is withdrawn for the optional sampling, the subject must inform their study doctor, and once AbbVie is informed, the optional samples will be destroyed. However, if the subject withdraws his/her consent and the samples have already been tested, those results will still remain as part of the overall research data.

10.0  Source Documents and Case Report Form Completion

10.1  Source Documents

Source documents are defined as original documents, data, and records. This may include joint evaluation form, hospital records, clinical and office charts, laboratory data/information, subjects' diaries or evaluation checklists, pharmacy dispensing and other records, recorded data from automated instruments, microfiches, photographic negatives, microfilm or magnetic media, and/or x-rays. Data collected during this study must be recorded on the appropriate source documents. The Investigator Awareness Date (SAE CRF) may serve as the source for this data point. This adverse event data point required for eCRF completion can be entered directly in the eCRF.

The Investigator(s)/Institution(s) will permit study-related monitoring, audits, IEC/IRB review, and regulatory inspection(s), providing direct access to source data documents.
10.2 Case Report Forms

Case report forms (CRFs) must be completed for each subject screened/enrolled in this study. These forms will be used to transmit information collected during the study to AbbVie and regulatory authorities, as applicable. The CRF data for this study are being collected with an EDC system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA. The EDC system and the study-specific eCRFs will comply with Title 21 CFR Part 11. The documentation related to the validation of the EDC system is available through the vendor, Medidata, while the validation of the study-specific eCRFs will be conducted by AbbVie and will be maintained in the Trial Master File at AbbVie.

The Investigator will document subject data in his/her own subject files. These subject files will serve as source data for the study. All eCRF data required by this protocol will be recorded by investigative site personnel in the EDC system. All data entered into the eCRF will be supported by source documentation.

The Investigator or an authorized member of the investigator's staff will make any necessary corrections to the eCRF. All change information, including the date and person performing the corrections, will be available via the audit trail, which is part of the EDC system. For any correction, a reason for the alteration will be provided. The eCRFs will be reviewed periodically for completeness, legibility, and acceptability by AbbVie personnel (or their representatives). AbbVie (or their representatives) will also be allowed access to all source documents pertinent to the study in order to verify eCRF entries. The Principal Investigator will review the eCRFs for completeness and accuracy and provide his or her electronic signature and date to eCRFs as evidence thereof.

Medidata will provide access to the EDC system for the duration of the study through a password-protected method of internet access. Such access will be removed from investigator sites at the end of the site's participation in the study. Data from the EDC system will be archived on appropriate data media (CD-ROM, etc.) and provided to the
Investigator at that time as a durable record of the site's eCRF data. It will be possible for the Investigator to make paper printouts from that media.

Patient and site reported data must be completed for each subject screened/enrolled in this study.

- The following data are being collected with an Electronic Patient-Reported Outcome (ePRO) system called Trialmax, provided by the technology vendor CRF Health of Plymouth Meeting, PA, USA:
  - Completed by Patient:
    - Patient Global Assessment of Disease Activity VAS
    - Patient's Assessment of Severity and Duration of Morning Stiffness
    - Patient's Assessment of Pain VAS
    - HAQ-DI
    - SF-36
    - EQ-5D-5L
    - WPAI RA
    - FACIT-F
  - Completed by Site:
    - Physician Global Assessment of Disease Activity VAS

The ePRO system is in compliance with Title 21 CFR Part 11. The documentation related to the system validation of the ePRO system is available through the vendor, CRF Health, while the user acceptance testing of the study-specific PRO design will be conducted and maintained at AbbVie.

The subject will be entering the data on an electronic device; these data will be uploaded to a server. The data on the server will be considered source and will be maintained and managed by CRF Health.

Internet access to the ePRO data will be provided by CRF Health for the duration of the trial. This access will be available for the duration of the trial to the site investigator, as
well as delegated personnel. Such access will be removed from investigator sites following the receipt of the study archive. Data from the ePRO system will be archived on appropriate data media (CD-ROM, etc.) and provided to the investigator at that time as a durable record of the site's ePRO data. It will be possible for the investigator to make paper print-outs from that media.

The ePRO data will be collected by the following method:

*Tablet Based*

- The instrument/scale will be collected electronically via a tablet device into which the subject will directly enter the required pieces of information. The electronic device will be programmed to allow data entry for only the visits specified in the protocol and will not allow for subjects to complete more than one of the same assessment at any one visit. All data entered on the device will be immediately stored to the device itself and automatically uploaded to a central server administrated by CRF Health. The Investigator and delegated staff will be able to access all uploaded subject entered data via a password protected website, up until the generation, receipt and confirmation of the study archive.

**11.0 Data Quality Assurance**

Prior to the initiation of the study, a meeting will be held with AbbVie personnel, the investigators and appropriate site personnel. This meeting will include a detailed discussion of the protocol, performance of study procedures, CRF, subject dosing diary, and specimen collection methods. Another alternative of site training may include module training via a study portal.

To ensure data integrity and subject safety, a study monitor will continuously and throughout the study, verify that all subjects sign the informed consent prior to any study specific procedures being conducted, that the protocol procedures are being followed
appropriately, and that the information provided in the eCRF is complete, accurate, and supported by information in the source documents.

The AbbVie monitor will monitor each site throughout the study. Source document review will be performed against entries on the CRF and a quality assurance check will be performed to ensure that the Investigator is complying with the protocol and regulations.

Data hand entered in the database will be verified at AbbVie. Any discrepancies will be reviewed against the CRF and corrected on-line. After completion of the entry process, computer logic and manual checks will be created by AbbVie to identify items such as inconsistent study dates. Any necessary corrections will be made by the site to the eCRF.

Routine hematology, serum chemistry and serology, and urinalysis, and other tests such as rheumatoid factor, anti-CCP, and HBV/HCV testing, will be conducted using a central laboratory (refer to Appendix D and Appendix F). The data from these analyses will be electronically transferred from the central laboratory to the study database.

Laboratory tests including, but not limited to, urine pregnancy testing and ESR, will be conducted locally by each study site (refer to Appendix D and Appendix F). Sites will provide AbbVie with laboratory certifications and normal ranges for each local laboratory used. The full name, address, phone number and fax number for each local laboratory will also be included.

12.0 Use of Information

Any research that may be done using optional exploratory research/validation samples from this study will be experimental in nature and the results will not be suitable for clinical decision making or patient management. Hence, the subject will not be informed of individual results, should analyses be performed, nor will anyone not directly involved in this research. Correspondingly, researchers will have no access to subject identifiers. Individual results will not be reported to anyone not directly involved in this research other than for regulatory purposes. Aggregate data from optional exploratory research/validation studies may be provided to investigators and used in scientific
publications or presented at medical conventions. Exploratory research/validation information will be published or presented only in a way that does not identify any individual subject.

13.0 Completion of the Study

The Investigator will conduct the study in compliance with the protocol and complete the study within the timeframe specified in the contract between the Investigator and AbbVie. Continuation of this study beyond this date must be mutually agreed upon in writing by both the Investigator and AbbVie. The Investigator will provide a final report to the IEC/IRB following conclusion of the study, and will forward a copy of this report to AbbVie or their representative.

The Investigator must submit, maintain, and archive any records related to the study according to ICH GCP and all other applicable regulatory requirements. If the Investigator is not able to retain the records, he/she must notify AbbVie to arrange alternative archiving options.

AbbVie will select the signatory Investigator from the Investigators who participate in the study. Selection criteria for this Investigator will include level of participation as well as significant knowledge of the clinical research, investigational drug, and study protocol. The signatory Investigator for the study will review and sign the final study report in accordance with the European Agency for the Evaluation of Medicinal Products Guidance on Investigator's Signature for Study Reports.

The end-of-study is defined as the date of the last subject's last visit.
14.0 Investigator's Agreement

1. I have received and reviewed the Investigator's Brochure for upadacitinib.

2. I have read this protocol and agree that the study is ethical.

3. I agree to conduct the study as outlined and in accordance with all applicable regulations and guidelines.

4. I agree to maintain the confidentiality of all information received or developed in connection with this protocol.

5. I agree that all electronic signatures will be considered the equivalent of a handwritten signature and will be legally binding.

Protocol Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

Protocol Date: 12 October 2017

____________________________  ______________________________
Signature of Principal Investigator Date

____________________________
Name of Principal Investigator (printed or typed)
15.0 Reference List


Appendix A. Responsibilities of the Clinical Investigator

Clinical research studies sponsored by AbbVie are subject to the Good Clinical Practices (GCP) and local regulations and guidelines governing the study at the site location. In signing the Investigator Agreement in Section 14.0 of this protocol, the investigator is agreeing to the following:

1. Conducting the study in accordance with the relevant, current protocol, making changes in a protocol only after notifying AbbVie, except when necessary to protect the safety, rights or welfare of subjects.

2. Personally conducting or supervising the described investigation(s).

3. Informing all subjects, or persons used as controls, that the drugs are being used for investigational purposes and complying with the requirements relating to informed consent and ethics committees (e.g., independent ethics committee [IEC] or institutional review board [IRB]) review and approval of the protocol and amendments.

4. Reporting adverse experiences that occur in the course of the investigation(s) to AbbVie and the site director.

5. Reading the information in the Investigator's Brochure/safety material provided, including the instructions for use and the potential risks and side effects of the investigational product(s).

6. Informing all associates, colleagues, and employees assisting in the conduct of the study about their obligations in meeting the above commitments.

7. Maintaining adequate and accurate records of the conduct of the study, making those records available for inspection by representatives of AbbVie and/or the appropriate regulatory agency, and retaining all study-related documents until notification from AbbVie.

8. Maintaining records demonstrating that an ethics committee reviewed and approved the initial clinical investigation and all amendments.
9. Reporting promptly, all changes in the research activity and all unanticipated problems involving risks to human subjects or others, to the appropriate individuals (e.g., coordinating investigator, institution director) and/or directly to the ethics committees and AbbVie.

10. Following the protocol and not make any changes in the research without ethics committee approval, except where necessary to eliminate apparent immediate hazards to human subjects.
Appendix B. List of Protocol Signatories

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Functional Area</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Therapeutic Area</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Therapeutic Area</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacovigilance and Patient Safety</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Statistics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Pharmacokinetics and Pharmacodynamics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bioanalysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Program Development</td>
</tr>
</tbody>
</table>
Appendix C. Local Requirements

Canada

Section 5.2.1 Inclusion Criteria

10. If female of childbearing potential, subject must be practicing two forms of contraception (one highly effective method combined with one effective method, refer to Contraception Recommendations for Females below) that are effective from Study Day 1 through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

11. Male subjects who are sexually active with female partner(s) of childbearing potential must agree from Study Day 1 through 30 days after the last dose of study drug to practice the protocol-specified contraception (refer to Contraception Recommendations for Males below).

Section 5.2.4 Contraception Recommendations

Contraception Recommendation for Females

A woman who is postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) is not considered to be a woman of childbearing potential and is not required to follow contraception recommendations. Postmenopausal is defined as:

- Age ≥ 55 years with no menses for 12 or more months without an alternative medical cause; or
- Age < 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level > 40 mIU/mL.
If the female subject is < 55 years of age:

AND has had no menses for $\geq 12$ months AND has no history of permanent surgical sterilization (defined above), FSH should be tested at Screening.

- If FSH is not tested, it is assumed that the subject is of childbearing potential and protocol-specified contraception is required.
- If the FSH is tested and the result is consistent with post-menopausal status, contraception is not required.
- If the FSH is tested and the result is consistent with pre-menopausal status, contraception is required.

For a female subject at any age:

- Female subject with menses within the past 12 months are of childbearing potential and FSH is therefore not required but contraception is required.
- Female subjects who are surgically sterile (defined above) are not of childbearing potential and therefore no FSH testing or contraception is required.

A woman who does not meet the definition of postmenopausal or permanently surgically sterile is considered of childbearing potential and is required to use two forms of contraception. This includes one form of highly effective contraception and one effective method of contraception that are effective from Study Day 1 (or earlier) through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

- Highly effective methods:
  - Hormonal contraceptives started at least 2 months prior to randomization (e.g., combined [estrogen and progestogen containing] oral contraceptives, patch, vaginal ring, injectables, and implants);
  - Intrauterine device (IUD) or intrauterine system (IUS);
  - Vasectomy and tubal ligation.
● Effective methods:
  ○ Barrier methods of contraception (e.g., male condom, female condom, cervical cap, diaphragm, contraceptive sponge).
  ○ Note: The proper use of diaphragm or cervical cap includes use of spermicide and is considered one barrier method. The cervical cap and contraceptive sponge are less effective in parous women. The use of spermicide alone is not considered a suitable barrier method for contraception. When used consistently and correctly, "double barrier" methods of contraception (e.g., male condom with diaphragm, male condom with cervical cap) can be used as an effective alternative to the highly effective contraception methods described above. Male and female condoms should not be used together as they can tear or become damaged.

**Contraception Recommendation for Males**

For a male subject who has a female partner who is postmenopausal or permanently sterile, no contraception is required.

A male subject who is sexually active with female partner(s) of childbearing potential must agree from Study Day 1 through 30 days after the last dose of study drug to practice contraception with:

- Condom use and female partner(s) using at least one of the highly effective contraceptive methods as defined in the protocol for female study subjects of childbearing potential.

Additionally, male subjects must agree not to donate sperm from Study Day 1 through 30 days after the last dose of study drug.

Male subjects are responsible for informing his partner(s) of the risk of becoming pregnant and for reporting any pregnancy to the study doctor. If a pregnancy occurs, a partner authorization form requesting pregnancy outcome information will be requested from the pregnant partner.
Section 5.2.1 Inclusion Criteria

10. If female, subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential practicing at least one protocol specified method of birth control (refer to Contraception Recommendations for Females, below), that is effective from Study Day 1 through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

11. If the male subject is sexually active with female partner(s) of childbearing potential, he must agree, from Study Day 1 through 30 days after the last dose of study drug, to practice the protocol-specified contraception (refer to Contraception Recommendations for Males below).

Section 5.2.4 Contraception Recommendations

**Contraception Recommendation for Females**

A woman who is postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) is not considered to be a woman of childbearing potential and is not required to follow contraception recommendations. Postmenopausal is defined as:

- Age $\geq$ 55 years with no menses for 12 or more months without an alternative medical cause; or
- Age < 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level $>$ 40 mIU/mL.

If the female subject is < 55 years of age:

AND has had no menses for $\geq$ 12 months AND has no history of permanent surgical sterilization (defined above), FSH should be tested at Screening.
● If FSH is not tested, it is assumed that the subject is of childbearing potential and protocol-specified contraception is required.
● If the FSH is tested and the result is consistent with post-menopausal status, contraception is not required.
● If the FSH is tested and the result is consistent with pre-menopausal status, contraception is required.

For a female subject at any age:

● Female subjects with menses within the past 12 months are of childbearing potential and FSH is therefore not required but contraception is required.
● Female subjects who are surgically sterile (defined above) are not of childbearing potential and therefore no FSH testing or contraception is required.

A woman who does not meet the definition of postmenopausal or permanently surgically sterile is considered of childbearing potential and is required to practice at least one of the following highly effective methods of birth control that is effective from Study Day 1 (or earlier) through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

● Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal, injectable) associated with the inhibition of ovulation, initiated at least 1 month prior to Study Day 1.
● Progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, initiated at least 30 days prior to Study Day 1.
● Bilateral tubal occlusion/ligation.
● Vasectomized partner(s), provided the vasectomized partner has received medical confirmation of the surgical success and is the sole sexual partner of the women of childbearing potential trial participant.
● Intrauterine device (IUD).
● Intrauterine hormone-releasing system (IUS).
If required per local practices, male or female condom with or without spermicide OR cap, diaphragm or sponge with spermicide should be used in addition to one of the highly effective birth control methods listed above.

**Contraception Recommendation for Males**

For a male subject who has a female partner who is postmenopausal or permanently sterile, no contraception is required.

A male subject who is sexually active with female partner(s) of childbearing potential must agree from Study Day 1 through 30 days after the last dose of study drug to practice contraception with:

- Condom use and female partner(s) using at least one of the contraceptive measures as defined in the protocol for female study subjects of childbearing potential.

Additionally, male subjects must agree not to donate sperm from Study Day 1 through 30 days after the last dose of study drug.

Male subjects are responsible for informing his partner(s) of the risk of becoming pregnant and for reporting any pregnancy to the study doctor. If a pregnancy occurs, a partner authorization form requesting pregnancy outcome information will be requested from the pregnant partner.
## Appendix D. Study Activities (Period 1)

<table>
<thead>
<tr>
<th>Activity</th>
<th>Screening D –35 to D –1</th>
<th>BL D1&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Wk 2 D15</th>
<th>Wk 4 D29</th>
<th>Wk 8 D57</th>
<th>Wk 12 D85</th>
<th>Wk 16 D113</th>
<th>Wk 20 D141</th>
<th>Wk 24/PD&lt;sup&gt;b&lt;/sup&gt;</th>
<th>30-Day F/U Visit&lt;sup&gt;b&lt;/sup&gt;</th>
<th>70-Day F/U Visit&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical/surgical history&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol and nicotine use</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse event assessment&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Only SAEs and protocol-related nonserious AEs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Prior/concomitant therapy</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires&lt;sup&gt;g&lt;/sup&gt;</td>
<td>PtGA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pain (VAS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HAQ-DI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morning Stiffness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires&lt;sup&gt;g&lt;/sup&gt;</td>
<td>WPAI RA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires&lt;sup&gt;g&lt;/sup&gt;</td>
<td>EQ-5D-5L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SF-36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaire&lt;sup&gt;g&lt;/sup&gt;</td>
<td>FACIT-F</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latent TB risk assessment form&lt;sup&gt;h&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Central lab Quantiferon-TB Gold test&lt;sup&gt;h&lt;/sup&gt; (and/or local PPD skin test)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> 30-Day F/U Visit<sup>b</sup> 70-Day F/U Visit<sup>b</sup>
<table>
<thead>
<tr>
<th>Activity</th>
<th>Screening</th>
<th>BL</th>
<th>Wk 2</th>
<th>Wk 4</th>
<th>Wk 8</th>
<th>Wk 12</th>
<th>Wk 16</th>
<th>Wk 20</th>
<th>Wk 24/25</th>
<th>30-Day F/U Visit&lt;sup&gt;b&lt;/sup&gt;</th>
<th>70-Day F/U Visit&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upadacitinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M15-925 Protocol Amendment 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EudraCT 2016-0009-37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upadacitinib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M15-925 Protocol Amendment 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EudraCT 2016-0009-37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activity</td>
<td>Screening</td>
<td>BL</td>
<td>Wk 2</td>
<td>Wk 4</td>
<td>Wk 8</td>
<td>Wk 12</td>
<td>Wk 16</td>
<td>Wk 20</td>
<td>Wk 24/25</td>
<td>30-Day F/U Visit&lt;sup&gt;b&lt;/sup&gt;</td>
<td>70-Day F/U Visit&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Chest x-ray&lt;sup&gt;j&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-lead ECG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height (screening only) and weight</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs&lt;sup&gt;m&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical exam&lt;sup&gt;n&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician Global Assessment (PhGA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TJC68/SJC66</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20% joint assessment (TJC and SJC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum pregnancy test at central lab&lt;sup&gt;o&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local urine pregnancy test&lt;sup&gt;p&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central Lab Tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsCRP&lt;sup&gt;q&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood chemistry&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology (CBC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinalysis&lt;sup&gt;s&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR (local lab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Central Lab Tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-CCP autoantibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV&lt;sup&gt;r&lt;/sup&gt;/HBV/HCV screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FSH (as applicable)&lt;sup&gt;t&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood samples for upadacitinib PK assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activity</td>
<td>Screening</td>
<td>BL</td>
<td>Wk 2</td>
<td>Wk 4</td>
<td>Wk 8</td>
<td>Wk 12</td>
<td>Wk 16</td>
<td>Wk 20</td>
<td>Wk 24/PD</td>
<td>30-Day F/U Visita</td>
<td>70-Day F/U Visita</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>-----------</td>
<td>----</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-----------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Blood samples for exploratory research and validation studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(optional – see Appendix E)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Randomization/Drug assignment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dispense study drug</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>IV study drug infusion (abatacept or matching placebo)</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dispense subject dosing diary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review and copy subject dosing diary and perform drug reconciliation</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BL = Baseline Visit; CBC = complete blood count; CCP = cyclic citrullinated peptide; D = Day; ECG = electrocardiogram; EQ-5D-5L = EuroQoL-5D; ESR = erythrocyte sedimentation rate; F/U = Follow-up; HAQ-DI = Health Assessment Questionnaire – Disability Index; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; hsCRP = high-sensitivity C-reactive protein; NRS = numerical rating scale; PD = Premature Discontinuation (completely from study [withdrawal of consent]); PhGA = Physician’s Global Assessment of Disease Activity; PK = pharmacokinetics; PPD = purified protein derivative; PtGA = Patient’s Global Assessment of Disease Activity; SAE = serious adverse event; SJC = Swollen Joint Count; SF-36 = 36-Item Short Form Health Survey; TB = tuberculosis; TJC = Tender Joint Count; VAS = visual analog scale; Wk = Week

a. If a subject prematurely discontinues study participation (withdrawal of informed consent), the procedures outlined for the Premature Discontinuation visit (PD visit) should be completed as soon as possible, preferably within 2 weeks of study drug discontinuation.
b. These visits are 30 and 70 days after last dose of study drug for those subjects who complete Period 1 and do NOT enter Period 2. The 30 and 70-day follow-up phone call to determine the status of any ongoing AEs/SAEs or the occurrence of any new AEs/SAEs may be allowed for subjects who prematurely discontinue from study and have completed the PD visit.
c. The Baseline visit procedures will serve as the reference for all subsequent visits with the exception of the ECG, which will be obtained at Screening only and used as the baseline reference.
d. Informed consent should be obtained at Screening prior to performing any study related procedures.
e. Document herpes zoster and hepatitis B vaccination status in medical history.
f. Collect serious adverse events and protocol-related nonserious AEs that occur after a subject signs the informed consent, prior to the first dose of study drug.

h. Refer to Section 5.3.1.1 Study Procedures TB Testing for specific requirements for TB testing and TB prophylaxis.

i. The chest x-ray will not be required if a subject had a previous normal chest-x-ray within 90 days of Screening, provided that all source documentation is available at the site (refer to Section 5.3.1.1 Chest X-Ray for specific requirements).

j. For subjects with a normal ECG taken within 90 days of Screening, a repeat ECG at Screening will not be required, provided all source documentation is available. Refer to Section 5.3.1.1 12-Lead ECG for additional details.

k. For subjects who do not enter Period 2 or prematurely discontinue from the study, an ECG will be performed.

l. Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blood draws are performed.

m. A full physical exam is required at the visits indicated. A symptom-directed physical exam may be performed when necessary.

n. Starting at Week 12 and thereafter, subjects who do not achieve ≥ 20% improvement in both TJC and SJC compared to baseline at 2 consecutive visits, should receive rescue medication as described in Section 5.2.3.3. Starting at Week 12 and thereafter, subjects who demonstrate worsening of joint count (SJC or TJC) from baseline at 2 consecutive visits should be discontinued from study drug and treated according to standard of care and at the discretion of the clinician.

p. For all women of childbearing potential, collect serum for pregnancy test only at Screening. If serum pregnancy test comes back borderline, a repeat test is necessary (pregnancy is an exclusion criterion). Refer to Section 5.3.1.1 Study Procedures Pregnancy Test for additional details.

q. In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject. Results of hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event management. Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib. In Period 2, the central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.

r. Minimum 8-hour fast. If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study source documentation.

s. A urine dipstick macroscopic urinalysis will be completed by the central laboratory at all required visits. A microscopic analysis will be performed in the event the dipstick results show leukocytes, nitrite, protein, ketones, or blood greater than negative or glucose greater than normal.
t. HIV testing will be performed at Screening, unless prohibited by local regulations. The Investigator must discuss any local reporting requirements to local health agencies with the subject. The site will report confirmed positive results to their health agency per local regulations, if necessary. If the result is confirmed as positive, then the Investigator will discuss with the subject potential implications to the subject’s health and next steps. If a subject has a confirmed positive result, the Investigator must discuss with the subject the potential implications to the subject’s health and subject should receive or be referred for clinical care promptly. A subject will not be eligible for study participation if test results indicate a positive HIV infection. AbbVie will not receive results from the testing and will not be made aware of any positive result.

u. FSH should be tested at Screening if the female subject is < 55 years of age AND has had no menses ≥ 12 months AND has no history of permanent surgical sterilization (defined in Section 5.2.4).

v. At Week 2 visits, PK samples should be collected prior to dosing and the subjects should take the study drug dose at the clinic after collecting the PK blood sample. However, if the subject normally takes the study drug dose at a time that is after the time of the scheduled study visit, the subject should follow the regular dosing schedule and the PK sample should be collected at any time during the visit.

w. PK samples should be collected at any time during the visit. Subject should follow the regular dosing schedule.

x. Samples only collected if subject provides written consent.

y. For subjects entering Period 2 only. Each subject will be dispensed one (1) bottle containing 100 tablets (a 12-week supply). One (1) bottle of 100 tablets will be dispensed every 12 weeks for the remaining Period 2 visits.

Note: Visit window is ± 3 days for Period 1. Any of the procedures may be performed at an unscheduled visit at the discretion of the Investigator. Subjects who choose to discontinue study drug treatment, but continue to participate in the study should follow the regular visit schedule and adhere to all study procedures except for dispensing study drug, PK sample collection, and blood sample collection for optional exploratory research and validation studies.
### Appendix E. Study Activities – Optional Samples for Exploratory Research and Validation Studies (Period 1 Only)

<table>
<thead>
<tr>
<th>Activity</th>
<th>Screening</th>
<th>BL</th>
<th>Wk 2</th>
<th>Wk 4</th>
<th>Wk 8</th>
<th>Wk 12</th>
<th>Wk 16</th>
<th>Wk 20</th>
<th>Wk 24/PD</th>
<th>30 or 70-Day F/U Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D–35 to D–1</td>
<td>D1</td>
<td>D15</td>
<td>D29</td>
<td>D57</td>
<td>D85</td>
<td>D113</td>
<td>D141</td>
<td>D169</td>
<td></td>
</tr>
<tr>
<td>Pharmacogenetic samples(^{a,b})</td>
<td>--</td>
<td>X</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Epigenetic samples(^b)</td>
<td>--</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>--</td>
<td>X</td>
<td>--</td>
<td>--</td>
<td>X</td>
<td>--</td>
</tr>
<tr>
<td>Transcriptomic and epigenetic samples(^b)</td>
<td>--</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>--</td>
<td>X</td>
<td>--</td>
<td>--</td>
<td>X</td>
<td>--</td>
</tr>
<tr>
<td>Plasma samples for proteomic and targeted protein investigations(^b)</td>
<td>--</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>--</td>
<td>X</td>
<td>--</td>
<td>--</td>
<td>X</td>
<td>--</td>
</tr>
<tr>
<td>Serum samples for proteomic and targeted protein investigations(^b)</td>
<td>--</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>--</td>
<td>X</td>
<td>--</td>
<td>--</td>
<td>X</td>
<td>--</td>
</tr>
</tbody>
</table>

**Notes:**
- Collections to be performed only if subject provides separate written consent to collect the exploratory research/validation studies samples; if the separate consent is not signed, no samples can be collected. The separate written consent may be part of the main consent form.
- It is preferred that the subject is fasting prior to sample collection, however it is not required. It must be recorded whether subject is fasting or non-fasting at the time of collection.

\(^{a}\) The sample is preferred to be collected at BL, but can be drawn at any time during the subject’s participation.

\(^{b}\) Based on the value of the different technologies, samples may also be used to assess other biomarker signatures, including but not limited to metabolomics, lipidomics, and other approaches.
## Appendix F. Study Activities (Period 2)

<table>
<thead>
<tr>
<th>Activity</th>
<th>Wk 28</th>
<th>Wk 32</th>
<th>Wk 36</th>
<th>Wk 48</th>
<th>Monthly</th>
<th>Every 12 Weeks Until Study Completion</th>
<th>Every 24 Weeks Until Study Completion</th>
<th>Every 48 Weeks Until Study Completion</th>
<th>Final/PD Visit</th>
<th>30-Day F/U Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDAI Calculation&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SJC/TJC&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse event assessment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant therapy</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PtGA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain (VAS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAQ-DI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morning Stiffness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ-5D-5L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF-36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FACIT-F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WPAI RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latent TB risk assessment form</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central lab QuantiFERON-TB Gold test&lt;sup&gt;e&lt;/sup&gt; (and/or local PPD skin test)</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest x-ray&lt;sup&gt;f&lt;/sup&gt;</td>
<td>X&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-lead ECG&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs and body weight&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical exam&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician Global Assessment (PhGA)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activity</td>
<td>Wk 28</td>
<td>Wk 32</td>
<td>Wk 36</td>
<td>Wk 48</td>
<td>Monthly</td>
<td>Every 12 Weeks Until Study Completion&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Every 24 Weeks Until Study Completion&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Every 48 Weeks Until Study Completion&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Final/PD Visit</td>
<td>30-Day F/U Visit&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>---------</td>
<td>-----------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------</td>
<td>---------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Local urine pregnancy test&lt;sup&gt;1&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>At home urine pregnancy test&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central lab tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>hsCRP&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood chemistry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology (CBC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinalysis&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR (local lab)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dispense study drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review and copy subject dosing diary and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>perform drug reconciliation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BL = Baseline Visit; CBC = complete blood count; csDMARD = conventional synthetic disease-modifying anti-rheumatic drug; ECG = electrocardiogram; F/U = Follow-up; HAQ-DI = Health Assessment Questionnaire – Disability Index; hsCRP = high-sensitivity C-reactive protein; NRS = numerical rating scale; PD = Premature Discontinuation; PhGA = Physician’s Global Assessment of Disease Activity; PPD = purified protein derivative; PtGA = Patient's Global Assessment of Disease Activity; SAE = serious adverse event; SJC = Swollen Joint Count; TB = tuberculosis; TJC = Tender Joint Count; VAS = visual analog scale; Wk = Week

<sup>a</sup> Every 12, 24, or 48 weeks from the Week 48 visit.

<sup>b</sup> This visit is 30 days after last dose of study drug for those subjects who complete Period 2. A 30-day follow-up phone call may be allowed for subjects who have completed PD visit to determine the status of any ongoing AEs/SAEs or the occurrence of any new AEs/SAEs.

<sup>c</sup> Starting at Week 28 and thereafter, study drug should be discontinued for subjects who fail to show at least 20% improvement in TJC and SJC compared to baseline at 2 consecutive visits despite optimization of background RA therapies. Starting at Week 28 and thereafter, subjects who achieve ≥ 20% improvement in both TJC and SJC but fail to achieve CDAI ≤ 10 at two consecutive visits will be given the option, at the discretion of the investigator, whether to continue study or discontinue study drug and be treated with standard of care at the discretion of the investigator.

<sup>d</sup> Prior to other procedures. For morning stiffness, duration will be captured only if NRS rating is > 0.

<sup>e</sup> TB testing should be performed every 48 weeks after Week 48 in subjects with previous negative TB test. Subjects with new evidence of latent TB must initiate prophylactic treatment immediately per local guidelines. Refer to Section 5.3.1.1 TB Testing/TB Prophylaxis for additional details.
f. Obtain chest x-ray every 48 weeks after Week 48 for subjects with TB risk factors as identified by the TB risk assessment form, or for subjects living in areas endemic for TB, or for subjects with a newly positive TB test after baseline.

g. In addition to ECG assessments as indicated above, an ECG may be performed at any visit if deemed necessary by the Investigator.

h. Blood pressure, pulse rate, body temperature, and respiratory rate should be performed before blood draws are performed.

i. A full physical exam is required every 24 weeks after Week 48. A symptom-directed physical exam may be performed when necessary.

j. For all women of childbearing potential, a urine pregnancy test will be performed at all visits and monthly at home between scheduled study visits. The results of the monthly at home tests will be communicated to the site. If a urine pregnancy test is positive, the subject must stop dosing, come in to the clinic and have blood drawn for a serum pregnancy test that will be analyzed at the central laboratory. Pregnant subjects must permanently discontinue study drug. Refer to Section 5.3.1.1 Study Procedures Pregnancy Test for additional details.

k. In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject. Results of hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event management. Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib. In Period 2, the central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.

l. Minimum 8-hour fast. If a subject is not able to fast when necessary, due to unforeseen circumstances, the non-fasting status will be recorded in study source documentation.

m. Dipstick urinalysis will be completed by the central lab at all required visits. Specified abnormal macroscopic urinalyses defined as leukocytes, nitrite, protein, ketones, or blood greater than negative, or glucose greater than normal will be followed up with a microscopic analysis at the central laboratory.

Note: Visit window is ±7 days for Period 2. Any of the procedures may be performed at an unscheduled visit at the discretion of the Investigator. Subjects who choose to discontinue study drug treatment, but continue to participate in the study should follow the regular visit schedule and adhere to all study procedures except for dispensing study drug and blood sample collection for optional exploratory research and validation studies.
Appendix G. Physician's Global Assessment of Disease Activity Example

**Visual Analog Scale (VAS)**

VAS will be used to assess the physician's global assessment of disease activity. The VAS consists of a horizontal 100 mm line anchored at either end by opposite adjectives reflecting the spectrum/severity of the parameters assessed:

- Physician's global assessment of disease activity (current status). The Physician will rate global assessment of subject's current disease activity ranging from 0 to 100 (see example below)

Mark the line below to indicate the subject's rheumatoid arthritis disease activity (independent of the subject's self-assessment).

<table>
<thead>
<tr>
<th>0</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Low</td>
<td>Very High</td>
</tr>
</tbody>
</table>
Appendix H. Joint Evaluation Worksheet Example

<p>| JOINT (Tick Correct Answer) | Subject Right | | | | Subject Left | | | |
|-----------------------------|---------------|-----------------|----------------|-----------------|-----------------|-----------------|-----------------|
|                             | Pain/Tenderness | Swelling | Joint | Pain/Tenderness | Swelling | Joint | Pain/Tenderness | Swelling | Joint |
| 1. Temporomandibular        | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 2. Sternoclavicular         | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 3. Acromio-clavicular       | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 4. Shoulder                 | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 5. Elbow                    | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 6. Wrist                    | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 7. Metacarpophalangeal I    | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 8. Metacarpophalangeal II   | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 9. Metacarpophalangeal III  | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 10. Metacarpophalangeal IV  | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 11. Metacarpophalangeal V   | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 12. Thumb Interphalangeal   | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 13. Prox. Interphalangeal II| 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 14. Prox. Interphalangeal III| 0           | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 15. Prox. Interphalangeal IV| 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 16. Prox. Interphalangeal V | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 17. Distal Interphalangeal II| 0            | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 18. Distal Interphalangeal III| 0          | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 19. Distal Interphalangeal IV| 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 20. Distal Interphalangeal V | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 21. Hip                      | 0             | 1            | --  | --             | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 22. Knee                    | 0             | 1            | 1    | 0              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 23. Ankle                   | 0             | 1            | 1    | 0              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 24. Tarsus                  | 0             | 1            | 1    | 0              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 25. Metatarsophalangeal I    | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |
| 26. Metatarsophalangeal II   | 0             | 1            | 0    | 1              | 1            | 9     | 0             | 1            | 1    | 9     | NA     |</p>
<table>
<thead>
<tr>
<th>JOINT (Tick Correct Answer)</th>
<th>Subject Right</th>
<th>9 = Replaced NA = No Assessment</th>
<th>Subject Left</th>
<th>9 = Replaced NA = No Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 = Absent 1 = Present</td>
<td></td>
<td>0 = Absent 1 = Present</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pain/Tenderness</td>
<td>Swelling</td>
<td>Joint</td>
<td>Pain/Tenderness</td>
</tr>
<tr>
<td>27. Metatarsophalangeal III</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>28. Metatarsophalangeal IV</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>29. Metatarsophalangeal V</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>30. Great Toe/Hallux</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>31. Interphalangeal II</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>32. Interphalangeal III</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>33. Interphalangeal IV</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>34. Interphalangeal V</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>TOTAL Joint Count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix I.  Latent TB Risk Assessment Form Example

1. Have you or an immediate family member or other close contact ever been diagnosed or treated for tuberculosis?

2. Have you lived in or had prolonged travels to countries in the following regions:
   - Africa
   - Eastern Europe
   - Asia
   - Latin America
   - Caribbean Islands
   - Russia

3. Have you lived or worked in a prison, homeless shelter/refugee camp, immigration center, health care worker in a hospital or nursing home?

4. Have you, or an immediate family member, had any of the following problems for the past 3 weeks or longer:
   - Chronic Cough
   - Chest pain, or pain with breathing or coughing
   - Blood-Streaked Sputum (coughing up blood)
   - Unexplained Weight Loss
   - Fever
   - Fatigue/Tiredness
   - Night Sweats
   - Shortness of Breath

From:  http://www.mayoclinic.org/diseases-conditions/tuberculosis/symptoms-causes/dxc-20188557
Appendix J. Patient's Global Assessment of Disease Activity Example

Visual Analog Scale (VAS)

VAS will be used to assess the subject's global assessment of disease activity. Each VAS consists of a horizontal 100 mm line anchored at either end by opposite adjectives reflecting the spectrum/severity of the parameters assessed:

- Subject's global assessment of disease activity (within last 24 hours)

The subject will rate the severity of the RA symptoms and how he/she is doing from 0 to 100. This assessment will be used for the DAS28 (CRP) calculation in this study (see example below):

Please place a vertical mark on the line below to indicate how well your rheumatoid arthritis has been doing during THE LAST 24 HOURS:

0
Very Well

100
Very Poorly
Appendix K. Patient's Assessment of Pain Example

Visual Analog Scale (VAS)

VAS will be used to assess the subject's assessment of pain. Each VAS consists of a horizontal 100 mm line anchored at either end by opposite adjectives reflecting the spectrum/severity of the parameters assessed:

How much pain have you had because of your condition within the previous week?

Place a mark on the line below to indicate how severe your pain has been.

NO PAIN

______________________________________________________________________

WORST
POSSIBLE PAIN
Appendix L. Health Assessment Questionnaire (HAQ-DI) Example

**HEALTH ASSESSMENT QUESTIONNAIRE**

In this section we are interested in learning how your illness affects your ability to function in daily life.

Please check the response which best describes your usual abilities OVER THE PAST WEEK:

<table>
<thead>
<tr>
<th>WITHOUT ANY DIFFICULTY</th>
<th>WITH SOME DIFFICULTY</th>
<th>WITH MUCH DIFFICULTY</th>
<th>UNABLE TO DO</th>
</tr>
</thead>
</table>

**DRESSING AND GROOMING**

Are you able to:

- Dress yourself, including tying shoelaces and doing buttons? 🍃 □ □ □ □ □
- Shampoo your hair? 🍃 □ □ □ □ □

**ARISING**

Are you able to:

- Stand up from a straight chair? 🍃 □ □ □ □ □
- Get in and out of bed? 🍃 □ □ □ □ □

**EATING**

Are you able to:

- Cut your own meat? 🍃 □ □ □ □ □
- Lift a full cup or glass to your mouth? 🍃 □ □ □ □ □
- Open a new milk carton? 🍃 □ □ □ □ □

**WALKING**

Are you able to:

- Walk outdoors on flat ground? 🍃 □ □ □ □ □
- Climb up five steps? 🍃 □ □ □ □ □

Please check any AIDS OR DEVICES that you usually use for any of these activities:

- Cane 🍃 Devices used for dressing (button hook, zipper pull, long handled shoe horn, etc.)
- Walker 🍃 Built up or special utensils
- Crutches 🍃 Special or built up chair
- Wheelchair 🍃 Other (Specify: ________________ )
Please check any categories for which you usually need HELP FROM ANOTHER PERSON:

- Dressing and Grooming
- Eating
- Arising
- Walking

Please check the response which best describes your usual abilities OVER THE PAST WEEK:

<table>
<thead>
<tr>
<th>HYGIENE</th>
<th>WITHOUT ANY DIFFICULTY</th>
<th>WITH SOME DIFFICULTY</th>
<th>WITH MUCH DIFFICULTY</th>
<th>UNABLE TO DO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wash and dry your body?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Take a tub bath?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Get on and off the toilet?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REACH</th>
<th>WITHOUT ANY DIFFICULTY</th>
<th>WITH SOME DIFFICULTY</th>
<th>WITH MUCH DIFFICULTY</th>
<th>UNABLE TO DO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reach and get down a 5-pound object (such as a bag of sugar) from just above your head?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Bend down to pick up clothing from the floor?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GRIP</th>
<th>WITHOUT ANY DIFFICULTY</th>
<th>WITH SOME DIFFICULTY</th>
<th>WITH MUCH DIFFICULTY</th>
<th>UNABLE TO DO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open car doors?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Open jars which have been previously opened?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Turn faucets on and off?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ACTIVITIES</th>
<th>WITHOUT ANY DIFFICULTY</th>
<th>WITH SOME DIFFICULTY</th>
<th>WITH MUCH DIFFICULTY</th>
<th>UNABLE TO DO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Run errands and shop?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Get in and out of a car?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Do chores such as vacuuming or yard work?</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

Please check any AIDS OR DEVICES that you usually use for any of these activities:

- Raised toilet seat
- Bathtub seat
- Jar opener (for jars previously opened)
- Bathtub bar
- Long-handled appliances for reach
- Long-handled appliances in bathroom
- Other (Specify: ________________ )
Please check any categories for which you usually need HELP FROM ANOTHER PERSON:

☐ Hygiene
☐ Reach
☐ Gripping and opening things
☐ Errands and chores

HAQ – United States/English
HAQ-DL_AU1.0-eng-USori.doc © Stanford University
Appendix M. Patient's Assessment of Severity and Duration of Morning Stiffness Example

Instructions:

Please clearly mark an 'x' in the box (☑) that best describes your experience with morning stiffness on awakening in the past 7 days.

No morning stiffness

Worst possible morning stiffness

When you experience morning stiffness, how long does it take to get as limber as possible: _____ hours _____ minutes
Appendix N.  EuroQoL-5D-5L Example

Under each heading, please check the ONE box that best describes your health TODAY:

Mobility

I have no problems walking  ☐
I have slight problems walking  ☐
I have moderate problems walking  ☐
I have severe problems walking  ☐
I am unable to walk  ☐

Self-Care

I have no problems washing or dressing myself  ☐
I have slight problems washing or dressing myself  ☐
I have moderate problems washing or dressing myself  ☐
I have severe problems washing or dressing myself  ☐
I am unable to wash or dress myself  ☐

Usual Activities (e.g., work, study, housework, family or leisure activities)

I have no problems with doing my usual activities  ☐
I have slight problems with doing my usual activities  ☐
I have moderate problems with doing my usual activities  ☐
I have severe problems with doing my usual activities  ☐
I am unable to do my usual activities  ☐
**Pain/Discomfort**

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

**Anxiety/Depression**

- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed
We would like to know how good or bad your health is TODAY.

This scale is numbered from 0 to 100.

100 means the best health you can imagine.
0 means the worst health you can imagine.

Mark an X on the scale to indicate how your health is TODAY.

Now, please write the number you marked on the scale in the box below.

YOUR HEALTH TODAY = ___
Appendix O.  Short Form-36 (SF-36™) Health Status Survey Questionnaire  
Example

Your Health and Well-Being

This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities. Thank you for completing this survey!

For each of the following questions, please mark an ☒ in the box that best describes your answer.

1. In general, would you say your health is:

<table>
<thead>
<tr>
<th>Excellent</th>
<th>Very good</th>
<th>Good</th>
<th>Fair</th>
<th>Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
</tr>
<tr>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
</tbody>
</table>

2. Compared to 1 year ago, how would you rate your health in general now?

<table>
<thead>
<tr>
<th>Much better now than one year ago</th>
<th>Somewhat better now than one year ago</th>
<th>About the same as one year ago</th>
<th>Somewhat worse now than one year ago</th>
<th>Much worse now than one year ago</th>
</tr>
</thead>
<tbody>
<tr>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
<td>![ ]</td>
</tr>
<tr>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
</tbody>
</table>
3. The following questions are about activities you might do during a typical day. Does your health now limit you in these activities? If so, how much?

<table>
<thead>
<tr>
<th></th>
<th>Yes, limited a lot</th>
<th>Yes, limited a little</th>
<th>No, not limited at all</th>
</tr>
</thead>
<tbody>
<tr>
<td>a</td>
<td>Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>b</td>
<td>Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>c</td>
<td>Lifting or carrying groceries</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>d</td>
<td>Climbing several flights of stairs</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>e</td>
<td>Climbing one flight of stairs</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>f</td>
<td>Bending, kneeling, or stooping</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>g</td>
<td>Walking more than a mile</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>h</td>
<td>Walking several hundred yards</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>i</td>
<td>Walking one hundred yards</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
<tr>
<td>j</td>
<td>Bathing or dressing yourself</td>
<td>[ ] 1</td>
<td>[ ] 2</td>
</tr>
</tbody>
</table>
4. During the past 4 weeks, how much of the time have you had any of the following problems with your work or other regular daily activities as a result of your physical health?

<table>
<thead>
<tr>
<th>Problem</th>
<th>All of the time</th>
<th>Most of the time</th>
<th>Some of the time</th>
<th>A little of the time</th>
<th>None of the time</th>
</tr>
</thead>
<tbody>
<tr>
<td>a  Cut down on the amount of time you spent on work or other activities</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>b  Accomplished less than you would like</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>c  Were limited in the kind of work or other activities</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>d  Had difficulty performing the work or other activities (for example, it took extra effort)</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
</tbody>
</table>
5. During the past 4 weeks, how much of the time have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious)?

<table>
<thead>
<tr>
<th></th>
<th>All of the time</th>
<th>Most of the time</th>
<th>Some of the time</th>
<th>A little of the time</th>
<th>None of the time</th>
</tr>
</thead>
<tbody>
<tr>
<td>a Cut down on the amount of time you spent on work or other activities</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>b Accomplished less than you would like</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
<tr>
<td>c Did work or other activities less carefully than usual</td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
</tbody>
</table>

6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?

<table>
<thead>
<tr>
<th></th>
<th>Not at all</th>
<th>Slightly</th>
<th>Moderately</th>
<th>Quite a bit</th>
<th>Extremely</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
</tr>
</tbody>
</table>

7. How much bodily pain have you had during the past 4 weeks?

<table>
<thead>
<tr>
<th></th>
<th>None</th>
<th>Very mild</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Very Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>☐ 1</td>
<td>☐ 2</td>
<td>☐ 3</td>
<td>☐ 4</td>
<td>☐ 5</td>
<td>☐ 6</td>
</tr>
</tbody>
</table>
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?

<table>
<thead>
<tr>
<th>Not at all</th>
<th>A little bit</th>
<th>Moderately</th>
<th>Quite a bit</th>
<th>Extremely</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐1</td>
<td>☐2</td>
<td>☐3</td>
<td>☐4</td>
<td>☐5</td>
</tr>
</tbody>
</table>

9. These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks:

<table>
<thead>
<tr>
<th>All of the time</th>
<th>Most of the time</th>
<th>Some of the time</th>
<th>A little of the time</th>
<th>None of the time</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐1</td>
<td>☐2</td>
<td>☐3</td>
<td>☐4</td>
<td>☐5</td>
</tr>
</tbody>
</table>

a. Did you feel full of life?  

b. Have you been very nervous?  

c. Have you felt so down in the dumps that nothing could cheer you up?  

d. Have you felt calm and peaceful?  

e. Did you have a lot of energy?  

f. Have you felt downhearted and depressed?  

g. Did you feel worn out?  

h. Have you been happy?  

i. Did you feel tired?
10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?

<table>
<thead>
<tr>
<th>All of the time</th>
<th>Most of the time</th>
<th>Some of the time</th>
<th>A little of the time</th>
<th>None of the time</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ 1</td>
<td>□ 2</td>
<td>□ 3</td>
<td>□ 4</td>
<td>□ 5</td>
</tr>
</tbody>
</table>

11. How TRUE or FALSE is each of the following statements for you?

<table>
<thead>
<tr>
<th>Definitely true</th>
<th>Mostly true</th>
<th>Don't know</th>
<th>Mostly false</th>
<th>Definitely false</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

a  I seem to get sick a little easier than other people

b I am as healthy as anybody I know

c I expect my health to get worse

d My health is excellent

THANK YOU FOR COMPLETING THESE QUESTIONS

SF-36v2™ Health Survey© 1996, 2000 by QualityMetric Incorporated and Medical Outcomes Trust. All Rights Reserved.
SF-36® is a registered trademark of Medical Outcomes Trust
(SF-36v2 Standard, US Version 2.0)
Appendix P. Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) Scale Example

Below is a list of statements that other people with your illness have said are important. Please circle or mark one number per line to indicate your response as it applies to the past 7 days.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>A little bit</th>
<th>Somewhat</th>
<th>Quite a bit</th>
<th>Very much</th>
</tr>
</thead>
<tbody>
<tr>
<td>E17</td>
<td>I feel fatigued.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>E12</td>
<td>I feel weak all over.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa1</td>
<td>I feel listless (“washed out”).</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa2</td>
<td>I feel tired.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa3</td>
<td>I have trouble starting things because I am tired.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa4</td>
<td>I have trouble finishing things because I am tired.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa5</td>
<td>I have energy.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa7</td>
<td>I am able to do my usual activities.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa8</td>
<td>I need to sleep during the day.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa12</td>
<td>I am too tired to eat.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa14</td>
<td>I need help doing my usual activities.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa15</td>
<td>I am frustrated by being too tired to do the things I want to.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Aa16</td>
<td>I have to limit my social activity because I am tired.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>
Appendix Q. Work Productivity and Activity Impairment Questionnaire: Rheumatoid arthritis V2.0 (WPAI:RA)

The following questions ask about the effect of your rheumatoid arthritis on your ability to work and perform normal daily activities. Please fill in the blanks or circle a number, as indicated.

1. Are you currently employed (working for pay)? _____ NO ___ YES

If 'NO,' tick "NO" and skip to question 6.

The next questions refer to the past seven days, not including today.

2. During the past 7 days, how many hours did you miss from work because of problems associated with your rheumatoid arthritis? Include hours you missed on sick days, times you went in late, left early, etc., because of your rheumatoid arthritis. Do not include time you missed to participate in this study.

_____ HOURS

3. During the past 7 days, how many hours did you miss from work because of any other reason, such as annual leave, holidays, time off to participate in this study?

_____ HOURS

4. During the past 7 days, how many hours did you actually work?

_____ HOURS (If "0," skip to question 6.)

5. During the past 7 days, how much did your rheumatoid arthritis affect your productivity while you were working?

Think about days you were limited in the amount or kind of work you could do, days you accomplished less than you would like, or days you could not do your work as carefully as usual. If rheumatoid arthritis affected your work only a little, choose a low number. Choose a high number if rheumatoid arthritis affected your work a great deal.
Consider only how much **rheumatoid arthritis** affected productivity while you were working.

<table>
<thead>
<tr>
<th>Rheumatoid arthritis had no effect on my work</th>
<th>Rheumatoid arthritis completely prevented me from working</th>
</tr>
</thead>
<tbody>
<tr>
<td>0    1    2    3    4    5    6    7    8    9    10</td>
<td></td>
</tr>
</tbody>
</table>

**CIRCLE A NUMBER**

6. During the past 7 days, how much did your rheumatoid arthritis problems affect your ability to perform your regular daily activities, other than work at a job?

*By regular activities, we mean the usual activities you perform, such as working around the house, shopping, childcare, exercising, studying, etc. Think about times you were limited in the amount or kind of activities you could perform and times you accomplished less than you would like. If rheumatoid arthritis affected your activities only a little, choose a low number. Choose a high number if rheumatoid arthritis affected your activities a great deal.*

Consider only how much **rheumatoid arthritis** affected your ability to perform your regular daily activities, other than work at a job.
Rheumatoid arthritis had no effect on my daily activities

0 1 2 3 4 5 6 7 8 9 10

CIRCLE A NUMBER

Rheumatoid arthritis completely prevented me from performing my daily activities

WPAI:RA V2.0 (US English)
Appendix R.  Rheumatology Common Toxicity Criteria v.2.0 Example

For designation of adverse event terms not shown in the Rheumatology Common Toxicity Criteria v.2.0 table, the approach described in Row 1 should be used.
<table>
<thead>
<tr>
<th>Tiers</th>
<th>Description</th>
<th>1 – Mild</th>
<th>2 – Moderate</th>
<th>3 – Severe</th>
<th>4 – Includes Life Threatening</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>No medication or OTC</td>
<td>Symptomatic</td>
<td>Prolonged symptoms, reversible, major functional impairment</td>
<td>At risk of death</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asymptomatic, or transient</td>
<td>Duration (1 – 2 weeks)</td>
<td>major functional impairment</td>
<td>Substantial disability, especially if permanent.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Short duration (&lt; 1 week)</td>
<td>Alter lifestyle occasionally</td>
<td>Prescription meds/partial relief</td>
<td>Multiple meds</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No change in lifestyle</td>
<td>Meds relieve, (may be prescription)</td>
<td>May be hospitalized &lt; 24 hr</td>
<td>Hospitalised &gt; 24 hr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Study drug continued</td>
<td>Temporary study drug discontinuation, or/and dose reduced</td>
<td>Study drug discontinued</td>
</tr>
</tbody>
</table>

A. Allergic/Immunologic

A1. Allergic reaction/ hypersensitivity (includes drug fever)

<table>
<thead>
<tr>
<th>Description</th>
<th>Transient rash: drug fever &lt; 38°C: transient, asymptomatic bronchospasm</th>
<th>Generalised urticaria responsive to meds; or drug fever &gt; 38°C, or reversible bronchospasm</th>
<th>Symptomatic bronchospasm requiring meds; symptomatic urticaria persisting with meds, allergy related oedema/angioedema</th>
<th>Anaphylaxis, laryngeal/pharyngeal oedema, requiring resuscitation</th>
</tr>
</thead>
</table>

A2. Autoimmune reaction

<table>
<thead>
<tr>
<th>Description</th>
<th>Seriologic or other evidence of autoimmune reaction, but patient asymptomatic: all organ function normal and no treatment is required (e.g., vitiligo)</th>
<th>Evidence of autoimmune reaction involving a non-essential organ or functions, requiring treatment other than immunosuppressive drugs (e.g., hypothyroidism)</th>
<th>Reversible autoimmune reaction involving function of a major organ or toxicity requiring short term immunosuppressive treatment (e.g., transient colitis or anaemia)</th>
<th>Causes major organ dysfunction, or progressive, not reversible, or requires long term administration of high dose immunosuppressive therapy</th>
</tr>
</thead>
</table>

A3. Rhinitis (includes sneezing, nasal stuffiness, post nasal discharge)

<table>
<thead>
<tr>
<th>Description</th>
<th>Transient, non-prescription meds relieve</th>
<th>Prescription med. required, slow</th>
<th>Corticosteroids or other prescription med. with persistent disabling symptoms such as impaired exercise tolerance</th>
<th>NA</th>
</tr>
</thead>
</table>

A4. Serum sickness

<table>
<thead>
<tr>
<th>Description</th>
<th>Transient, non-prescription meds relieve</th>
<th>Symptomatic, slow response to meds (e.g., oral corticosteroids)</th>
<th>Prolonged; symptoms only partially relieved by meds; parenteral corticosteroids required</th>
<th>Major organ dysfunction, requires long-term high-dose immunosuppressive therapy</th>
</tr>
</thead>
</table>
### A. Allergic/Immunologic (continued)

<table>
<thead>
<tr>
<th>A5. Vasculitis</th>
<th>Localised, not requiring treatment; or rapid response to meds; cutaneous</th>
<th>Symptomatic, slow response to meds (e.g., oral corticosteroids)</th>
<th>Generalised, parenteral corticosteroids required or/and short duration hospitalisation</th>
<th>Prolonged, hospitalisation, ischemic changes, amputation</th>
</tr>
</thead>
</table>

### B. Cardiac

<table>
<thead>
<tr>
<th>B1. Arrhythmia</th>
<th>Transient, asymptomatic</th>
<th>Transient, but symptomatic or recurrent, responds to meds</th>
<th>Recurrent/persistent; maintenance prescription</th>
<th>Unstable, hospitalisation required, parenteral meds</th>
</tr>
</thead>
<tbody>
<tr>
<td>B2. Cardiac function decreased</td>
<td>Asymptomatic decline in resting ejection fraction by &gt; 10%, but &lt; 20% of baseline value</td>
<td>Asymptomatic decline of resting ejection fraction ≥ 20% of baseline value</td>
<td>CHF responsive to treatment</td>
<td>Severe or refractory CHF</td>
</tr>
<tr>
<td>B3. Edema</td>
<td>Asymptomatic (e.g., 1 + feet/calves), self-limited, no therapy required</td>
<td>Symptomatic (e.g., 2 + feet/calves), requires therapy</td>
<td>Symptoms limiting function (e.g., 3 + feet/calves, 2 + thighs), partial relief with treatment prolonged</td>
<td>Anasarca; no response to treatment</td>
</tr>
<tr>
<td>B4. Hypertension (new onset or worsening)</td>
<td>Asymptomatic, transient increase by &gt; 20 mmHg (diastolic) or to &gt; 150/100 if previously normal, no therapy required</td>
<td>Recurrent or persistent increase &gt; 150/100 or by &gt; 10 mmHg (diastolic), requiring and responding readily to treatment</td>
<td>Symptomatic increase &gt; 150/100, &gt; 20 mmHg, persistent, requiring multi agency therapy, difficult to control</td>
<td>Hypertensive crisis</td>
</tr>
<tr>
<td>B5. Hypotension (without underlying diagnosis)</td>
<td>Transient, intermittent, asymptomatic, orthostatic decrease in blood pressure &gt; 20 mmHg</td>
<td>Symptomatic, without interference with function, recurrent or persistent &gt; 20 mmHg decrease, responds to treatment</td>
<td>Syncope or symptomatic, interferes with function, requiring therapy and sustained medical attention, dose adjustment or drug discontinuation</td>
<td>Shock</td>
</tr>
<tr>
<td>B6. Myocardial ischaemia</td>
<td>Transient chest pain/ECG changes; rapid relief with nitro</td>
<td>Recurring chest pain, transient ECG ST-T changes; treatment relieves</td>
<td>Angina with infarction, no or minimal functional compromise, reduce dose or discontinue study drug</td>
<td>Acute myocardial infarction, arrhythmia or/and CHF</td>
</tr>
</tbody>
</table>
### B. Cardiac (continued)

<table>
<thead>
<tr>
<th>B7. Pericarditis/pericardial effusion</th>
<th>Rub heard, asymptomatic</th>
<th>Detectable effusion by echocardiogram, symptomatic NSAID required</th>
<th>Detectable on chest x-ray, dyspnoea; or pericardiocentesis; requires corticosteroids</th>
<th>Pulsus alternates with low cardiac output; requires surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>B8. Phlebitis/thrombosis/Embolism (excludes injection sites)</td>
<td>Asymptomatic, superficial, transient, local, or no treatment required</td>
<td>Symptomatic, recurrent, deep vein thrombosis, no anticoagulant therapy required</td>
<td>Deep vein thrombosis requiring anticoagulant therapy</td>
<td>Pulmonary embolism</td>
</tr>
</tbody>
</table>

### C. General (Constitutional)

<table>
<thead>
<tr>
<th>C1. Fatigue/malaise (asthenia)</th>
<th>Increase over baseline; most usual daily functions maintained, short term</th>
<th>Limits daily function intermittently over time</th>
<th>Interferes with basic ADL, persistent</th>
<th>Unable to care for self, bed or wheelchair bound &gt; 50% of day debilitating, hospitalisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>C2. Fever (pyrexia) (note: fever due to drug allergy should be coded as allergy)</td>
<td>Transient, few symptoms 37.7 – 38.5°C</td>
<td>Symptomatic, recurrent 38.6 – 39.9°C. Relieved by meds</td>
<td>≥ 40°C; ≤ 24 h, persistent symptoms; partial response to meds.</td>
<td>≥ 40°C, debilitating, &gt; 24 h, hospitalisation; no relief with meds</td>
</tr>
<tr>
<td>C3. Headache</td>
<td>Transient or intermittent, no meds or relieved with OTC</td>
<td>Persistent, recurring, non-narcotic analgesics relieve</td>
<td>Prolonged with limited response to narcotic medicine</td>
<td>Intractable, debilitating, requires parenteral meds.</td>
</tr>
<tr>
<td>C4. Insomnia</td>
<td>Difficulty sleeping, short term, no interfering with function</td>
<td>Difficulty sleeping interfering with function, use of prescription med.</td>
<td>Prolonged symptoms, with limited response to narcotic meds</td>
<td>Debilitating, hospitalisation; no relief with meds</td>
</tr>
<tr>
<td>C5. Rigors, chills</td>
<td>Asymptomatic, transient, no meds, or non-narcotic meds relieve</td>
<td>Symptomatic, narcotic meds relieve.</td>
<td>Prolonged symptoms, with limited response to narcotic meds</td>
<td>Debilitating, hospitalisation; no relief with meds</td>
</tr>
<tr>
<td>C6. Sweating (diaphoresis)</td>
<td>Episodic, transient</td>
<td>Frequent, short term</td>
<td>Frequent, drenching, disabling</td>
<td>Dehydration, requiring IV fluids/hospitalization &gt; 24 hrs</td>
</tr>
<tr>
<td>C7. Weight gain</td>
<td>5% – 9.9%</td>
<td>10% – 19.9%</td>
<td>20% – 30%</td>
<td>NA</td>
</tr>
<tr>
<td>C8. Weight loss</td>
<td>5% – 9.9%</td>
<td>10% – 19.9%</td>
<td>20% – 30%</td>
<td>NA</td>
</tr>
<tr>
<td>D. Dermatologic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td><strong>D1. Alopecia</strong></td>
<td>Subjective, transient</td>
<td>Objective, fully reversible</td>
<td>Patchy, wig used, partly reversible</td>
<td>Complete, or irreversible even if patchy</td>
</tr>
<tr>
<td><strong>D2. Bullous eruption</strong></td>
<td>Localised, asymptomatic</td>
<td>Localised, symptomatic, requiring treatment</td>
<td>Generalised, responsive to treatment; reversible</td>
<td>Prolonged, generalised, or requiring hospitalisation for treatment</td>
</tr>
<tr>
<td><strong>D3. Dry skin</strong></td>
<td>Asymptomatic, controlled with emollients</td>
<td>Symptoms eventually (1 – 2 wks)</td>
<td>Generalised, interfering with ADL &gt; 2 wks, persistent pruritis, partially responsive to treatment</td>
<td>Disabling for extended period, unresponsive to ancillary therapy and requiring study drug discontinuation for relief</td>
</tr>
<tr>
<td><strong>D4. Injection site reaction</strong></td>
<td>Local erythema, pain, pruritis, &lt; few days</td>
<td>Erythema, pain, oedema, may include superficial phlebitis, 1 – 2 wks</td>
<td>Prolonged induration, superficial ulceration; includes thrombosis</td>
<td>Major ulceration necrosis requiring surgery</td>
</tr>
<tr>
<td><strong>D5. Petechiae (without vasculitis)</strong></td>
<td>Few, transient asymptomatic</td>
<td>Dependent areas, persistent up to 2 wks</td>
<td>Generalised, responsive to treatment; reversible</td>
<td>Prolonged, irreversible, disabling</td>
</tr>
<tr>
<td><strong>D6. Photosensitivity</strong></td>
<td>Transient erythema</td>
<td>Painful erythema and oedema requiring topical treatment</td>
<td>Blistering or desquamation, requires systemic corticosteroids</td>
<td>Generalised exfoliation or hospitalisation</td>
</tr>
<tr>
<td><strong>D7. Pruritis</strong></td>
<td>Localised, asymptomatic, transient, local treatment</td>
<td>Intense, or generalised, relieved by systemic medication</td>
<td>Intense or generalised; poorly controlled despite treatment</td>
<td>Disabling, irreversible</td>
</tr>
<tr>
<td><strong>D8. Rash (not bullous)</strong></td>
<td>Erythema, scattered macular/popular eruption; pruritis transient; TOC or no meds</td>
<td>Diffuse macular/popular eruption or erythema with pruritus; dry desquamation; treatment required</td>
<td>Generalised, moist desquamation, requires systemic corticosteroids; responsive to treatment; reversible</td>
<td>Exfoliative or ulcerating; or requires hospitalisation; or parenteral corticosteroids</td>
</tr>
<tr>
<td><strong>D9. Indurartion/fibrosis/Thickening (not sclerodermal)</strong></td>
<td>Localized, high density on palpation, reversible, no effect on ADL and not disfiguring</td>
<td>Local areas &lt; 50% body surface, not disfiguring, transient interference with ADL, reversible</td>
<td>Generalized, disfiguring, interferes with ADL, reversible</td>
<td>Disabling, irreversible, systemic symptoms</td>
</tr>
</tbody>
</table>

| E. Ear/Nose/Throat |  |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **E1. Hearing loss** | Transient, intermittent, no interference with function | Symptomatic, treatment required, reversible | Interferes with function; incomplete response to treatment | Irreversible deafness |
| **E2. Sense of smell** | Slightly altered | Markedly altered | Complete loss, reversible | Complete loss, without recovery |
### E. Ear/Nose/Throat (continued)

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>E3. Stomatitis</td>
<td>Asymptomatic</td>
<td>Painful, multiple, can eat</td>
<td>Interferes with nutrition, slowly reversible</td>
<td>Requires enteral support; residual dysfunction</td>
</tr>
<tr>
<td>E4. Taste disturbance (dysgeusia)</td>
<td>Transiently altered; metallic</td>
<td>Persistently altered; limited effect on eating</td>
<td>Disabling, effect on nutrition</td>
<td>NA</td>
</tr>
<tr>
<td>E5. Tinnitus</td>
<td>Intermittent, transient, no interference with function</td>
<td>Requires treatment, reversible</td>
<td>Disabling, or associated with hearing loss</td>
<td>Irreversible deafness</td>
</tr>
<tr>
<td>E6. Voice changes (includes hoarseness, loss of voice, laryngitis)</td>
<td>Intermittent hoarseness, able to vocalise</td>
<td>Persistent hoarseness, able to vocalise</td>
<td>Whispered speech, slow return of ability to vocalise</td>
<td>Unable to vocalise for extended</td>
</tr>
<tr>
<td>E7. Xerostomia (dry mouth)</td>
<td>Transient dryness</td>
<td>Relief with meds</td>
<td>Interferes with nutrition, slowly reversible</td>
<td>Extended duration interference with nutrition, requires parenteral nutrition</td>
</tr>
</tbody>
</table>

### F. Eye/Ophthalmologic

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>F1. Cataract</td>
<td>Asymptomatic, no change in vision, non-progressive</td>
<td>Symptomatic, partial visual loss, progressive</td>
<td>Symptoms impairing function, vision loss requiring treatment, including surgery</td>
<td>NA</td>
</tr>
<tr>
<td>F2. Conjunctivitis</td>
<td>Asymptomatic, transient, rapid response to treatment</td>
<td>Symptomatic, responds to treatment, changes not interfering with function</td>
<td>Symptoms prolonged, partial response to treatment, interferes with function</td>
<td>NA</td>
</tr>
<tr>
<td>F3. Lacrimation increased (tearing, watery eyes)</td>
<td>Symptoms not requiring treatment, transient</td>
<td>Symptomatic, treatment required, reversible</td>
<td>Unresponsive to treatment with major effect on function</td>
<td>NA</td>
</tr>
<tr>
<td>F4. Retinopathy</td>
<td>Asymptomatic, non-progressive, no treatment</td>
<td>Reversible change in vision; readily responsive to treatment</td>
<td>Disabling change in vision ophthalmological findings reversible, sight improves over time</td>
<td>Loss of sight</td>
</tr>
<tr>
<td>F. Eye/Ophthalmologic (continued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>F5. Vision changes</strong> (e.g., blurred, photophobia, night blindness, vitreous floaters)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asymptomatic, transient, no treatment required</td>
<td>Symptomatic, vision changes not interfering with function, reversible</td>
<td>Symptomatic, vision changes interfering with function</td>
<td>Loss of sight</td>
<td></td>
</tr>
<tr>
<td><strong>F6. Xerophthalmia</strong> (dry eyes)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild scratchiness</td>
<td>Symptomatic without interfering with function, requires artificial tears</td>
<td>Interferes with vision/function, corneal ulceration</td>
<td>Loss of sight</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>G. Gastrointestinal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>G1. Anorexia</strong></td>
</tr>
<tr>
<td>Adequate food intake, minimal weight loss</td>
</tr>
<tr>
<td><strong>G2. Constipation</strong></td>
</tr>
<tr>
<td>Asymptomatic, transient, responds to stool softener, OTC laxatives</td>
</tr>
<tr>
<td><strong>G3. Diarrhea</strong></td>
</tr>
<tr>
<td>Transient, increase of 2 – 3 stools/day over pre-treatment (no blood or mucus), OTC agents relieve</td>
</tr>
<tr>
<td><strong>G4. Dyspepsia</strong> (heartburn)</td>
</tr>
<tr>
<td>Transient, intermittent, responds to OTC antacids, H-2 blockers</td>
</tr>
<tr>
<td><strong>G5. GI bleed</strong> (gastritis, gastric or duodenal ulcer diagnosed-define aetiology)</td>
</tr>
<tr>
<td>Asymptomatic, endoscopic finding, haemocult + stools, no transfusion, responds rapidly to treatment</td>
</tr>
<tr>
<td><strong>G6. Haematochezia</strong> (rectal bleeding)</td>
</tr>
<tr>
<td>Haemorrhoidal, asymptomatic, no transfusion</td>
</tr>
</tbody>
</table>
### G. Gastrointestinal (continued)

<table>
<thead>
<tr>
<th>G7. Hepatitis</th>
<th>Laboratory abnormalities, asymptomatic, reversible</th>
<th>Symptomatic laboratory abnormalities, not interfering with function, slowly reversible</th>
<th>Laboratory abnormalities persistent &gt; 2 wks, symptoms interfere with function</th>
<th>Progressive, hepato-renal, anasarca, pre-coma or coma</th>
</tr>
</thead>
<tbody>
<tr>
<td>G8. Nausea, or nausea/vomiting (use diagnostic term)</td>
<td>Transient, intermittent, minimal interference with intake, rapid response to meds.</td>
<td>Persistent, recurrent, requires prescription meds, intake maintained</td>
<td>Prolonged, interferes with daily function and nutritional intake, periodic iv fluids</td>
<td>Hypotensive, hospitalization, parenteral nutrition, unresponsive to out-patient management</td>
</tr>
<tr>
<td>G9. Pancreatitis</td>
<td>Amylase elevation, intermittent nausea/vomiting, transient, responds rapidly to treatment</td>
<td>Amylase elevation with abdominal pain, nausea, occasional vomiting, responsive to treatment</td>
<td>Severe, persistent abdominal pain with pancreatic enzyme elevation, incomplete or slow response to treatment</td>
<td>Complicated by shock, haemorrhage (acute circulatory failure)</td>
</tr>
<tr>
<td>G10. Proctitis</td>
<td>Perianal pruritus, haemorrhoids (new onset), transient, or intermittent, relieved by OTC meds</td>
<td>Tenesmus or ulcerations, anal fissure, responsive to treatment, minimal interference with function</td>
<td>Unresponsive to treatment, marked interference with function</td>
<td>Mucosal necrosis with haemorrhage, infection, surgery required.</td>
</tr>
</tbody>
</table>

### H. Musculoskeletal

<table>
<thead>
<tr>
<th>H1. Avascular necrosis</th>
<th>Asymptomatic MRI changes, non-progressive</th>
<th>MRI changes and symptoms responsive to rest and analgesia</th>
<th>MRI changes, symptoms requiring surgical intervention</th>
<th>Wheelchair bound; surgical repair not possible</th>
</tr>
</thead>
<tbody>
<tr>
<td>H2. Arthralgia</td>
<td>Intermittent transient symptoms, no meds or relieved by OTC meds</td>
<td>Persistent or recurrent symptoms, resolve with meds, little effect on function</td>
<td>Severe symptoms despite meds impairs function</td>
<td>Debilitating, hospitalisation required for treatment</td>
</tr>
<tr>
<td>H3. Leg cramps</td>
<td>Transient, intermittent, does not interfere with function</td>
<td>Recurrent symptoms, minimally interferes with function or sleep, responds to meds</td>
<td>Persistent, prolonged interference with function or sleep, partial or no response to meds</td>
<td>NA</td>
</tr>
<tr>
<td>H4. Myalgia</td>
<td>Occasional; does not interfere with function</td>
<td>Frequent, requires meds (non-narcotic); minor effects on function</td>
<td>Major change in function/lifestyle, narcotic pain meds</td>
<td>Debilitating, profound weakness, requires wheelchair, unresponsive to meds</td>
</tr>
</tbody>
</table>
### I. Neuropsychiatric

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11. Anxiety or Depression (mood alteration)</strong></td>
<td>Symptomatic, does not interfere with function; no meds</td>
<td>Frequent symptoms, responds to meds; interferes with ADL at times</td>
<td>Persistent, prolonged symptoms, partial or no response to meds, limits daily function</td>
<td>Suicidal ideation or danger to self</td>
</tr>
<tr>
<td><strong>12. Cerebrovascular ischaemia</strong></td>
<td>NA</td>
<td>Single transient ischaemic event, responsive to treatment</td>
<td>Recurrent transient ischaemic events</td>
<td>Cerebrovascular vascular accident with permanent disability</td>
</tr>
<tr>
<td><strong>13. Cognitive disturbance</strong></td>
<td>Subjective symptoms, transient, intermittent, not interfering with function</td>
<td>Objective symptoms, persisting, interferes with daily function occasionally</td>
<td>Persistent, or worsening objective symptoms; interferes with routine daily routine</td>
<td>Debilitating/disabling and permanent; toxic psychosis</td>
</tr>
<tr>
<td><strong>14. Depressed consciousness (somnolence)</strong></td>
<td>Observed, transient, intermittent, not interfering with function</td>
<td>Somnolence or sedation, interfering with function</td>
<td>Persistent, progressive, obundation, stupor</td>
<td>Coma</td>
</tr>
<tr>
<td><strong>15. Inability to concentrate</strong></td>
<td>Subjective symptoms, does not interfere with function</td>
<td>Objective findings, interferes with function</td>
<td>Persistent, prolonged objective findings or organic cause</td>
<td>NA</td>
</tr>
<tr>
<td><strong>16. Insomnia (in absence of pain)</strong></td>
<td>Occasional difficulty sleeping, transient intermittent, not interfering with function</td>
<td>Recurrent difficulty sleeping; requires meds for relief; occasional interference with function</td>
<td>Persistent or worsening difficulty sleeping; severely interferes with routine daily function</td>
<td>NA</td>
</tr>
<tr>
<td><strong>17. Libido decreased</strong></td>
<td>Decrease in interest</td>
<td>Loss of interest; influences relationship</td>
<td>Persistent, prolonged interfering with relationship</td>
<td>NA</td>
</tr>
<tr>
<td><strong>18. Peripheral motor neuropathy</strong></td>
<td>Subjective or transient loss of deep tendon reflexes; function maintained</td>
<td>Objective weakness, persistent, no significant impairment of daily function</td>
<td>Objective weakness with substantial impairment of function</td>
<td>Paralysis</td>
</tr>
<tr>
<td><strong>19. Peripheral sensory neuropathy (sensory disturbance)</strong></td>
<td>Subjective symptoms without objective findings, transient, not interfering with function</td>
<td>Objective sensory loss, persistent, not interfering with function</td>
<td>Prolonged sensory loss or paraesthesias interfering with function</td>
<td>NA</td>
</tr>
<tr>
<td><strong>10. Seizure</strong></td>
<td>NA</td>
<td>Recurrence of old seizures, controlled with adjustment of medication</td>
<td>Recurrence/exacerbation with partial response to medication</td>
<td>Recurrence not controlled, requiring hospitalization; new seizures</td>
</tr>
</tbody>
</table>
### I. Neuropsychiatric (continued)

<table>
<thead>
<tr>
<th>I11. Vertigo (dizziness)</th>
<th>Subjective symptoms, transient, intermittent, no treatment</th>
<th>Objective findings, recurrent, meds relieve, occasionally interfering with function</th>
<th>Persistent, prolonged, interfering with daily function; partial response to medication</th>
<th>Debilitating without response to medication, hospitalization</th>
</tr>
</thead>
</table>

### J. Pulmonary

<table>
<thead>
<tr>
<th>J1. Asthma</th>
<th>Occasional wheeze, no interference with activities</th>
<th>Wheezing, requires oral meds, occasional interference with function</th>
<th>Debilitating, requires nasal O₂</th>
<th>Requires ventilator assistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2. Cough</td>
<td>Transient, intermittent, occasional OTC meds relieve</td>
<td>Persistent, requires narcotic or other prescription meds for relief</td>
<td>Recurrent, persistent coughing spasms without consistent relief by meds, interferes with function</td>
<td>Interferes with oxygenation; debilitating</td>
</tr>
<tr>
<td>J3. Dyspnea</td>
<td>Subjective, transient, no interference with function</td>
<td>Symptomatic, intermittent or recurring, interferes with exertional activities</td>
<td>Symptomatic during daily routine activities, interferes with function, treatment with intermittent nasal O₂ relieves</td>
<td>Symptomatic at rest, debilitating, requires constant nasal O₂</td>
</tr>
<tr>
<td>J4. Pleuritic pain (pleurisy)</td>
<td>Transient, intermittent symptoms, no treatment or OTC meds relieve</td>
<td>Persistent symptoms, requires prescription meds for relief</td>
<td>Prolonged symptoms, interferes with function, requires frequent narcotic pain relief</td>
<td>Deblilation, requiring hospitalisation</td>
</tr>
<tr>
<td>J5. Pneumonitis (pulmonary infiltrates)</td>
<td>Asymptomatic radiographic changes, transient, no treatment required</td>
<td>Symptomatic, persistent, requiring corticosteroids</td>
<td>Symptomatic, requiring treatment including O₂</td>
<td>Deblilation, not reversible; or requiring assisted ventilation</td>
</tr>
<tr>
<td>J6. Pulmonary function decreased (FVC or carbon monoxide diffusion capacity – DLCO)</td>
<td>76% – 90% of pre-treatment value</td>
<td>51% – 75% of pre-treatment value</td>
<td>26% – 50% of pre-treatment value</td>
<td>≤ 25% of pre-treatment value</td>
</tr>
</tbody>
</table>
### Laboratory Data

#### K. Haematology

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>K1. Hgb (g/dl) decrease from pre-treatment</td>
<td>1.0 – 1.4</td>
<td>1.5 – 2.0</td>
<td>2.1 – 2.9, or Hgb &lt; 8.0, &gt; 7.0</td>
<td>≥ 3.0; or Hgb &lt; 7.0</td>
</tr>
<tr>
<td>K2. Leukopenia (total WBC) × 1000</td>
<td>3.0 – 3.9</td>
<td>2.0 – 2.9</td>
<td>1.0 – 1.9</td>
<td>&lt; 1.0</td>
</tr>
<tr>
<td>K3. Neutropenia (× 1000)</td>
<td>1.5 – 1.9</td>
<td>1.0 – 1.4</td>
<td>0.5 – 0.9</td>
<td>&lt; 0.5</td>
</tr>
<tr>
<td>K4. Lymphopenia (× 1000)</td>
<td>1.5 – 1.9</td>
<td>1.0 – 1.4</td>
<td>0.5 – 0.9</td>
<td>&lt; 0.5</td>
</tr>
<tr>
<td>K5. Platelets (× 1000)</td>
<td>75 – LLN</td>
<td>50 – 74.9</td>
<td>20 – 49.9; platelet transfusion required</td>
<td>&lt; 20; recurrent platelet transfusions</td>
</tr>
</tbody>
</table>

#### L. Chemistry

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>L1. Hypercalcaemia (mg/dl)</td>
<td>1.1 × ULN – 11.5</td>
<td>11.6 – 12.5</td>
<td>12.6 – 13.5; or symptoms present</td>
<td>&gt; 13.5; or associated coma</td>
</tr>
<tr>
<td>L2. Hyperglycemia (mg/dl) Fasting</td>
<td>140 – 160</td>
<td>161 – 250</td>
<td>251 – 500</td>
<td>&gt; 500, or associated with ketoacidosis</td>
</tr>
<tr>
<td>L3. Hyperkalaemia (mg/dl)</td>
<td>5.5 – 5.9</td>
<td>6.0 – 6.4</td>
<td>6.5 – 7.0 or any ECG change</td>
<td>&gt; 7.0 or any arrhythmia</td>
</tr>
<tr>
<td>L5. Hypocalcaemia (mg/dl)</td>
<td>0.9 × LLN – 7.8</td>
<td>7.7 – 7.0</td>
<td>6.9 – 6.5; or associated with symptoms</td>
<td>&lt; 6.5 or occurrence of tetany</td>
</tr>
<tr>
<td>L6. Hypoglycemia (mg/dl)</td>
<td>55 – 64 (no symptoms)</td>
<td>40 – 54 (or symptoms present)</td>
<td>30 – 39 (symptoms impair function)</td>
<td>&lt; 30 or coma</td>
</tr>
<tr>
<td>L7. Hyponatraemia (mg/dl)</td>
<td>--</td>
<td>125 – 129</td>
<td>120 – 124</td>
<td>&lt; 120</td>
</tr>
<tr>
<td>L8. Hypokalaemia (mg/dl)</td>
<td>--</td>
<td>3.0 – 3.4</td>
<td>2.5 – 2.9</td>
<td>&lt; 2.5</td>
</tr>
</tbody>
</table>
### L. Chemistry (continued)

| L9. CPK (also if polymyositis-disease) | 1.2 – 1.9 × ULN | 2.0 – 4.0 × ULN | 4.0 × ULN with weakness but without life-threatening signs or symptoms | > 4.0 × ULN with signs or symptoms of rhabdomyolysis or life-threatening |
| L10. Serum uric acid | 1.2 – 1.6 × ULN | 1.7 – 2.9 × ULN | 3.0 – 5.0 × ULN or gout | NA |
| L11. Creatinine (mg/dL) | 1.1 – 1.3 × ULN | 1.3 – 1.8 × ULN | 1.9 – 3.0 × ULN | > 3.0 × ULN |
| L12. SGOT (AST) | 1.2 – 1.5 × ULN | 1.6 – 3.0 × ULN | 3.1 – 8.0 × ULN | > 8.0 × ULN |
| L13. SGPT (ALT) | 1.2 – 1.5 × ULN | 1.6 – 3.0 × ULN | 3.0 – 8.0 × ULN | > 8.0 × ULN |
| L14. Alkaline phosphatase | 1.1 – 2.0 × ULN | 1.6 – 3.0 × ULN | 3.0 – 5.0 × ULN | > 5.0 × ULN |
| L15. T. bilirubin | 1.1 – 1.4 × ULN | 1.5 – 1.9 × ULN | 2.0 – 3.0 × ULN | > 3.0 × ULN |
| L16. LDH | 1.3 – 2.4 × ULN | 2.5 – 5.0 × ULN | 5.1 – 10 × ULN | > 10 × ULN |

### M. Urinalysis

| M1. Haematuria | Micro only | Gross, no clots | Clots, transfusion < 2 units | Transfusion required |
| M2. Proteinuria (per 24 h) | 300 – 500 mg (tr/1+) | 501 – 1999 mg (2+) | 2 – 5.0 g (3+) nephrotic syndrome | 5.0 g (4+) anasarca |
| M3. WBC in urine | NA | NA | Indicating acute interstitial nephritis | Associated with acute renal failure |
| M4. Uric acid crystals | Present without symptoms | NA | With stones or symptoms of stones (e.g., renal colic) | Causing renal outflow obstruction and hospitalization |

OTC = over-the-counter medication; ADL = activities of daily living; IV = intravenous; ECG = electrocardiogram; CHF = congestive heart failure; MRI = magnetic resonance imaging; Hb = haemoglobin; LLN = lower limit of normal; ULN = upper limit of normal; WBC = white blood cells; SLE = systemic lupus erythematosus; ANA = antinuclear antibodies; H-2 blockers = histamine-2 blockers; FVC = forced vital capacity
Appendix S.  Protocol Amendment:  List of Changes

A summary of changes is listed in Section 1.1.

Global Protocol Changes

"ABT-494" has been changed to read "upadacitinib" throughout the protocol.

Specific Protocol Changes

Section 1.0  Title Page
"Sponsor/Emergency Contact:
Add:  "Emergency 24 hour Number:" 

Emergency 24 hour Number: 

Section 1.2  Synopsis
Previously read:

<table>
<thead>
<tr>
<th>AbbVie Inc.</th>
<th>Protocol Number:  M15-925</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Study Drug:  ABT-494</td>
<td>Phase of Development:  3</td>
</tr>
<tr>
<td>Name of Active Ingredient:  ABT-494</td>
<td>Date of Protocol Synopsis:  28 March 2017</td>
</tr>
</tbody>
</table>

Protocol Title:  A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

Objectives:

Period 1
To compare the safety and efficacy of ABT-494 30 mg once daily (QD) versus abatacept intravenous (IV) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA.

Period 2
To evaluate the long-term safety, tolerability, and efficacy of ABT-494 30 mg QD in subjects with RA who have completed Period 1.

Investigators:  Multicenter

Study Sites:  Approximately 200
Study Population:
Adult female and male subjects who are at least 18 years of age with a diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA. Subjects who have been treated ≥ 3 months prior to the screening visit with ≥ 1 bDMARD therapy and ≥ 3 months with csDMARDs and have never received abatacept, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration may be enrolled. Eligible study subjects must have ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits, and high-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L (central lab) at Screening. Subjects must have been on a stable dose of csDMARD therapy (restricted to methotrexate [MTX], chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for ≥ 4 weeks prior to the first dose of study drug.

Number of Subjects to be Enrolled: Approximately 550

Methodology:
This is a Phase 3, multicenter study that includes two periods. Period 1 is a 24-week randomized, double-blind, parallel-group, active-controlled treatment period designed to compare the safety and efficacy of ABT-494 30 mg QD versus abatacept IV for the treatment of signs and symptoms of subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapies other than abatacept and are currently on a stable dose of csDMARDs. Period 2 is an open-label extension to evaluate the long-term safety, tolerability, and efficacy of ABT-494 30 mg QD in subjects with RA who have completed Period 1.
Methodology (Continued):

The study duration will include a 35-day maximum screening period; a 24-week randomized, double blind, parallel-group, active controlled treatment period, with 30-day and 70-day follow-ups (Period 1); an open-label long term extension period (up to 5 years) with a 30-day follow-up call or site visit (Period 2);

Subjects who meet eligibility criteria will be randomized in a 1:1 ratio to one of two treatment groups:
- Group 1: ABT-494 30 mg QD, N = 275 (Period 1)
- Group 2: Abatacept IV at Day 1, Weeks 2, 4, 8, 12, 16 and 20 (< 60 kg: 500 mg; 60 – 100 kg: 750 mg; > 100 kg: 1,000 mg, N = 275 (Period 1)

Randomization will be stratified by number of prior bDMARD use (stratum 1: failed 1 or 2 biologics of the same class; stratum 2: failed ≥ 3 biologics of the same class or failed biologics of multiple classes) AND geographic region. Once 20% of total subjects have been randomized who have not completed > 3 months of methotrexate, further screening of such methotrexate inexperienced subjects may be suspended.

Subjects must have been on stable csDMARD(s) treatment for ≥ 4 weeks prior to the first dose of study drug and must remain on a stable dose until Week 12; the csDMARD dose may be decreased only for safety reasons. Starting at Week 12 (after Week 12 assessments have been performed), initiation of or change in corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or increasing doses for up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of MTX and leflunomide) is allowed as per local label.

Rescue therapy will be offered to subjects who meet the following criteria:
- Starting at Week 12, subjects who do not achieve ≥ 20% improvement in both TJC and SJC at two consecutive visits will be rescued with optimizing (initiate or increase) background RA medications: NSAIDs, corticosteroids, low-potency analgesics, acetaminophen or adding or increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of MTX and leflunomide) and, if necessary, a burst of systemic corticosteroids (prednisone equivalent ≤ 0.5 mg/kg/day for 3 consecutive days), intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of corticosteroids, dosage and frequency per standard of care, are allowed.

Subjects who complete the Week 24 visit (end of Period 1) will enter the open-label long term extension portion of the study, Period 2 (up to 5 years). Subjects who are assigned to ABT-494 treatment group in Period 1 will continue to receive ABT-494 30 mg QD per original randomization assignment. Subjects who are assigned to abatacept IV in Period 1 will be switched to receive ABT-494 30 mg QD.

An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24). Period 2 is open-label.

Diagnosis and Main Criteria for Inclusion/Exclusion:

Main Inclusion:
1. Adult male or female, at least 18 years old.
2. Diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/EULAR classification criteria for RA.
3. Subjects have been treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration AND have never received abatacept prior to first dose of study drug.
Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):

Main Inclusion (Continued):
4. Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug:
   - The following csDMARDs are allowed (stable dose for ≥ 4 weeks prior to the first dose of study drug): oral or parenteral MTX (7.5 to 25 mg/week), sulfasalazine (≤ 3000 mg/day), hydroxychloroquine (≤ 400 mg/day), chloroquine (≤ 250 mg/day), and leflunomide (≤ 20 mg/day).
   - A combination of up to two background csDMARDs is allowed EXCEPT the combination of MTX and leflunomide.
5. Subject meets both of the following minimum disease activity criteria:
   c. ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits; and
d. hsCRP ≥ 3 mg/L (central lab) at Screening Visit.

Main Exclusion:
1. Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to ABT-494, tofacitinib, baricitinib, and filgotinib).
2. Prior exposure to abatacept.
3. History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms], or any arthritis with onset prior to age 17 years). History of secondary Sjogren's Syndrome is permitted.
4. Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase > 2 × upper limit of normal (ULN); serum alanine transaminase > 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula < 40 mL/min/1.73 m²; total white blood cell count < 2,500/μL; absolute neutrophil count < 1,500/μL; platelet count < 100,000/μL; absolute lymphocyte count < 800/μL; and hemoglobin < 10 g/dL.

<table>
<thead>
<tr>
<th>Investigational Product:</th>
<th>ABT-494</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose:</td>
<td>30 mg QD</td>
</tr>
<tr>
<td>Mode of Administration:</td>
<td>Oral</td>
</tr>
</tbody>
</table>

| Reference Therapy:       | Period 1 only: Placebo for ABT-494 30 mg QD |
| Dose:                    | N/A     |
| Mode of Administration:  | Oral    |

| Reference Therapy:       | Period 1 only: abatacept |
| Dose:                    | < 60 kg: 500 mg; 60 – 100 kg: 750 mg; > 100 kg: 1,000 mg |
| Mode of Administration:  | IV: Day 1, Weeks 2, 4, 8, 12, 16, and 20 |
### Reference Therapy:
Period 1 only: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)

### Dose:
N/A

### Mode of Administration IV:
Day 1, Weeks 2, 4, 8, 12, 16, and 20

### Duration of Treatment:
Period 1: 24 weeks; Period 2: up to 5 years

### Criteria for Evaluation:
#### Efficacy:

**Period 1:**
- The primary endpoint is the change from baseline in DAS28 (CRP) at Week 12 (non-inferiority)
- Key secondary endpoints are:
  - Change from baseline in DAS28 (CRP) at Week 12 (superiority)
  - Proportion of subjects achieving Clinical Remission (CR) at Week 12 (superiority)
- CR is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) < 2.6.
- Additional endpoints are:
  - Proportion of subjects achieving low disease activity (LDA) at Week 12 (non-inferiority).
  - LDA is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) ≤ 3.2.
  - ACR20/50/70 response rates at all visits;
  - ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale [VAS]), Patient's Global Assessment of Disease Activity (VAS), Physician's Global Assessment of Disease Activity (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), or hsCRP.
  - Change from baseline in individual components of ACR response at all visits;
  - Change from baseline in DAS28(CRP) and DAS28 (erythrocyte sedimentation rate [ESR]) at all visits;
  - Change from baseline in SF 36 at Weeks 4, 12 and 24;
  - Change from baseline in morning stiffness at all visits;
  - Proportion of subjects achieving LDA or CR based on DAS28 (CRP), DAS28 (ESR), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) criteria (see below) at all visits;
  - Change from baseline in EQ-5D-5L at Weeks 4, 12 and 24;
  - Change from baseline in Functional Assessment of Chronic Illness Therapy – fatigue (FACIT-F) at Weeks 4, 8, 12 and 24;
  - Change from baseline in Work Productivity and Activity Impairment (WPAI) at Weeks 4, 8, 12 and 24;
  - Change from baseline in CDAI and SDAI at all visits;
  - Proportion of subjects achieving MCID in change from baseline in HAQ-DI (defined as change from baseline in HAQ-DI ≤ –0.3) at all visits;
  - ACR/EULAR Boolean remission at all visits.
  - Systemic corticosteroid dose (including cumulative dose at serial time points in Period 1)
Criteria for Evaluation (Continued):

Efficacy (Continued):

Period 1 (Continued):

<table>
<thead>
<tr>
<th></th>
<th>DAS28 (CRP) and DAS28 (ESR)</th>
<th>SDAI</th>
<th>CDAI</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDA</td>
<td>≤ 3.2</td>
<td>≤ 11.0</td>
<td>≤ 10</td>
</tr>
<tr>
<td>CR</td>
<td>&lt; 2.6</td>
<td>≤ 3.3</td>
<td>≤ 2.8</td>
</tr>
</tbody>
</table>

Period 2:
Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Weeks 36, 48, and every 12 weeks thereafter until completion of the study:

- Change from baseline in DAS28 (CRP);
- Proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- Proportion of subjects achieving LDA based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- ACR20/50/70 response rates;
- Change from baseline in individual ACR components;
- Change from baseline in DAS28 (ESR);
- Change from baseline in HAQ-DI at all visits;
- Change from baseline in SF 36 at all visits;
- Change from baseline in morning stiffness;
- Concomitant corticosteroid use.
- ACR/EULAR Boolean remission

Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Week 48 only:

- Change from baseline in EQ-5D-5L;
- Change from baseline in FACIT-F;
- Change from baseline in WPAI RA.

Pharmacokinetic (Period 1 Only):
Blood samples for assay of ABT-494 and possibly other concomitant medications in plasma will be collected at Weeks 2, 4, 8, 12, 16, 20 and 24/Premature Discontinuation.

Exploratory Research Variables and Validation Studies (Optional) (Period 1 Only):
Prognostic and predictive biomarker signatures may be evaluated. Samples for pharmacogenetic, epigenetic, transcriptomic, and proteomic and targeted protein investigations will be collected at various time points. Assessments will include but may not be limited to nucleic acids, proteins, metabolites, or lipids.

Safety:
Safety evaluations include adverse event (AE) monitoring, physical examinations, vital sign measurements, electrocardiogram (ECG), and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration.
Statistical Methods:

Efficacy:
All efficacy analyses will be carried out using the Full Analysis Set population, which includes all randomized subjects who receive at least one dose of study drug.

Period 1 Efficacy:
Analysis of the Primary and Key Secondary Endpoints:
The primary efficacy endpoint will be assessed via non-inferiority comparison of ABT-494 to abatacept in change from baseline in DAS28 (CRP) at Week 12 using the 95% confidence interval (CI) of treatment difference against the pre-specified non-inferiority margin.
The two key secondary efficacy endpoints involve the superiority comparisons of ABT-494 to abatacept on change from baseline in DAS28(CRP) at Week 12 as well as the proportion of subjects achieving CR based on DAS28 (CRP) at Week 12. The overall type I error rate of the primary and key secondary endpoints will be strongly controlled via sequential testing.
For the binary endpoint of CR, frequencies and percentages will be reported for each treatment group, and comparison of ABT-494 to abatacept will be conducted using the Cochran-Mantel-Haenszel test adjusting for main stratification factors. Non-responder imputation will serve as the primary analysis approach for missing data handling.
For the continuous endpoint of change from baseline in DAS28 (CRP), the mean, standard deviation, median, and range will be reported for each treatment group. Comparison between ABT-494 and abatacept will be carried out using the analysis of covariance model with treatment group as the fixed factor, and the corresponding baseline value and the main stratification factors as the covariates. Multiple imputations will serve as the primary analysis approach for missing data handling.

Long-Term Efficacy for Period 1 and Period 2 Combined:
Long-term efficacy by time point will be summarized using descriptive statistics.

Pharmacokinetic:
A non-linear mixed-effects modeling approach will be used to estimate the population central values and the empirical Bayesian estimates of the individual values of ABT-494 oral clearance (CL/F) and volume of distribution (V/F). Additional parameters may be estimated if useful in the interpretation of the data.

Safety:
Safety analyses will be carried out using the Safety Analysis Set, which includes all subjects who receive at least one dose of study drug. Analyses will be conducted for Period 1 alone, as well as for Period 1 and Period 2 combined. Safety will be assessed by AEs, physical examination, laboratory assessments, ECG, and vital signs. Frequency tables and lists of subjects with treatment-emergent AEs by preferred term as in the Medical Dictionary for Regulatory Activities dictionary, by system organ class, by severity, and by relationship to the study drug as assessed by the Investigator will be provided. The changes from baseline in vital signs, physical examination results, and clinical laboratory values will be analyzed in a descriptive manner. Shift of laboratory values from baseline to defined time points will be tabulated.
Has been changed to read:

<table>
<thead>
<tr>
<th>AbbVie Inc.</th>
<th>Protocol Number: M15-925</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Study Drug: Upadacitinib</td>
<td>Phase of Development: 3</td>
</tr>
<tr>
<td>Name of Active Ingredient: Upadacitinib</td>
<td>Date of Protocol Synopsis: 12 October 2017</td>
</tr>
</tbody>
</table>

**Protocol Title:** A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

**Objectives:**

**Period 1**
To compare the safety and efficacy of upadacitinib 15 mg once daily (QD) versus abatacept intravenous (IV) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA.

**Period 2**
To evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.

**Investigators:** Multicenter

**Study Sites:** Approximately 200

**Study Population:**
Adult female and male subjects who are at least 18 years of age with a diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA. Subjects who have been treated ≥ 3 months prior to the screening visit with ≥ 1 bDMARD therapy and ≥ 3 months with csDMARDs and have never received abatacept, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration may be enrolled. Eligible study subjects must have ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits, and high-sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L (central lab) at Screening. Subjects must have been on a stable dose of csDMARD therapy (restricted to methotrexate [MTX], chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for ≥ 4 weeks prior to the first dose of study drug.

**Number of Subjects to be Enrolled:** Approximately 550

**Methodology:**
This is a Phase 3, multicenter study that includes two periods. Period 1 is a 24-week randomized, double-blind, parallel-group, active-controlled treatment period designed to compare the safety and efficacy of upadacitinib 15 mg QD versus abatacept IV for the treatment of signs and symptoms of subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapies other than abatacept and are currently on a stable dose of csDMARDs. Period 2 is an open-label extension to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.
Methodology (Continued):

The study duration will include a 35-day maximum screening period; a 24-week randomized, double blind, parallel-group, active controlled treatment period, with 30-day and 70-day follow-ups (Period 1); an open-label long term extension period (up to 5 years) with a 30-day follow-up call or site visit (Period 2);

Subjects who meet eligibility criteria will be randomized in a 1:1 ratio to one of two treatment groups:

- **Group 1**: upadacitinib 15 mg QD, N = 275 (Period 1)
- **Group 2**: Abatacept IV at Day 1, Weeks 2, 4, 8, 12, 16 and 20 (< 60 kg: 500 mg; 60 – 100 kg: 750 mg; > 100 kg: 1,000 mg, N = 275 (Period 1)

NOTE: In Period 1, subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose. This study began enrolling under Amendment 3. Starting with Amendment 4, subjects randomized to Group 1 will receive 15 mg QD dose. In Period 2, subjects who enrolled under Amendment 3, including subjects randomized to both Group 1 and Group 2, will continue to receive open-label upadacitinib 30 mg QD.

Subjects who enroll under Amendment 4 or later will receive open-label upadacitinib 15 mg QD.

Subjects enrolled under Amendment 3 will follow the requirements and study procedures specified in Amendment 3.

Randomization will be stratified by number of prior bDMARD use (stratum 1: failed 1 or 2 biologics of the same class; stratum 2: failed ≥ 3 biologics of the same class or failed biologics of multiple classes) AND geographic region. Once 20% of total subjects have been randomized who have not completed > 3 months of methotrexate, further screening of such methotrexate inexperienced subjects may be suspended.

Subjects must have been on stable csDMARD(s) treatment for ≥ 4 weeks prior to the first dose of study drug and must remain on a stable dose until Week 12; the csDMARD dose may be decreased only for safety reasons. Starting at Week 12 (after Week 12 assessments have been performed), initiation of or change in corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or increasing doses for up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of MTX and leflunomide) is allowed as per local label.

Rescue therapy will be offered to subjects who meet the following criteria:

- Starting at Week 12, subjects who do not achieve ≥ 20% improvement in both TJC and SJC at two consecutive visits will be rescued with optimizing (initiate or increase) background RA medications: NSAIDs, corticosteroids, low-potency analgesics, acetaminophen or adding or increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of MTX and leflunomide) and, if necessary, a burst of systemic corticosteroids (prednisone equivalent ≤ 0.5 mg/kg/day for 3 consecutive days), intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, and intra-tendon sheath injections of corticosteroids, dosage and frequency per standard of care, are allowed.

Subjects who complete the Week 24 visit (end of Period 1) will enter the open-label long term extension portion of the study, Period 2 (up to 5 years). Subjects who are assigned to upadacitinib treatment group in Period 1 will continue to receive upadacitinib 15 mg QD per original randomization assignment.

Subjects who are assigned to abatacept IV in Period 1 will be switched to receive upadacitinib 15 mg QD.

An unblinded analysis will be conducted after all subjects have completed Period 1 (Week 24). Period 2 is open-label.
Diagnosis and Main Criteria for Inclusion/Exclusion:

Main Inclusion:

1. Adult male or female, at least 18 years old.
2. Diagnosis of RA for ≥ 3 months who also fulfill the 2010 ACR/EULAR classification criteria for RA.
3. Subjects have been treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration AND have never received abatacept prior to first dose of study drug.
4. Subjects have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug:
   - The following csDMARDs are allowed (stable dose for ≥ 4 weeks prior to the first dose of study drug): oral or parenteral MTX (7.5 to 25 mg/week), sulfasalazine (≤ 3000 mg/day), hydroxychloroquine (≤ 400 mg/day), chloroquine (≤ 250 mg/day), and leflunomide (≤ 20 mg/day).
   - A combination of up to two background csDMARDs is allowed EXCEPT the combination of MTX and leflunomide.
5. Subject meets both of the following minimum disease activity criteria:
   - ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits; and
   - hsCRP ≥ 3 mg/L (central lab) at Screening Visit.

Main Exclusion:

1. Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib).
2. Prior exposure to abatacept.
3. History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms], or any arthritis with onset prior to age 17 years). Current diagnosis of secondary Sjogren's Syndrome is permitted.
4. Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase > 2 × upper limit of normal (ULN); serum alanine transaminase > 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula < 40 mL/min/1.73 m²; total white blood cell count < 2,500/μL; absolute neutrophil count < 1,500/μL; platelet count < 100,000/μL; absolute lymphocyte count < 800/μL; and hemoglobin < 10 g/dL.

Investigational Product: Upadacitinib
Dose: 15 mg QD
Mode of Administration: Oral
## Reference Therapy:
**Period 1 only:** Placebo for upadacitinib 15 mg QD  
**Dose:** N/A  
**Mode of Administration:** Oral

## Reference Therapy:
**Period 1 only:** abatacept  
**Dose:**  
- < 60 kg: 500 mg  
- 60 – 100 kg: 750 mg  
- > 100 kg: 1,000 mg  
**Mode of Administration:** IV: Day 1, Weeks 2, 4, 8, 12, 16, and 20

## Reference Therapy:
**Period 1 only:** Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)  
**Dose:** N/A  
**Mode of Administration:** IV: Day 1, Weeks 2, 4, 8, 12, 16, and 20

## Duration of Treatment:
**Period 1:** 24 weeks; **Period 2:** up to 5 years

## Criteria for Evaluation:
### Efficacy:
**Period 1:**
- The primary endpoint is the change from baseline in DAS28 (CRP) at Week 12 (non-inferiority)

**Key secondary endpoints are:**
- Change from baseline in DAS28 (CRP) at Week 12 (superiority)
- Proportion of subjects achieving Clinical Remission (CR) at Week 12 (superiority)
  - CR is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) < 2.6.

**Additional endpoints are:**
- Proportion of subjects achieving low disease activity (LDA) at Week 12 (non-inferiority).
  - LDA is defined as Disease Activity Score (DAS)28 (C-reactive protein [CRP]) ≤ 3.2.
- ACR20/50/70 response rates at all visits;
  - ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale [VAS]), Patient's Global Assessment of Disease Activity (VAS), Physician's Global Assessment of Disease Activity (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI), or hsCRP.
- Change from baseline in individual components of ACR response at all visits;
- Change from baseline in DAS28(CRP) and DAS28 (erythrocyte sedimentation rate [ESR]) at all visits;
- Change from baseline in SF 36 at Weeks 4, 12 and 24;
- Change from baseline in morning stiffness at all visits;
- Proportion of subjects achieving LDA or CR based on DAS28 (CRP), DAS28 (ESR), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) criteria (see below) at all visits;
- Change from baseline in EQ-5D-5L at Weeks 4, 12 and 24;
Criteria for Evaluation (Continued):

Efficacy (Continued):

Period 1 (Continued):

- Change from baseline in Functional Assessment of Chronic Illness Therapy – fatigue (FACIT-F) at Weeks 4, 8, 12, 16 and 24;
- Change from baseline in Work Productivity and Activity Impairment (WPAI) at Weeks 4, 8, 12 and 24;
- Change from baseline in CDAI and SDAI at all visits;
- Proportion of subjects achieving MCID in change from baseline in HAQ-DI (defined as change from baseline in HAQ-DI $\leq -0.3$) at all visits;
- ACR/EULAR Boolean remission at all visits.
- Systemic corticosteroid dose (including cumulative dose at serial time points in Period 1)

<table>
<thead>
<tr>
<th>DAS28 (CRP) and DAS28 (ESR)</th>
<th>SDAI</th>
<th>CDAI</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDA</td>
<td>$\leq 3.2$</td>
<td>$\leq 11.0$</td>
</tr>
<tr>
<td>CR</td>
<td>$&lt; 2.6$</td>
<td>$\leq 3.3$</td>
</tr>
</tbody>
</table>

Period 2:
Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Weeks 36, 48, and every 12 weeks thereafter until completion of the study:

- Change from baseline in DAS28 (CRP);
- Proportion of subjects achieving CR based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- Proportion of subjects achieving LDA based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria (as defined for Period 1);
- ACR20/50/70 response rates;
- Change from baseline in individual ACR components;
- Change from baseline in DAS28 (ESR);
- Change from baseline in HAQ-DI at all visits;
- Change from baseline in SF 36 at all visits;
- Change from baseline in morning stiffness;
- Concomitant corticosteroid use.
- ACR/EULAR Boolean remission

Assessments to evaluate efficacy of treatment in Period 2 will be analyzed for the following measures at Week 48 only:

- Change from baseline in EQ-5D-5L;
- Change from baseline in FACIT-F;
- Change from baseline in WPAI RA.

Pharmacokinetic (Period 1 Only):
Blood samples for assay of upadacitinib and possibly other concomitant medications in plasma will be collected at Weeks 2, 4, 8, 12, 16, 20 and 24/Premature Discontinuation.
### Criteria for Evaluation (Continued):

#### Exploratory Research Variables and Validation Studies (Optional) (Period 1 Only):
Prognostic and predictive biomarker signatures may be evaluated. Samples for pharmacogenetic, epigenetic, transcriptomic, and proteomic and targeted protein investigations will be collected at various time points. Assessments will include but may not be limited to nucleic acids, proteins, metabolites, or lipids.

#### Safety:
Safety evaluations include adverse event (AE) monitoring, physical examinations, vital sign measurements, electrocardiogram (ECG), and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration.

### Statistical Methods:
#### Efficacy:
All efficacy analyses will be carried out using the Full Analysis Set population, which includes all randomized subjects who receive at least one dose of study drug.

#### Period 1 Efficacy:
**Analysis of the Primary and Key Secondary Endpoints:**
The primary efficacy endpoint will be assessed via non-inferiority comparison of upadacitinib to abatacept in change from baseline in DAS28 (CRP) at Week 12 using the 95% confidence interval (CI) of treatment difference against the pre-specified non-inferiority margin.

The two key secondary efficacy endpoints involve the superiority comparisons of upadacitinib to abatacept on change from baseline in DAS28 (CRP) at Week 12 as well as the proportion of subjects achieving CR based on DAS28 (CRP) at Week 12. The overall type I error rate of the primary and key secondary endpoints will be strongly controlled via sequential testing.

For the binary endpoint of CR, frequencies and percentages will be reported for each treatment group, and comparison of upadacitinib to abatacept will be conducted using the Cochran-Mantel-Haenszel test adjusting for main stratification factors. Non-responder imputation will serve as the primary analysis approach for missing data handling.

For the continuous endpoint of change from baseline in DAS28 (CRP), the mean, standard deviation, median, and range will be reported for each treatment group. Comparison between upadacitinib and abatacept will be carried out using the analysis of covariance model with treatment group as the fixed factor, and the corresponding baseline value and the main stratification factors as the covariates. Multiple imputations will serve as the primary analysis approach for missing data handling.

**Long-Term Efficacy for Period 1 and Period 2 Combined:**
Long-term efficacy by time point will be summarized using descriptive statistics.

#### Pharmacokinetic:
A non-linear mixed-effects modeling approach will be used to estimate the population central values and the empirical Bayesian estimates of the individual values of upadacitinib oral clearance (CL/F) and volume of distribution (V/F). Additional parameters may be estimated if useful in the interpretation of the data.
Statistical Methods (Continued):

Safety:
Safety analyses will be carried out using the Safety Analysis Set, which includes all subjects who receive at least one dose of study drug. Analyses will be conducted for Period 1 alone, as well as for Period 1 and Period 2 combined. Safety will be assessed by AEs, physical examination, laboratory assessments, ECG, and vital signs. Frequency tables and lists of subjects with treatment-emergent AEs by preferred term as in the Medical Dictionary for Regulatory Activities dictionary, by system organ class, by severity, and by relationship to the study drug as assessed by the Investigator will be provided. The changes from baseline in vital signs, physical examination results, and clinical laboratory values will be analyzed in a descriptive manner. Shift of laboratory values from baseline to defined time points will be tabulated.

Section 3.2 Benefits and Risks

Last paragraph previously read:
The dose of ABT-494 selected for the Study M15-925 (once-daily formulation 30 mg QD) was chosen based on an optimal benefit to risk profile from the Phase 2b studies (Studies M13-537 [MTX-IR: methotrexate inadequate responder] and M13-550 [TNF-IR: anti-tumor necrosis factor inadequate responder]. The 12 mg BID dose of immediate-release (IR) formulation of ABT-494 is bioequivalent to the dose proposed in Study M15-925 (once-daily formulation of 30 mg QD), with equivalent daily AUC and comparable C\text{max} and C\text{min}.

Has been changed to read:
The dose of upadacitinib selected for the Study M15-925 (once-daily formulation 15 mg QD) was chosen based on an optimal benefit to risk profile from the first two Phase 3 studies from the RA program: Study M13-549 (csDMARD-IR) and Study M13-542 (bDMARD-IR). The data from these studies showed that both the 15 mg and 30 mg QD doses achieved superior responses to placebo for all primary and ranked secondary endpoints at Week 12 with a safety profile consistent with the known profile from Phase 2b studies (Studies M13-537 [MTX-IR: methotrexate inadequate responder] and M13-550 [TNF IR: anti-tumor necrosis factor inadequate responder].
Section 3.2 Benefits and Risks
Subsection Risks
Add: new fifth, sixth, seventh, eighth, ninth, and tenth paragraph

Many adverse events (AEs) (serious infections, herpes zoster reactivation, malignancies, and hematologic AEs) observed with pan-JAK inhibition are thought to be a consequence of lack of selectivity against the members of the JAK family of proteins. Upadacitinib is a novel selective JAK1 inhibitor with the ability to decrease inflammation mediated by JAK1 signaling while having less inhibitory effects on JAK2 and JAK3. This could potentially minimize some of the reported safety concerns with non-selective JAK inhibition which are thought to be mediated by inhibition of JAK2 and JAK3 signaling pathways.

The safety profile specific to upadacitinib is evolving with safety results to date consistent with those known to be associated with JAK inhibition. AEs in the categories of infection such as urinary tract infection, upper respiratory tract infection and herpes zoster reactivation have been reported as well as AEs in the categories of malignancies, and gastrointestinal disorders such as gastrointestinal perforation.

In addition, laboratory changes observed with upadacitinib include elevations of serum transaminases, lipids, creatinine and creatine phosphokinase; both increased and reduced hemoglobin, depending on baseline inflammatory burden; and reductions in white blood cell counts, including Natural Killer (NK) cells.

The results of all genetic toxicology testing indicate that upadacitinib is not genotoxic, however upadacitinib may be teratogenic, which necessitates avoidance of pregnancy in women of childbearing potential.

A detailed discussion of the pre-clinical and clinical toxicology, metabolism, pharmacology and safety experience with upadacitinib can be found in the current Investigator's Brochure.
Taken together, the safety and efficacy data from upadacitinib studies to date show a favorable benefit:risk profile for upadacitinib in the treatment of various autoimmune/inflammatory disorders and support the continued investigation of upadacitinib in patients with autoimmune/inflammatory conditions.

Section 4.0 Study Objectives
Previously read:

Period 1

To compare the safety and efficacy of ABT-494 30 mg QD versus abatacept on a background of csDMARD(s) for the treatment of signs and symptoms of RA in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA who have never received abatacept.

Period 2

To evaluate the long-term safety, tolerability, and efficacy of ABT-494 30 mg QD in subjects with RA who have completed Period 1.

Has been changed to read:

Period 1

To compare the safety and efficacy of upadacitinib 15 mg QD versus abatacept on a background of csDMARD(s) for the treatment of signs and symptoms of RA in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA who have never received abatacept.

Period 2

To evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.
Section 5.1 Overall Study Design and Plan: Description

First paragraph, second and third sentence previously read:

Period 1 is the 24-week randomized, double-blind, parallel-group, active-controlled treatment period designed to compare the safety and efficacy of ABT-494 30 mg versus abatacept for the treatment of signs and symptoms of subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapy and are currently on a stable dose of csDMARDs and have never received abatacept. Period 2 is an open-label long-term extension to evaluate the long-term safety, tolerability, and efficacy of ABT-494 30 mg QD in subjects with RA who have completed Period 1.

Has been changed to read:

Period 1 is the 24-week randomized, double-blind, parallel-group, active-controlled treatment period designed to compare the safety and efficacy of upadacitinib 15 mg versus abatacept for the treatment of signs and symptoms of subjects with moderately to severely active RA who have an inadequate response to or intolerance to bDMARD therapy and are currently on a stable dose of csDMARDs and have never received abatacept. Period 2 is an open-label long-term extension to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1.

First bullet previously read:

Group 1:  ABT-494 30 mg QD, N = 275 (Period 1)

Has been changed to read:

Group 1:  upadacitinib 15 mg QD, N = 275 (Period 1)

Section 5.1 Overall Study Design and Plan: Description

Add:  new fifth paragraph

NOTE: In Period 1, subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose. This study began enrolling under Amendment 3. Starting with Amendment 4,
subjects randomized to Group 1 will receive 15 mg QD dose. In Period 2, subjects who enrolled under Amendment 3, including subjects randomized to both Group 1 and Group 2, will continue to receive open-label upadacitinib 30 mg QD. Subjects who enroll under Amendment 4 or later will receive open-label upadacitinib 15 mg QD. Subjects enrolled under Amendment 3 will follow the requirements and study procedures specified in Amendment 3.

Section 5.1 Overall Study Design and Plan: Description
Seventh paragraph, second and third sentence previously read:
Subjects who are assigned to ABT-494 in Period 1 will continue to receive ABT-494 30 mg QD per original randomization assignment in an open-label manner. Subjects who are assigned to abatacept for 24 weeks of Period 1 will be switched to receive ABT-494 30 mg QD in Period 2.

Has been changed to read:
Subjects who are assigned to upadacitinib in Period 1 will continue to receive upadacitinib 15 mg QD per original randomization assignment in an open-label manner. Subjects who are assigned to abatacept for 24 weeks of Period 1 will be switched to receive upadacitinib 15 mg QD in Period 2.
Figure 1. Period 1 Study Design

Previously read:

csDMARD = conventional synthetic disease modifying anti-rheumatic drug; DMARD = disease modifying anti-rheumatic drug; n = number; QD = once daily; RA = rheumatoid arthritis; W = week

* The follow-up period is only for subjects who do not enter Period 2.
Has been changed to read:

```
csDMARD = conventional synthetic disease modifying anti-rheumatic drug; DMARD = disease modifying anti-rheumatic drug; n = number; QD = once daily; RA = rheumatoid arthritis; W = week

* The follow-up period is only for subjects who do not enter Period 2.

** Subjects randomized to Group 1 under Amendment 3 received 30 mg QD dose. Starting with Amendment 4, subjects randomized to Group 1 will receive 15 mg QD dose.
```
Figure 2. Period 2 Study Design
Previously read:

<table>
<thead>
<tr>
<th>End of Period 1</th>
<th>PERIOD 2: Open-Label Extension Period (≈ 5 years)</th>
<th>Follow-Up Period (≈ 30 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ABT-494 30 MG QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abatacept IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ABT-494 30 MG QD</td>
<td></td>
</tr>
</tbody>
</table>

QD = once daily; W = week
Has been changed to read:

<table>
<thead>
<tr>
<th>End of Period 1</th>
<th>PERIOD 2: Open-Label Extension Period (± 5 years)</th>
<th>Follow-Up Period (± 30 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1: Upadacitinib 15 MG QD*</td>
<td>Upadacitinib 15 MG QD*</td>
<td></td>
</tr>
<tr>
<td>Group 2: Abatacept IV</td>
<td>Upadacitinib 15 MG QD*</td>
<td></td>
</tr>
</tbody>
</table>

QD = once daily; W = week

* Subjects who enrolled under Amendment 3, including subjects on both upadacitinib and abatacept will continue to receive open-label upadacitinib 30 mg QD. Subjects who enroll under Amendment 4 or later will receive open-label upadacitinib 15 mg QD.

Section 5.2.2 Exclusion Criteria
Criterion 19 previously read:

History of an allergic reaction or significant sensitivity to constituents of the study drugs (and its excipients) and/or other products in the same class including Maltose and Sodium dihydrogen phosphate monohydrate.

Has been changed to read:

History of an allergic reaction or significant sensitivity to constituents of the study drugs (and its excipients) and/or other products in the same class.
Section 5.2.3.1 Permitted Background RA Therapy
Fifth paragraph, first bullet, first sentence previously read:

Initiation of or change in corticosteroids, NSAIDs, acetaminophen or adding or increasing
doses in csDMARDs (concomitant use of up to 2 csDMARDs except the combination of
MTX and leflunomide; see Inclusion Criterion 4) is allowed as per local label.

Has been changed to read:

Initiation of or change in corticosteroids, NSAIDs, acetaminophen or adding or increasing
doses in csDMARDs (restricted to oral or parenteral MTX, sulfasalazine,
hydroxychloroquine, chloroquine and leflunomide except the combination of MTX and
leflunomide; see Inclusion Criterion 4) is allowed as per local label.

Table 1. Examples of Commonly Used Strong CYP3A Inhibitors and Inducers
Column "Strong CYP3A Inducers"
Add:

Rifapentine

Section 5.2.3.2 Prohibited Therapy
Subsection Traditional Chinese Medicine
Previously read:

Traditional Chinese medicine is not permitted during the study, and subjects must have
discontinued traditional Chinese medicine at least 4 weeks prior to the first dose of study
drug.

Has been changed to read:

Traditional oral Chinese medicine is not permitted during the study as these may interfere
with upadacitinib metabolism and exposure and may impact efficacy and safety of
upadacitinib treatment. Subjects must have discontinued traditional Chinese medicine at
least 4 weeks prior to the first dose of study drug.
Section 5.2.4 Contraception Recommendations
Subsection Contraception Recommendation for Females
Fifth paragraph previously read:

A woman who does not meet the definition of postmenopausal or permanently surgically sterile is considered of childbearing potential and is required to practice at least one of the following highly effective methods of birth control that is effective from Study Day 1 (or earlier) through at least 98 days (Period 1)/30 days (Period 1) after the last dose of study drug.

Has been changed to read:

A woman who does not meet the definition of postmenopausal or permanently surgically sterile is considered of childbearing potential and is required to practice at least one of the following highly effective methods of birth control that is effective from Study Day 1 (or earlier) through at least 98 days (Period 1)/30 days (Period 2) after the last dose of study drug.

Section 5.2.4 Contraception Recommendations
Subsection Contraception Recommendation for Females
Fifth paragraph, first bullet previously read:

Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation, initiated at least 30 days prior to Study Day 1.

Has been changed to read:

Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal, injectable) associated with the inhibition of ovulation, initiated at least 30 days prior to Study Day 1.
Section 5.2.4 Contraception Recommendations

Subsection Contraception Recommendation for Females

Fifth paragraph, last bullet previously read:

True abstinence: Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable].

Has been changed to read:

True abstinence (if acceptable per local requirements): Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject [periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable].

Section 5.2.4 Contraception Recommendations

Subsection Contraception Recommendation for Females

Add: new seventh paragraph

If during the course of the study a woman becomes surgically sterile or post-menopausal (defined above) and complete documentation is available, contraceptive measures as defined above are no longer required.

Section 5.2.4 Contraception Recommendations

Subsection Contraception Recommendation for Males

First paragraph previously read:

For a male subject who has a female partner who is postmenopausal or permanently sterile, no contraception is required.

Has been changed to read:

Based on data from animal studies (including a fertility study) there is no effect of upadacinib on male reproduction. The effects of upadacinib on human male reproduction have not been determined.
For a male subject who is surgically sterile (vasectomy with medical assessment confirming surgical success) OR has a female partner who is postmenopausal or permanently sterile, no contraception is required.

Section 5.2.4 Contraception Recommendations
Subsection Contraception Recommendation for Males
First bullet previously read:

Condom use and female partner(s) using at least one of the contraceptive measures as defined in the protocol for female study subjects of childbearing potential.

Has been changed to read:

Condom use and female partner(s) using at least one of the contraceptive measures as defined in the protocol for female study subjects of childbearing potential. OR

Section 5.3.1.1 Study Procedures
Subsection TB Testing/TB Prophylaxis
Previously read:

The TB screening tests are diagnostic test results to be interpreted in the context of the subject's epidemiology, history, exam findings, etc., and it is the responsibility of the Investigator to determine if a subject has previous, active, or latent TB.

At screening, all subjects will be assessed for evidence of increased risk for TB by a risk assessment form (Appendix I) and tested for TB infection by QuantiFERON-TB Gold test. The PPD Skin Test should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless both tests are required per local guidelines). The site staff will complete the TB risk assessment form and enter the data into an appropriate eCRF.

If a subject had a negative QuantiFERON-TB Gold (and/or PPD) test (or IGRA equivalent such as T-SPOT TB test) within 90 days prior to Screening and source documentation is available, the test does not need to be repeated, provided nothing has changed in the subject's medical history to warrant a repeat test. These cases may be
discussed with the AbbVie Therapeutic Area Medical Director. The results of the TB
test(s) will be retained at the site as the original source documentation.

For subjects with a negative TB test result at Screening or most recent evaluation, an
annual TB re-test will be performed. The TB test(s) to be performed depends on local
guidelines and whether or not the site has capacity to perform QuantiFERON-TB Gold
testing (see below). If an annual TB test is newly positive (seroconversion), a chest x-ray
(CXR) needs to be performed as soon as possible to aid in distinguishing active versus
latent TB. Any positive TB screen after the patient has started the study, should be
reported as an adverse event. Expert consultation can be considered per Investigator's
discretion.

TB test:

- For regions that require both PPD and QuantiFERON-TB Gold testing, both
  will be performed. A positive TB test is defined by local guidelines (for
  example, in some countries, both PPD and QuantiFERON-TB Gold are
  performed, and if either one is positive, the TB test is considered positive).

- In the absence of local guidelines defining a positive result when both PPD
  and QuantiFERON-TB Gold tests are performed, then the QuantiFERON-TB
  Gold test result will be the TB test result (QuantiFERON-TB Gold supersedes
  PPD).

- If a site has the capacity to perform both PPD and QuantiFERON-TB Gold
tests, and local guidelines require only one test to be performed, then the
  QuantiFERON-TB Gold is the preferred test. At a site with capacity to
  perform both tests, if a PPD is placed as the only form of TB test at screening,
  then the TB test to be used for the remainder of the study for that subject is the
  PPD. Similarly, if a subject enters the study with a Quantiferon TB Gold test
  alone (negative result), then the subject should have their annual TB test
  performed with the Quantiferon TB Gold test.

- If the QuantiFERON-TB Gold Test is NOT possible (or if both the
  QuantiFERON-TB Gold Test and the PPD Skin Test are required per local
  guidelines): the PPD Skin Test (also known as a TB Skin Test) will be
performed according to standard clinical practice. The TB Skin Test should be read by a licensed healthcare professional between 48 and 72 hours after administration. A subject who does not return within 72 hours will need to be rescheduled for another skin test. The reaction will be measured in millimeters (mm) of induration and induration $\geq 5$ mm for RA subjects is considered a positive reaction. The absence of induration will be recorded as "0 mm" not "negative." Subjects who have had an ulcerating reaction to the TB Skin Test in the past should not be re-exposed and the TB Skin Test should be considered positive.

Subjects with a negative TB test and chest x-ray (CXR) not suggestive of active TB or prior TB exposure may be enrolled.

If the QuantiFERON-TB Gold test is indeterminate, the site should repeat the test with another blood sample. If the second QuantiFERON-TB Gold test is also indeterminate, then the subject is considered to be positive.

Subjects with a positive TB test must be assessed for evidence of active TB versus latent TB, including signs and symptoms and CXR. Subjects with no signs or symptoms and a CXR not suggestive of active TB may be enrolled after initiation of TB prophylaxis (see below). Subjects with evidence of active TB must not be enrolled.

TB prophylaxis:

At screening, if the subject has evidence of latent TB infection (positive TB test and the subject has a CXR not suggestive of active TB), prophylactic treatment must be initiated at least 2 weeks prior to administration of study drug (or per local guidelines, whichever is longer); the prophylaxis needs to be completed; however, the full course of prophylaxis does not need to be completed prior to the first dose of study drug. If the Investigator deems that it is necessary, consultation with a TB expert could be considered.

Of note: Rifampicin is not allowed for TB prophylaxis.
Subjects with a prior history of latent TB that have documented completion of a full course of anti-TB therapy within 1 year prior to first study drug administration will be allowed to enter the study provided nothing has changed in the subject's medical history to warrant repeat treatment.

Obtain a CXR every 48 weeks for subjects with TB risk factors as identified by the TB risk assessment form (Appendix I) or for subjects living in areas endemic for TB or for subjects with newly positive PPD or QuantiFERON-TB Gold test.

Subjects with documented completion of a full course of anti-TB therapy greater than 1 year prior to first study drug administration may be allowed to enter the study only after consultation with the AbbVie Therapeutic Area Medical Director.

Newly initiated prophylactic treatment should be captured in the eCRF and in the source documents. Prior therapy should be captured in the eCRF.

During the study, subjects with new evidence of latent TB should initiate prophylactic treatment immediately per local guidelines. Study drug(s) should not be withheld and Isoniazid should be initiated and 2 to 4 weeks later (per local guidelines), subject should be re-evaluated (unscheduled visit) for signs and symptoms of isoniazid toxicity.

If the subject is experiencing signs or symptoms suspicious for TB or something has changed in the subject's medical history to warrant a repeat test before the next scheduled annual TB re-test, the case (including the TB test results) must be discussed with the AbbVie Therapeutic Area Medical Director.

**Has been changed to read:**

The TB screening tests are diagnostic test results to be interpreted in the context of the subject's epidemiology, history, exam findings, etc., and it is the responsibility of the Investigator to determine if a subject has previous, active, or latent TB. Expert consultation for the evaluation and/or management of TB may be considered per Investigator discretion.
At screening, all subjects will be assessed for evidence of increased risk for TB by a risk assessment form (Appendix I) and tested for TB infection by QuantiFERON-TB Gold test. The PPD Skin Test should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless both tests are required per local guidelines). The site staff will complete the TB risk assessment form and enter the data into an appropriate eCRF. TB risk assessment form will be completed annually for all subjects, regardless of TB test results.

If a subject had a negative QuantiFERON-TB Gold (and/or PPD) test (or IGRA equivalent such as T-SPOT TB test) within 90 days prior to Screening and source documentation is available, the test does not need to be repeated, provided nothing has changed in the subject's medical history to warrant a repeat test. These cases may be discussed with the AbbVie Therapeutic Area Medical Director. The results of the TB test(s) will be retained at the site as the original source documentation.

Subjects with a negative TB test and chest x-ray (CXR) not suggestive of active TB or prior TB exposure may be enrolled.

Subjects with a positive TB test must be assessed for evidence of active TB versus latent TB, including signs and symptoms and CXR. Subjects with no signs or symptoms and a CXR not suggestive of active TB may be enrolled after initiation of TB prophylaxis (see below).

Subjects with evidence of active TB must not be enrolled.

For subjects with a negative TB test result at Screening or most recent evaluation, an annual TB follow-up test will be performed. If an annual TB test is newly positive (seroconversion), a chest x-ray (CXR) needs to be performed as soon as possible to aid in distinguishing active versus latent TB. Any positive TB screen after the patient has started the study, should be reported as an adverse event of latent TB or active TB (as applicable).
If the subject is experiencing signs or symptoms suspicious for TB or something has changed in the subject's medical history to warrant a repeat test before the next scheduled annual TB re-test, the case (including the TB test results) must be discussed with the AbbVie TA MD.

TB test:

- Subjects with documentation of prior positive result of QuantiFERON-TB Gold Test (or equivalent) and/or PPD are not required to repeat either test at Screening or during the study and should be considered positive.
- For regions that require both PPD and QuantiFERON-TB Gold testing, both will be performed. If either PPD or QuantiFERON-TB Gold is positive, the TB test is considered positive.
- The PPD Skin Test (also known as a TB Skin Test or Mantoux Test) should be utilized only when a QuantiFERON-TB Gold Test is not possible for any reason (unless both tests are required per local guidelines).
- If only a PPD is placed at screening, then the TB test to be used for the remainder of the study for that subject is the PPD. Similarly, if a subject enters the study with a QuantiFERON-TB Gold test (or equivalent) alone, then the subject should have their annual TB test performed with a QuantiFERON-TB Gold test.
- If the QuantiFERON-TB Gold Test is NOT possible (or if both the QuantiFERON-TB Gold Test and the PPD Skin Test are required per local guidelines): the PPD Skin Test (also known as a TB Skin Test) will be performed. The TB Skin Test should be read by a licensed healthcare professional between 48 and 72 hours after administration. A subject who does not return within 72 hours will need to be rescheduled for another skin test. The reaction will be measured in millimeters (mm) of induration and induration \( \geq 5 \) mm for RA subjects is considered a positive reaction. The absence of induration will be recorded as "0 mm" not "negative." Subjects who have had an ulcerating reaction to the TB Skin Test in the past should not be re-exposed and the TB Skin Test should be considered positive.
● If the QuantiFERON-TB Gold test is indeterminate, then the investigator should perform a local QuantiFERON-TB Gold test (or through the central laboratory if not locally available) to rule out a positive test result. If testing remains indeterminate or is positive, then the subject is considered to be positive for the purpose of this study. If the testing result is negative, then the patient is considered to be negative.

TB prophylaxis:

At screening, if the subject has evidence of latent TB, prophylactic treatment must be initiated at least 2 weeks prior to administration of study drug (or per local guidelines, whichever is longer); At least 6 months of prophylaxis needs to be completed to remain in the study.

Of note: Rifampicin or Rifapentine is not allowed for TB prophylaxis.

Subjects with a prior history of latent TB that have documented completion of a full course of anti-TB therapy will be allowed to enter the study provided nothing has changed in the subject's medical history to warrant repeat treatment. For subjects with completion of a full course of anti-TB therapy, but insufficient documentation, the investigator should consult with the AbbVie TA MD.

Newly initiated prophylactic treatment should be captured in the eCRF and in the source documents. Prior therapy should be captured in the eCRF.

During the study, subjects with new evidence of latent TB should initiate prophylactic treatment immediately per local guidelines and complete at least 6 months of prophylaxis. TB prophylaxis should be initiated and study drug(s) should not be withheld. 2 to 4 weeks later, the subject should be re-evaluated (unscheduled visit) for signs and symptoms as well as laboratory assessment of toxicity to TB prophylaxis.
Section 5.3.1.1 Study Procedures
Subsection Chest X-Ray (CXR)

Last paragraph, first sentence previously read:
A radiologist must perform an assessment of the CXR.

Has been changed to read:
A radiologist or pulmonologist must perform an assessment of the CXR.

Section 5.3.1.1 Study Procedures
Subsection CDAI

Third paragraph previously read:
CDAI = TJC28 + SJC28 + PtGA + PhGA

Has been changed to read:
CDAI = TJC28 + SJC28 + PtGA (cm) + PhGA (cm)

Section 5.3.1.1 Study Procedures
Subsection Pregnancy Test

Second paragraph, first bullet, last sentence previously read:
In the event a pregnancy test comes back borderline, a repeat test is required.

Has been changed to read:
In the event a serum pregnancy test comes back borderline, a repeat test is required (≥ 3 days later) to document continued lack of a positive result.

Section 5.3.1.1 Study Procedures
Subsection Pregnancy Test

Second paragraph, last bullet
Add: new last sentence

In the event a serum pregnancy test comes back borderline, a repeat test is required (≥ 3 days later) to document continued lack of a positive result.
Section 5.3.1.1 Study Procedures
Subsection Pregnancy Test
Last paragraph previously read:

A pregnant or breastfeeding female will not be eligible for participation in this study or be allowed to continue study drug.

Has been changed to read:

If during the course of the study a woman becomes surgically sterile or post-menopausal and complete documentation as described in Section 5.2.4 is available, pregnancy testing is no longer required.

A pregnant or breastfeeding female will not be eligible for participation in this study or continuation on study drug.

Section 5.3.1.1 Study Procedures
Subsection Clinical Laboratory Tests
Last paragraph
Add: new last sentence

Other laboratory abnormalities, including those which meet the toxicity management criteria outlined in Section 6.1.7 (Toxicity Management), may be recorded as AEs at the discretion of the investigator.

Table 2. Clinical Laboratory Tests
Table note "g." previously read:

The hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject.

Has been changed to read:

In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject. Results of hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical
utility in the setting of a possible safety assessment or adverse event management. Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib. In Period 2, the central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.

Section 5.3.1.1 Study Procedures
Subsection Hepatitis Screen
Heading "Hepatitis B:"
Heading title previously read:

Hepatitis B:

Has been changed to read:

Hepatitis B Virus (HBV):

Section 5.3.1.1 Study Procedures
Subsection Hepatitis Screen
Heading "Hepatitis B:"
First paragraph, first and second bullet previously read:

- HBs Ag
- HBe Ab/anti-HBe

Has been changed to read:

- HBs Ag (Hepatitis B surface antigen)
- HBe Ab/anti-HBe (Hepatitis B core antibody)

Section 5.3.1.1 Study Procedures
Subsection Hepatitis Screen
Heading "Hepatitis C:"
Heading title previously read:

Hepatitis C:
Has been changed to read:

Hepatitis C Virus (HCV):

Section 5.3.1.1 Study Procedures
Subsection Hepatitis Screen
Heading "Hepatitis C:"
Add: new second sentence

A positive HCV Ab will trigger an HCV RNA test.

Section 5.3.1.1 Study Procedures
Subsection Randomization/Drug Assignment
First bullet previously read:

Group 1: ABT-494 30 mg QD, N = 275 (Period 1)

Has been changed to read:

Group 1: upadacitinib 15 mg QD, N = 275 (Period 1)

Section 5.3.3.1.3 Additional Variables
Last paragraph and bullet list previously read:

Additional endpoints (at Weeks 4, 8, 12 and 24) are:

- Change from baseline in SF-36;
- Change from baseline in EQ-5D-5L;
- Change from baseline in FACIT-F;
- Change from baseline in WPAI RA.

Has been changed to read:

Additional endpoints are:

- Change from baseline in SF-36 (at Weeks 4, 12 and 24);
- Change from baseline in EQ-5D-5L (at Weeks 4, 12 and 24);
● Change from baseline in FACIT-F (at Weeks 4, 8, 12, 16 and 24);
● Change from baseline in WPAI RA (at Weeks 4, 8, 12 and 24).

Section 5.5.1 Treatments Administered
Fifth and sixth paragraph previously read:

Subjects will be dispensed with oral study drug QD (either ABT-494 30 mg or matching placebo) and receive IV study drug infusions on Day 1, Week 2, Week 4, then q4 thereafter (either abatacept or matching placebo).

Starting at Week 24 (after all assessments have been completed), subjects will be dispensed study drug (ABT-494 30 mg QD) in an open-label fashion until the completion of Period 2.

Has been changed to read:

Subjects will be dispensed with oral study drug QD (either upadacitinib 15 mg or matching placebo) and receive IV study drug infusions on Day 1, Week 2, Week 4, then q4 thereafter (either abatacept or matching placebo).

Starting at Week 24 (after all assessments have been completed), subjects will be dispensed study drug (upadacitinib 15 mg QD) in an open-label fashion until the completion of Period 2.
Table 3. Identity of Investigational Product

<table>
<thead>
<tr>
<th>Investigational Product</th>
<th>Mode of Administration</th>
<th>Formulation</th>
<th>Strength</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT-494</td>
<td>Oral</td>
<td>Tablet</td>
<td>30 mg</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Placebo for ABT-494</td>
<td>Oral</td>
<td>Tablet</td>
<td>NA</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Infusion</td>
<td>Powder</td>
<td>250 mg</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Placebo for abatacept</td>
<td>Infusion</td>
<td>0.9 Sodium Chloride Injection or Solution for Infusion 100 mL</td>
<td>NA</td>
<td>Various**</td>
</tr>
</tbody>
</table>

** Can be sourced from approved marketed products from various commercial manufacturers depending on availability.

Has been changed to read:

<table>
<thead>
<tr>
<th>Investigational Product</th>
<th>Mode of Administration</th>
<th>Formulation</th>
<th>Strength</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upadacitinib (ABT-494)</td>
<td>Oral</td>
<td>Film-coated Tablet</td>
<td>15 mg</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Upadacitinib (ABT-494)</td>
<td>Oral</td>
<td>Film-coated Tablet</td>
<td>30 mg</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Placebo for upadacitinib (ABT-494)</td>
<td>Oral</td>
<td>Film-coated Tablet</td>
<td>NA</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Infusion</td>
<td>Powder</td>
<td>250 mg</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Placebo for abatacept</td>
<td>Infusion</td>
<td>0.9 Sodium Chloride Injection or Solution for Infusion 100 mL</td>
<td>NA</td>
<td>Various**</td>
</tr>
</tbody>
</table>

** Can be sourced from approved marketed products from various commercial manufacturers depending on availability.

Section 5.5.3 Method of Assigning Subjects to Treatment Groups

First bullet previously read:

Group 1: ABT-494 30 mg QD, N = 275 (Period 1)

Has been changed to read:

Group 1: Upadacitinib 15 mg QD, N = 275 (Period 1)
Section 5.5.5.1 Blinding of Investigational Product
Second paragraph, last sentence previously read:

The unblinded pharmacist (or designated unblinded personnel) will prepare the dosing of abatacept, or placebo, (in a blinded manner) following the commercially available preparation instructions as appropriate based on the subject's assigned treatment group.

Has been changed to read:

The unblinded pharmacist (or designated unblinded personnel) will prepare the dosing of abatacept, or placebo, (in a blinded manner) following the commercially available preparation instructions as appropriate based on the subject's assigned treatment group and then provide to blinded site personnel. The blinded site personnel will administer infusions to subjects.

Section 5.6.1 Discussion of Study Design and Choice of Control Groups
Last paragraph previously read:

The purpose of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of ABT-494 30 mg QD in subjects with RA who have completed Period 1. Subjects will continue to receive ABT-494 30 mg QD in an open-label manner.

Has been changed to read:

The purpose of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with RA who have completed Period 1. Subjects will continue to receive upadacitinib 15 mg QD in an open-label manner.

Section 5.6.4 Selection of Doses in the Study
Previously read:

One dose of the once-daily formulation of ABT-494 will be evaluated: ABT-494 30 mg QD. The dose selection in this study is based on analyses of data from two Phase 2 studies in RA subjects (Studies M13-537 and M13-550). The dose selected for
Study M15-925, ABT-494 30 mg QD, dosed for up to 5 years, is expected to be efficacious with an acceptable safety profile.

Results from two Phase 2b trials in subjects with RA with ABT-494 immediate release capsule formulation indicate that all evaluated doses (3 mg BID, 6 mg BID, 12 mg BID, 18 mg BID, and 24 mg QD) were generally well tolerated and without unexpected safety concerns. The Phase 2 dose-response and exposure-response results in RA show that the 6 mg BID dose approaches the plateau of efficacy, and increasing the dose to 12 mg BID appears to result in some incremental efficacy benefit, particularly in the more refractory subjects with inadequate response or intolerance to anti TNF (anti-TNF-IR) biologic therapy. Therefore, ABT-494 exposures associated with 12 mg BID were selected as the target exposures to evaluate in this Phase 3 trials in RA patients who are intolerant or inadequate responders to prior biologic DMARDs.

In order to enhance patients' compliance and to provide a more convenient dosing regimen than BID administration, AbbVie developed a once-daily tablet formulation which will be used in Phase 3.

The 30 mg QD dose of ABT-494 once-daily formulation achieves equivalent daily AUC and comparable, $C_{\text{max}}$, and $C_{\text{min}}$ to 12 mg BID IR formulation. In Phase 2 studies, the 12 mg BID dose was clearly shown to achieve the plateau of efficacy.

**Has been changed to read:**

One dose of the once-daily formulation of upadacitinib will be evaluated: upadacitinib 15 mg QD. The dose selection in this study is based on analyses of data from two Phase 2 studies in RA subjects (Studies M13-537 and M13-550) as well as results from the first two Phase 3 studies in the RA program: Study M13-549 (csDMARD-IR) and Study M13-542 (bDMARD-IR). The dose selected for Study M15-925, upadacitinib 15 mg QD, dosed for up to 5 years, is expected to be efficacious with an acceptable safety profile.
Results from Studies M13-549 (csDMARD-IR) and M13-542 (bDMARD-IR) showed that both the 15 and 30 mg QD doses of upadacitinib achieved superior responses to placebo for all primary and ranked secondary endpoints at Week 12 and demonstrated a safety profile consistent with the known profile of upadacitinib from Phase 2 studies. Therefore, upadacitinib 15 mg was selected for comparison to abatacept in this Phase 3 trial in RA patients who are intolerant or inadequate responders to prior biologic DMARDs.

Section 6.1.1.3 Adverse Events of Special Interest

Bullet list previously read:

- Serious infections, opportunistic infections, herpes zoster, and TB;
- Malignancy and lymphoproliferative disorders;
- Gastrointestinal perforations;
- Cardiovascular events (e.g., major adverse cardiovascular event [MACE]);
- Lipid profile changes;
- Anemia and hemoglobin effects;
- Decreased neutrophil counts;
- Decreased lymphocyte counts;
- Increased serum creatinine and renal dysfunction;
- Hepatic events and increased hepatic transaminases;
- Increased creatine phosphokinase (CPK).

Has been changed to read:

- Serious infections
- Opportunistic infections
- Herpes Zoster
- Tuberculosis
- Malignancy
- Non-Melanoma Skin Cancer (NMSC)
- Malignancy excluding NMSC
- Lymphoma
- Gastrointestinal Perforations
- Adjudicated cardiovascular events (e.g., major adverse cardiovascular event [MACE])
- Lipid Profile Changes
- Anemia
- Neutropenia
- Lymphopenia
- Increased serum creatinine and renal dysfunction
- Hepatic events and increased hepatic transaminases
- Elevated creatine phosphokinase
- Embolic and thrombotic events (non-cardiac, non-CNS)

Section 6.1.4 Adverse Event Collection Period
First paragraph
Add: new second sentence

Subjects who discontinue study drug treatment but continue to participate in the study will have SAEs and nonserious AEs collected for the remainder of study participation.

Section 6.1.4 Adverse Event Collection Period
Third, fourth, and fifth paragraph previously read:

Additionally, in order to assist the adjudication process, additional information on any potential MACE will be collected, if applicable.

In the case of any of the following reported events, an appropriate supplemental MACE eCRF should be completed:

- Cardiac events;
- Myocardial infarction or unstable angina;
- Heart failure;
- Cerebral vascular accident and transient ischemic attack;
- Cardiovascular procedures (SAE Supplemental Procedure eCRF).

In the case of any of the following AEs, the corresponding Supplemental AE eCRF should be completed:

- Hepatic (discontinuation or interruption of study drug due to a hepatic related AE; a hepatic related SAE; a subject experiencing an ALT/AST > 8 × ULN or ALT/AST > 3 × ULN in conjunction with a total bilirubin > 2 × ULN);
- Renal (renal impairment; renal dysfunction; renal failure; a subject experiencing a serum creatinine > 2 mg/dL);
- Herpes Zoster infection;
- CPK increases considered by the investigator to be an AE

Has been changed to read:

Additionally, in order to assist the adjudication process, additional information on any potential cardiovascular events will be collected, if applicable.

In the case of any of the following reported events, the supplemental cardiovascular events eCRF should be completed:

- Cardiac events;
- Myocardial infarction or unstable angina;
- Heart failure;
- Cerebral vascular accident and transient ischemic attack;

In the case of a reported AE of herpes zoster infection, a Supplemental AE eCRF should be completed.
Section 6.1.5  Adverse Event Reporting
Last paragraph, first sentence previously read:

The sponsor will be responsible for Suspected Unexpected Serious Adverse Reactions (SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with Directive 2001/20/EC.

Has been changed to read:

The sponsor will be responsible for Suspected Unexpected Serious Adverse Reactions (SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with Global and Local Regulations.

Section 6.1.6  Pregnancy
Second paragraph, last sentence previously read:

Pregnancies in study subjects and their partners will be collected from the date of the first dose through 98 days (Period 1)/30 days (Period 2) following the last dose of study drug.

Has been changed to read:

Pregnancies in study subjects and their partners will be identified from the date of the first dose through 98 days (Period 1)/30 days (Period 2) following the last dose of study drug and the pregnancy will be followed to outcome.

Section 6.1.7  Toxicity Management
Third paragraph, last sentence previously read:

If any serious allergic or anaphylactic reaction occurs, intravenous or subcutaneous abatacept therapy should be discontinued immediately and appropriate therapy initiated, and the use of abatacept should be permanently discontinued.
Has been changed to read:

If any serious allergic or anaphylactic reaction occurs, intravenous abatacept therapy should be discontinued immediately and appropriate therapy initiated, and the use of abatacept should be permanently discontinued.

Section 6.1.7 Toxicity Management
Fourth paragraph, fifth, sixth, and seventh sentence previously read:

Re-challenge with study drug may occur once the infection has been successfully treated. If study drug has been interrupted for a serious infection for more than 7 consecutive days during the first 24 weeks of the study (Period 1) or 30 consecutive days thereafter (Period 2), the subject must be discontinued from study drug. Subjects who develop active TB must be discontinued from study drug.

Has been changed to read:

Study drug may be restarted once the infection has been successfully treated. Subjects who develop active TB or experience Hepatitis B reactivation must be discontinued from study drug.

Section 6.1.7 Toxicity Management
Eighth and ninth paragraph previously read:

ECG Abnormality: Subjects must be discontinued from study drug for an ECG change considered clinically significant OR a confirmed absolute QTcF value > 500 msec.

Management of Select Laboratory Abnormalities: For any given laboratory abnormality, the Investigator should assess the subject, apply the standard of care for medical evaluation and treatment following any local guidelines. Specific toxicity management guidelines for abnormal laboratory values are described in Table 4 and may require an appropriate supplemental eCRF be completed.
Has been changed to read:

ECG Abnormality: Subjects must be discontinued from study drug for an ECG change considered clinically significant and with reasonable possibility of relationship to study drug OR a confirmed absolute QTcF value > 500 msec.

Management of Select Laboratory Abnormalities: For any given laboratory abnormality, the Investigator should assess the subject, apply the standard of care for medical evaluation and treatment following any local guidelines. Specific toxicity management guidelines for abnormal laboratory values are described in Table 4 and may require an appropriate supplemental eCRF be completed. All abnormal laboratory tests that are considered clinically significant by the Investigator will be followed to a satisfactory resolution. If a repeat test is required per Table 4, the repeat testing must occur as soon as possible.

Table 4. Specific Toxicity Management Guidelines for Abnormal Laboratory Values
Parameter "AST or ALT," "Serum Creatinine," and "Creatine Phosphokinase" previously read:

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Toxicity Management Guideline</th>
</tr>
</thead>
</table>
| AST or ALT           | • Discontinue study drug if confirmed ALT or AST > 3 × ULN by repeat testing with new sample and either a total bilirubin > 2 × ULN or an international normalized ratio > 1.5.  
  o INR will only be measured in subjects with ALT or AST > 3 × ULN by the central lab by reflex testing and confirmation is not needed for consideration in toxicity management criteria.  
• Discontinue study drug if confirmed ALT or AST > 3 × ULN by repeat testing with new sample along with appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).  
• Discontinue study drug if confirmed ALT or AST > 8 × ULN by repeat testing with new sample.  
• Discontinue study drug if confirmed ALT or AST > 5 × ULN by repeat testing with new sample for more than 2 weeks.  
For all of the above ALT or AST elevation scenarios, complete supplemental hepatic eCRF. |
<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Toxicity Management Guideline</th>
</tr>
</thead>
</table>
| Serum Creatinine     | • If serum creatinine is $> 1.5 \times$ the baseline value, repeat the test for serum creatinine (with subject in an euvoletic state) to confirm the results. If the results of the repeat testing still meet this criterion then interrupt study drug and re-start study drug once serum creatinine returns to $\leq 1.5 \times$ baseline value.  
• If confirmed serum creatinine $\geq 2$ mg/dL interrupt study drug, and re-start study drug once serum creatinine returns to normal reference range or its baseline value.  
For the above serum creatinine elevation scenarios, complete supplemental renal eCRF. |
| Creatine Phosphokinase | • If any confirmed CPK value $\geq 4 \times$ ULN (if symptomatic or asymptomatic), complete supplemental CPK eCRF.  
• If confirmed CPK $\geq 4 \times$ ULN accompanied by symptoms suggestive of myositis or rhabdomyolysis, interrupt study drug, complete supplemental CPK eCRF, and contact AbbVie Therapeutic Area Medical Director. |
Has been changed to read:

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Toxicity Management Guideline</th>
</tr>
</thead>
</table>
| AST or ALT           | • Interrupt study drug immediately if confirmed ALT or AST > 3 × ULN by repeat testing with new sample and either a total bilirubin > 2 × ULN or an international normalized ratio > 1.5.  
  o INR will only need to be measured in subjects with ALT or AST > 3 × ULN by the central lab. A repeat test of INR is not needed for determination if above toxicity management criteria are met.  
• Interrupt study drug immediately if confirmed ALT or AST > 3 × ULN by repeat testing with new sample along with appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).  
• Interrupt study drug immediately if confirmed ALT or AST > 5 × ULN by repeat testing with new sample for more than 2 weeks.  
• Interrupt study drug immediately if confirmed ALT or AST > 8 × ULN by repeat testing with new sample.  
Subjects who meet any of the above criteria should be evaluated for an alternative etiology of the ALT or AST elevation and managed as medically appropriate. The investigator should contact the AbbVie TA MD to discuss the management of a subject when an alternative etiology has been determined. The alternative etiology should be documented appropriately in the eCRF; study drug should be discontinued if no alternative etiology can be found.  
For any confirmed ALT or AST elevations > 3 ULN, complete supplemental hepatic eCRF.  
• Subjects with HBe Ab+ (irrespective of HBs Ab status) and negative HBV DNA at screening who develop the following should have HBV DNA by PCR testing performed within one week:  
  o ALT > 5 × ULN OR  
  o ALT or AST > 3 × ULN and either a total bilirubin > 2 × ULN or INR > 1.5 OR  
  o ALT or AST > 3 × ULN along with clinical signs of possible hepatitis  
• A positive result for HBV DNA PCR testing in these subjects will require immediate interruption of study drug and a hepatologist consultation should occur within one week for recommendation regarding subsequent treatment. |
### Laboratory Parameter | Toxicity Management Guideline
--- | ---
Serum Creatinine | • If serum creatinine is $> 1.5 \times$ the baseline value and $> \text{ULN}$, repeat the test for serum creatinine (with subject in an euvolemic state) to confirm the results. If the results of the repeat testing still meet this criterion then interrupt study drug and re-start study drug once serum creatinine returns to $\leq 1.5 \times$ baseline value and $\leq \text{ULN}$.
• If confirmed serum creatinine $\geq 2$ mg/dL interrupt study drug, and re-start study drug once serum creatinine returns to normal reference range or its baseline value.
For the above serum creatinine elevation scenarios, complete supplemental renal eCRF.

Creatine Phosphokinase | • If confirmed CPK value $\geq 4 \times \text{ULN}$ (if symptomatic or asymptomatic), complete supplemental CPK eCRF.
• If confirmed CPK $\geq 4 \times \text{ULN}$ accompanied by symptoms suggestive of myositis or rhabdomyolysis, interrupt study drug, complete supplemental CPK eCRF, and contact AbbVie Therapeutic Area Medical Director.

### Section 6.1.7 Toxicity Management

**Subsection Period 2**

**First bullet previously read:**

Allow study drug interruption up to 30 consecutive days for AEs and emergency surgery during Period 2.

**Has been changed to read:**

Allow study drug interruption up to 30 consecutive days.

**Section 6.1.9 Cardiovascular Adjudication Committee**

Add: new section title and text

#### 6.1.9 Cardiovascular Adjudication Committee

An independent committee of physician experts in cardiovascular adjudication will be utilized to assess potential cardiovascular AEs in a blinded manner as defined by the Cardiovascular Adjudication Committee charter.
Section 6.2.2  Reporting
First paragraph, first sentence previously read:

Product Complaints concerning the investigational product must be reported to the Sponsor within 24 hours of the study site's knowledge of the event via the Product Complaint form.

Has been changed to read:

Product Complaints concerning the investigational product must be reported to the Sponsor within 1 business day of the study site's knowledge of the event via the Product Complaint form.

Section 8.1  Statistical and Analytical Plans
Add: new third paragraph

The statistical analysis described in this section applies to subjects who are enrolled under Amendment 4 or later. For the subjects enrolled under Amendment 3, no formal statistical analysis is intended.

Section 8.1.5.2.1  Treatment-Emergent Adverse Events (TEAE)
Seventh paragraph, first sentence previously read:

The AEs of special interest (including but not limited to infection, opportunistic infection, herpes zoster, TB, gastrointestinal perforations, malignancies, MACE, renal dysfunction, anemia, increased CPK, and drug-related hepatic disorders) will be summarized.

Has been changed to read:

The AEs of special interest (including but not limited to serious infection, opportunistic infection, herpes zoster, TB, gastrointestinal perforations, malignancies, MACE, renal dysfunction, anemia, increased CPK, and drug-related hepatic disorders) will be summarized.
Section 8.3  Randomization Methods
First bullet previously read:

Group 1:  ABT-494 30 mg QD, N = 275 (Period 1)

Has been changed to read:

Group 1:  Upadacitinib 15 mg QD, N = 275 (Period 1)

Appendix B.  List of Protocol Signatories
Previously read:

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Functional Area</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Therapeutic Area</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Therapeutic Area</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacovigilance and Patient Safety</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Statistics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Pharmacokinetics and Pharmacodynamics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bioanalysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Program Development</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Global Clinical Drug Supply</td>
</tr>
</tbody>
</table>

Has been changed to read:

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Functional Area</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Therapeutic Area</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Therapeutic Area</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacovigilance and Patient Safety</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Statistics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Pharmacokinetics and Pharmacodynamics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bioanalysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Program Development</td>
</tr>
</tbody>
</table>
Appendix C. Local Requirements
Subsection Korea
Heading "Contraception Recommendation for Females"
Fifth paragraph, first bullet previously read:

Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation, initiated at least 1 month prior to Study Day 1.

Has been changed to read:

Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal, injectable) associated with the inhibition of ovulation, initiated at least 1 month prior to Study Day 1.

Appendix D. Study Activities (Period 1)
Table note "q." previously read:

hsCRP results will remain blinded to the Sponsor, Investigator, study site personnel, and subject for all visits except Screening.

Has been changed to read:

In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject. Results of hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event management. Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib. In Period 2, the central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.
Appendix F. Study Activities (Period 2)
Table note "k." previously read:

hsCRP results will remain blinded to Sponsor, Investigator, study site personnel, and the subject. Treatment assignment may be unblinded to Sponsor only when the last subject completes Period 1 (Week 24 visit) for an interim analysis for regulatory purposes.

Has been changed to read:

In Period 1, the central lab hsCRP results starting from Baseline (Day 1) will not be reported to the Sponsor, Investigator, study site personnel, and the subject. Results of hsCRP may be blunted in subjects taking a JAK inhibitor, thereby limiting its clinical utility in the setting of a possible safety assessment or adverse event management. Any local hsCRP or CRP tests should not be reported to the investigator until treatment allocation is unblinded or subject is known to be receiving upadacitinib. In Period 2, the central lab hsCRP results will remain blinded to the Investigator, study site personnel, and the subject.

Appendix R. Rheumatology Common Toxicity Criteria v.2.0 Example
Column "1 – Mild"
Delete:

No medication or OTC